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Abstract 
 
 
A new class of non-steroidal 17β-HSD1 inhibitors was designed and synthesized as potential 
therapeutics for the treatment of estrogen-dependent pathologies like breast cancer and 
endometriosis. Using the combination of a ligand- and a structure-based approach, a 
pharmacophore model was generated and a tricyclic core structure bearing two hydroxyphenyl 
moieties connected to an additional aromatic ring was derived. At a first stage, the scaffold of 
these steroidomimetics was optimized varying two different parameters: the OH-OH 
substitution pattern and the nature of the central aromatic system. At a second stage, 
supplementary substituents were added to the most active core to enhance activity and 
selectivity. Following this strategy, 120 new compounds were prepared, most of them being 
highly potent 17β-HSD1 inhibitors with IC50 values in the low nanomolar range. Besides an 
excellent selectivity over 17β-HSD2 and the estrogen receptors (ERs) α and β, the most 
promising compounds of this study showed also no estrogenicity, good cell permeability (T-
47D), good metabolic stability in rat liver microsomes, high CaCo-2 permeability, moderate 
inhibition of CYP3A4 and CYP2D6 and excellent plasma-levels after peroral application to 
rats. In conclusion, the present thesis provides an extensive structure-activity study regarding 
17β-HSD1 inhibition which can be used in the future development of new molecules to further 
investigate in vivo the concept 17β-HSD1 as a target for the treatment of estrogen-dependent 
diseases.  
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Zusammenfassung 
 
 
Eine neue Klasse von nicht-steroidalen 17β-HSD1 Hemmstoffen wurde zunächst rational am 
PC entwickelt. Anschließend wurden die entsprechenden Verbindungen als potentielle 
Wirkstoffe zur Behandlung von estrogen-abhängigen Erkrankungen synthetisiert. Durch die 
Kombination eines Ligand- und Struktur-basierten Ansatzes wurde ein Pharmakophormodell 
erstellt und ein trizyklisches Grundgerüst abgeleitet. Die Leitstruktur besteht aus zwei 
Hydroxyphenylresten, die über einen zusätzlichen aromatischen Kern verknüpft sind. In einem 
ersten Schritt wurde die Struktur dieser Steroidomimetika durch die Variation zweier 
Parameter optimiert: das OH-OH Substitutionsmuster und die Art des zentralen Aromaten. 
Ausgehend von der aktivsten Verbindung wurden zusätzliche Substituenten eingefügt um 
Aktivität und Selektivität zu steigern. Im Verlauf dieses Projektes wurden 120 neue Moleküle 
hergestellt und deren biologische Aktivität untersucht. Die meisten der hier vorgestellten 
Substanzen sind hochpotente 17β-HSD1 Inhibitoren mit IC50-Werten im nanomolaren Bereich. 
Außerdem verfügen diese Hemmstoffe über eine sehr gute Selektivität gegenüber 17β-HSD2 
sowie den Estrogen-Rezeptoren α und β und zeigen selbst keine Estrogenizität. Weiterhin 
wurde eine hohe Zellgängigkeit (T-47D), eine gute metabolische Stabilität in 
Rattenlebermikrosomen, hohe CaCo-2 Permeabilität, nur eine moderate Hemmung der 
hepatischen CYP Enzyme 3A4 und 2D6 sowie hervorragende Plasmaspiegel nach peroraler 
Gabe an Ratten nachgewiesen. Zusammenfassend lässt sich feststellen, daß die vorliegende 
Arbeit einen tiefen Einblick in die Struktur-Wirkungsbeziehung eine neuer Klasse von 17β-
HSD1 Hemmstoffe liefert, die eine Grundlage für die Entwicklung weiterer Inhibitoren zur in-
vivo Validierung des Konzeptes 17β-HSD1 als Target für die Therapie estrogen-abhängiger 
Krankheiten darstellt. 
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1. Introduction 
 
1.1  Sex steroid hormones 
 
1.1.1  General features 
 
Natural sex steroids are produced by the gonads (ovaries or testes), by adrenal glands, or by 
conversion from other sex steroids in peripheral tissues such as liver or fatty tissues.1, 2 These 
hormones are then released into the blood circulation and transported to the target organs. After 
passive diffusion of the cell membrane, they bind with a receptor protein, which then binds to 
the hormone response element on the nuclear DNA, activating or suppressing specific 
sequences in the regulatory regions of the gene responsive element that control cell growth and 
differentiation (Figure 1). 
Figure 1: schematic representation of the hormone mechanism of action  
 
Sex steroids play a crucial role in the induction of body changes known as primary and 
secondary sex characteristics. They are divided in two main classes: androgens and estrogens, 
of which the most important and active human derivatives are testosterone and estradiol (E2), 
respectively. In general, androgens are considered as "male sex hormones", since they have 
masculinizing effects, while estrogens are considered as "female sex hormones".  
The strength of these hormones is modulated in the target cell with the aid of different 
enzymes. This implicate that besides to the classical way of action (endocrine), where the 
active hormones are secreted in specific glands and transported to distant cells to exert their 
action, it exists an another mechanism (intracrine),3, 4 in which the active steroid is directly 
synthesized in the target cell without release into the pericellular compartment (Figure 2). 
 
Figure 2: schematic representation of endocrine (A) and intracrine (B) mechanism (taken 
from5) 
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1.1.2  Estrogens 
 
The classical role of estrogens in female reproduction and development is well defined. In 
the ovary, E2 stimulates the proliferation of granulosa cells and the growth of follicles.6, 7 In 
the uterus, E2 in combination with progesterone regulates the cyclic growth of the 
endometrium.8 In addition, estrogens together with progesterone are also crucial for the 
maintenance of pregnancy and fetal development.9, 10 Moreover, to their roles in reproduction 
and female development, estrogens affect a large number of other physiological systems: in the 
skeleton, for example, estrogens are important for maintaining bone mass in adult women’s by 
suppressing bone remodelling and keeping a balance between the osteoblasts and the 
osteoclasts.11 Moreover, a large number of studies have pointed out the influence of estrogens 
on the cardiovascular system,12 central nervous system13, 14 and immune system.15  
Estrogens mainly exist in three molecular forms: estrone (E1), E2 and estriol (E3). Since 
the biological activity of E2 is much higher than that of the other types, E2 is physiologically 
the most important estrogen. The primary source of estrogen in premenopausal women is the 
ovary, but circulating E1 and androgens originating from the adrenal glands could also be 
converted into E2 in peripheral tissues16 (Figure 3).  
 
Figure 3: schematic representation of gonadal and adrenal sources of sex steroids in 
premenopausal women (taken from17) 
 
However, after menopause, estrogens are produced only through conversion of androgens 
by adrenal origins. It has been shown that the conversion of androgen to E1 occur principally 
in peripheral tissues, including skin, muscle, fat and bone.18 This conversion is catalyzed by the 
aromatase enzyme. E1 is subsequently reduced to E2 by members of the 17β-hydroxysteroid 
dehydrogenase family (17β-HSD), which are also widely distributed in various peripheral 
tissues19 (Figure 4). 
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Figure 4: schematic representation of the local production of sex steroids in breast tissues 
  
 1.2  Hydroxysteroid dehydrogenases (HSDs) 
 
The hydroxysteroid dehydrogenases (HSDs) belong to a group of pyridine nucleotide-
dependent enzymes which catalyze stereoselective reactions at specific positions of the steroid 
backbone.20 In fact, for each sex hormone an isoform pair is responsible for either inactivation 
or provision of an active ligand. This is achieved either by the oxidation of the alcohol group 
(oxidase activity) or by the reduction of the keto function (reductase activity, Figure 5) on the 
steroid skeleton. These reductase/oxidase activities allow, therefore, the HSDs to function as a 
molecular switch. 
 
 
 
 
 
Figure 5: general reaction catalyzed by hydroxysteroid dehydrogenases 
 
Aiming the structural characteristics, the HSD family is split into 2 superfamilies: the SDR 
(Short-Chain Dehydrogenase/Reductase) and the AKR (Aldo-Keto Reductase). The SDR 
family members often function as multimers and share a low sequence identity (less than 25%). 
Despite to this relatively low homology, SDR family members share identical protein folds.21 
A part of the protein fold includes an arrangement of α-helix and β-strands (β-α-β-α-β)2 to 
produce the “Rossmann fold” motif for cofactor binding. They also contain a conserved 
catalytic motif of Tyr-X-X-X-Lys where Tyr is the catalytic general acid/base22 of the reaction. 
 
The AKRs are monomeric, soluble enzymes utilising NAD(P)(H) as cofactor. They share a 
high amino sequence identity (> 67%) compared to the SDR subfamily. Invariant to their 
active site is a catalytic tetrad consisting of Asp, Tyr, Lys and His motif. Site-directed 
mutagenesis supports the crucial role for the amino acids Tyr and Lys in the catalytic 
mechanism23 in a manner similar to that described for the SDR family but the disposition of 
these residues on the enzyme structure is different compared to the SDRs. 
OH O
+ + +     H+NAD(P)+ NAD(P)H
switch "off"
active inactive
switch "on"
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1.3  17β-HSDs 
 
1.3.1  General features 
 
17β-Hydroxysteroid dehydrogenase (17β-HSD) are a group of enzymes responsible for the 
stereospecific oxido-reduction reaction of hydroxy or carbonyl groups at position 17 of the 
steroid backbone using NAD(P)H or NAD(P)+ as cofactor.23-25 They are expressed in the 
gonads as well as in peripheral tissues, where they serve as key enzymes in the regulation of 
potent androgens and estrogens.17, 24 Until now, 15 mammalian 17β-HSDs have been 
described, 12 of them exist in humans.19 They all belong the SDR superfamily except 17β-
HSD type 5, which is an AKR.19 The nomenclature of 17β-HSD enzymes follows the 
chronological order of description.26 They have relatively low sequence identity (25-30 %) and 
differ in catalytic direction, substrate and cofactor specificity, subcellular localisation and 
tissue distribution.27 
 
1.3.2  Importance of the 2’-phosphate group of the cofactor for the determination 
of the catalytic reaction 
 
17β-HSDs drive unidirectional reactions in intact cells while in cell homogenates, it has 
been shown that these enzymes are able to catalyze either the oxidation or the reduction 
depending on which cofactor form (reducent or oxidant) is present. 
In cells, NADPH is a major source of electrons, and reducing equivalents from NADPH are 
used in different metabolic reactions. In contrast NAD+ is a versatile electron acceptor, and 
most enzymatic oxidations deposit these electrons on NAD+. To maintain constant this 
cofactor abundance, the cell constantly recycles these compounds from other oxidation states. 
As shown in Figure 6, the cellular concentration of NADPH is higher (500 times) than the 
NADP+ concentration.28 In contrast, cells maintain the opposite concentration for the non 
phosphorylated NAD: NAD+ is generally 700 times more abundant than NADH.29, 30  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: interplay between metabolism and HSD reactions 
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Besides these cofactor concentration differences observed in intact cells, kinetic studies 
showed that the 17β-HSDs exhibit huge KM value differences between NADP(H) and 
NAD(H). This implicates that it exists in the cofactor binding sites of each 17β-HSD isoform 
amino acids which allow the enzyme to distinguish the non-phosphorylated from the 
phosphorylated cofactor form.2, 31 
Crystal structure analysis of reductive HSD enzymes, such as 17β-HSD1, show that an 
arginine residue in the N-terminal region of the Rossmann fold is responsible for this 
discrimination.32-35 The positively charged guanidinium group of the arginine forms a salt 
bridge with 2’-phosphate moiety of NADPH, which further enhance the affinity of these 
enzyme for NADPH (Figure 7). 
In contrast, oxidative SDRs like 17β-HSD2, contain a negatively charged amino acid at the 
position corresponding to the stabilizing arginine of the reductive enzymes: the carboxylate 
groups of aspartate and glutamate induce repulsive interactions with the 2’-phosphate group of 
NADP+ but might be able to form hydrogen bonds with the 2’-OH function of NAD+ (Figure 
7) enhancing therefore the affinity for the non-phosphorylated cofactor form. 
Furthermore, mutagenesis experiments on these enzymes demonstrated that exchanging 
this arginine with an aspartate moiety in the case of a reductive HSD enzyme increases the 
affinity for NADH (vs. NADPH) while exchanging this aspartate with arginine moiety in the 
case of an oxidative HSD enzyme enhances the affinity for NADP+ (vs. NAD+).36-38 
 
 
Figure 7: binding preferences of NADPH and NAD+ for reductive/oxidative HSDs 
 
 
1.3.3 Oxidizing / NAD+ binding enzymes 
 
As it is presented in chart 1, oxidizing 17β-HSDs are widespread distributed in the body 
and not especially only in steroidogenic tissues but also in case of 17β-HSD4 in the lung or in 
central nervous system for 17β-HSD10. As they catalyze a oxidation reaction, they lower the 
concentration of active sex hormone in the target tissues and therefore play a protective role.19  
 
enzyme localisation substrates physiological role 
17β-HSD2 
microsomes 
breast, endometrium, 
ovary, placenta 
androgens 
estrogens 
protective: decrease of active 
sex hormones in target tissues 
    
17β-HSD4 peroxisomes breast, liver, lung estrogens 
decrease of E2 level 
deficiency: Zellweger 
syndrome 
    
17β-HSD8 microsomes liver, ovary 
androgens 
estrogens 
decrease of active hormone in 
target tissues, may play role in 
fatty acid metabolism 
    
17β-HSD10 mitochondria 
central nervous system 
androgens 
estrogens 
pathogenesis of Alzheimer 
diseases 
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enzyme localisation substrates physiological role 
17β-HSD11 microsomes kidney, liver, lung androgens 
decrease of active androgens 
in target tissue, may play role 
in fatty acid metabolism 
    
17β-HSD14 cytosol breast, kidney 
androgens 
estrogens 
decrease of active androgens 
in target tissue, may play role 
in fatty acid metabolism 
Chart 1: characteristics of the oxidizing 17β-HSD isoforms 
 
1.3.4 Reducing/NADPH binding enzymes 
 
 Until now, six reductive 17β-HSDs enzymes are described in the literature (Chart 2). They 
are widespread distributed and are responsible for a high level of active sex steroids in target 
tissues. 
 Aiming the estrogens, only three subtypes (1, 7 and 12) are involved in the biosynthesis of 
E2, the most important being 17β-HSD1. The primary physiological role of 17β-HSD7 and 
17β-HSD12 is supposed to be in the cholesterol synthesis39 and in the regulation of the lipid 
biosynthesis,40 respectively. Recently, Day et al.41 showed that 17β-HSD12, although highly 
expressed in breast cancer cell lines, is inefficient in E2 formation. These results strongly 
suggest that in case of breast cancer cells, only 17β-HSD1 is responsible for intracellular high 
E2 level and might therefore a good target for the treatment of hormone dependent breast 
cancers. 
 
enzyme localisation substrates physiological role 
17β-HSD1 
cytosol 
breast, endometrium, 
ovary, placenta 
estrogens 
in a minor 
extent 
androgens 
high concentration of active 
steroids (E2 and T) in target 
tissues 
    
17β-HSD3 microsomes testis androgens 
formation of T 
deficiency: 
pseudohermaphroditism 
    
17β-HSD5 cytosol breast, liver, prostate androgens 
formation of active androgens 
responsible for the rising level 
of androgens at puberty in 
cases of 
pseudohermaphroditism 
    
17β-HSD7 membrane breast, liver, placenta estrogens 
formation of active estrogens 
may play role in cholesterol 
synthesis, deficiency leads to 
similar malformation as 
CHILD syndrome 
    
17β-HSD12 
microsomes 
breast, kidney, liver, 
placenta 
estrogens formation of active estrogens, 
regulator of lipid biosynthesis 
    
17β-HSD15 prostate androgens pathogenesis of prostate 
cancer 
Chart 2: characteristics of the reducing human 17β-HSD enzymes 
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1.4  17β-HSD1 
 
1.4.1 Biological characteristics 
 
17β-HSD type 1 (EC 1.1.1.62) was first described in 1958 by Langer & Engel.42 It is active 
as a soluble cytosolic homodimer,43 both subunits have a molecular mass of 34.9 kDa and 
contain 327 amino acids.44 
It catalyzes the final step of the E2 biosynthesis. The enzyme has also the ability to reduce 
some androgens,45, 46 such as DHEA, into di-hydrotestosterone, but only in a minor extent 
(KM(E1)= 0.03 µM vs. KM(DHEA)= 33 µM).47 Site directed mutagenesis experiments revealed 
that the androgen discrimination is due to the steric hindrance of the C19 methyl group of the 
steroidal β-face with Leu149.47 
 
 
 
 
 
 
 
Figure 8: Conversion of E1 into E2 by 17β-HSD1 
 
In vivo, 17β-HSD1 is only a unidirectional reductive enzyme, catalyzing the reduction of 
the weak active E1 into the most potent estrogen E2 (Figure 8), whereas the purified enzyme or 
cell homogenates can be driven to catalyze also the oxidative direction depending on the 
presence of the oxidative cofactor form.28 The enzyme is widespread expressed, most 
abundantly in ovaries, placenta, breast tissues and endometrium but also in other peripheral 
tissues like adipose tissues and skin. 
Using site-directed mutagenesis experiments, critical amino acid residues (Ser142, Tyr155, 
His221) for the enzyme activity and substrate binding were identified.38, 48, 49 
 
 
1.4.2 Structural characteristics 
 
The first X-ray structure of 17β-HSD1 as native form was published in 1995.50 Since then, 
several crystal structures of binary or ternary complexes with estrogenic34, 51, 52, androgenic47, 
53, 54
 ligands or with steroid based inhibitors35, 55 are available at the Protein Data Bank 
(PDB).56 
The monomeric form of 17β-HSD1 consists of seven parallel β-strands, forming a β-sheet 
and 11 α-helices.50, 51 The β-sheet is surrounded on both sides by three parallel α-helices 
bearing the classical Rossmann fold, which is associated with NAD(P)H binding (Figure 9).  
 
O
OH
OH
OH
17β-HSD1, NADPH
E1 E2
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Figure 9: 3D structure of human 17β-HSD1 monomer crystallised with E2 (coloured in pink) 
and NADP+ resolved to 2.2 Å (PDB-ID: 1FDT) 
 
The analysis of the available crystal structures furnish useful information about the enzyme 
architecture: a substrate binding site, a cofactor binding pocket and an entry channel can be 
defined.  
The 17β-HSD1 substrate binding cleft is a narrow hydrophobic tunnel showing a high 
degree of complementarity to the steroid. As a member of the SDR superfamily, 17β-HSD1 
contains the highly conserved and catalytically crucial tetrad57 Tyr-x-x-x-Lys sequence 
(Asn114, Ser 142, Tyr155 and Lys 159). E2, the product of the catalytic reaction, is stabilized 
into the active site via four hydrogen bond contacts51 (OH at C3 position with His221 and 
Glu282, OH at C17 position with Ser142 and Tyr155), as well as via several hydrophobic 
interactions with the apolar amino acids of the binding cavity (Val143, Leu149, Pro187, 
Val225, Phe226, Phe259). Interestingly, two polar amino acids (Tyr218 and Ser222) are 
located in the same area without any interaction with the steroid (Figure 10).  
 
 
Figure 10: schematic representation of the active site of 17β-HSD1 containing E2 (PDB-code: 
1A27). Blue labels denote polar amino acids and yellow labels stand for lipophilic amino acids. 
Hydrogen bonds are marked in red. 
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Additionally, a flexible loop delimited in its extend by Pro187 and Pro200 can be 
visualized (Figure 11). This loop can adopt various conformations or is not resolved at all 
depending on which X-ray structure is considered. Since the loop borders both substrate and 
cofactor binding sites, its conformational variation influences strongly the volume and shape of 
each binding cavity and its location might be of relevance for the design of inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: representation of the border loop conformations  
(A: PDB: 1IOL, B: PDB: 1FDT_B, C: PDB: 1I5M) 
 
In 1FDT two distinct conformations of the loop are present referred as 1FDT_A and 
1FDT_B, respectively. The main difference between the two loops concerns the four amino 
acids Phe192, Met193, Glu194 and Lys195. In 1FDT_A Phe192 and Met193 are turned 
towards the outer part of the enzyme, while Glu194 and Lys195 are oriented towards the 
substrate and cofactor, extending the area of the substrate binding site into the cofactor binding 
area. On the other hand, in 1FDT_B these two couples of residues show a reversed orientation 
limiting significantly the length (and so the volume) of the substrate binding pocket. 
 
1.4.3 Postulated mechanism of the hydride transfer 
 
In the postulated mechanism, the pro-S hydride of the cofactor nicotineamide moiety is 
transferred to the α-face of the steroid at the C17 carbon, whereas the keto oxygen at C17 
forms a strong hydrogen bond with the OH group of Tyr155. The proton transfer between C17 
oxygen and Tyr155 is facilitated by the close neighbourhood of the protonated side chain of 
Lys159, the 2’-OH of the ribose and a water molecule bound to the backbone carbonyl group 
of Asn114 which are responsible for the decrease of the apparent pKa of the tyrosine residue 
allowing the proton transfer (Figure 12).50, 51 
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Figure 12: scheme of the postulated mechanism of reduction of E1 into E2. Hydrogen bonds 
are represented in dashed lines. 
 
1.5  Estrogen-dependent diseases 
 
1.5.1 Breast cancer 
 
Most breast cancers are hormone-dependent, i.e. tumor cells express estrogen receptors 
(ER), and it is well known that estrogens, especially E2, have a pivotal role in the development 
and progression of these diseases.58  
Breast carcinomas can be divided in two categories: estrogen receptor positive (ER+) and 
estrogen receptor negative (ER-) tumors. Around 50% of breast cancers in premenopausal 
women and 75% of breast cancers in postmenopausal women are ER+,59 i.e. the progression of 
the tumor is dependent on the physiological concentration of estrogens present in the diseased 
tissue.  
In addition to surgery, chemotherapy and radiotherapy, hormone-dependent breast cancers 
can be treated via different endocrine therapies:60-62 SERMs (Selective Estrogen Receptor 
Modulators), like tamoxifene and raloxifene constrain the estrogen action at the receptor level, 
aromatase inhibitors (e.g. fadrozole, letrozole) suppress the estrogen formation by inhibiting 
the last step of E1 biosynthesis and GnRH analogues completely block the ovarian steroid 
formation. (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: schematic representation of the existing endocrine therapies 
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These strategies are already used in therapy but they show some limitations. Many breast 
tumors fail to respond to anti-estrogen therapy or progress after a period of time. SERMs are 
also known to induce carcinoma in other tissues like endometrium, where tamoxifene acts as 
an estrogen agonist. Aromatase inhibitors block the formation of estrogens but do not prevent 
the formation of the non-aromatic estrogen 5-androstene-3β-diol from DHEA which also 
stimulates the proliferation of cancer cells after binding to the ER. Aromatase inhibitors are 
restricted to postmenopausal women because in premenopausal women they induce a strong 
ovarian stimulation by hypothalamic/pituitary feedback. GnRH analogues do not affect adrenal 
formation of androgens which are converted into estrogens by peripheral aromatase. 
 
1.5.2 Endometriosis 
 
Endometriosis is one of the most common causes of pelvic pain and infertility in women. 
In this condition endometrial tissue grows abnormally outside the uterus, often in locations 
such as the ovaries, fallopian tubes and abdominal cavity. It causes adhesions and scarring, 
pain, heavy bleeding and can damage the reproductive organs leading to infertility. The 
specific causes of endometriosis are still not clear. The most widely accepted theory is that the 
disorder originates from retrograde menstruation of endometrial tissue through the fallopian 
tubes into the peritoneal cavity.63, 64 
Currently available medical therapies are designed to suppress the estrogen biosynthesis. 
Oral contraceptive, androgenic agents and GnRH-analogues are used to inhibit the 
menstruation, a source of much of the pain associated with endometriosis and to restrain the 
growth of endometriotic tissue.61 Analgesics are also applied in combination to the classical 
hormonal therapy in order to relieve the pain triggered by endometriosis. However, the 
available therapies focused on the symptoms of the disease but do not provide a cure. Due to 
the alteration of the hormone balance, it leads also to several side effects such as weight gain 
and acne.65 
 
1.6  Is 17β-HSD1 a good target for the treatment of EDD ? 
 
As it has been described in chapter 1.5.1, estrogens have a crucial role in supporting the 
growth of hormone-dependent breast cancer in women. Although both 17β-HSD1 and 17β-
HSD2 are present in healthy women, several studies have indicated that the ratio of 17β-HSD1 
to 17β-HSD2 is increased in the tumors of patients with ER+ breast cancer.66 This results in 
increased levels of E2 which drive the proliferation of the tumor tissue via activation of the 
ERs. Additionally, several studies indicate that patients with tumors showing high 17β-HSD1 
expression have significantly shortened disease free and overall survival.67, 68  
Recently, the in vivo efficacy of 17β-HSD1 inhibitors to reduce E1 induced tumour growth 
on two different mouse models41, 69, 70 has been demonstrated suggesting that the 17β-HSD1 
inhibition is a suitable concept for the treatment of estrogen dependent breast cancers which 
could be applied in both pre- and postmenopausal womens. 
In endometriotic tissues, a change in the expression of the steroidogenic enzymes is 
responsible for a high concentration of E2, which stimulates proliferation of the tissues.71 A 
recent study, indicate that there is down regulation of 17β-HSD2 mRNA expression in 
endometriotic lesions, while both aromatase and 17β-HSD1 activity are up regulated, in 
comparison to normal tissues.72, 73 Thus, therapies aiming the inhibition of 17β-HSD1, the 
enzyme which catalyze the last step of the E2 biosynthesis, would give an innovative approach 
to the treatment of this disorder.  
In conclusion, development of potent, selective and in vivo active inhibitors of 17β-HSD1 
should be attractive for the treatment of estrogen dependent diseases and should be useful tools 
to get further insight into the intracrine regulation of estrogen-dependent tissues.  
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1.7  State of the art on 17β-HSD1 inhibition 
 
During the last decade, the number of patents74-79 and publications (for reviews see80, 81) 
dealing with 17β-HSD1 inhibitors increased constantly. Most of the known inhibitors are based 
on steroidal structures, while only a few numbers of non-steroidal scaffolds are described.  
An inhibitor of 17β-HSD1 should be selective over 17β-HSD2 and, most importantly, 
should not trigger unwanted estrogenic effects. Antiestrogenic effects or inhibitory activity 
against aromatase or E1-sulfatase can be considered as an extra benefit. Furthermore, a good 
17β-HSD1 inhibitor should exhibit drug-like properties in order to have sufficient absorption 
and permeation in biological systems (Lipinski rule of five).82  
Aiming at steroid based 17β-HSD1 inhibitors large libraries based on E1 and E2 cores with 
substitution at the C2, C6, C7, C15, C16 positions were synthesized. Table 3 lists 
representative 17β-HSD1 inhibitors exhibiting high inhibitory activity toward the enzyme. 
From the biological results, it becomes apparent that the C15 and C16 positions and especially 
the corresponding β-isomers are suitable for introduction of side chains (Table 3). In order to 
reduce the estrogenic activity of these compounds, small or flexible hydrophobic groups were 
introduced in C2 position. Docking studies showed that these types of inhibitors establish 
interactions with both binding sites of the enzyme: the steroid part being anchored in the 
substrate binding cleft while the side chain is able to interact with a part of the cofactor.83  
 
Table 3: selection of described highly active steroidal 17β-HSD1 inhibitors 
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Concerning the non-steroidal cores, less work has been published. As compared with 
inhibitors based on steroid structures non-steroidal compounds could have advantages such as 
synthetic accessibility, drug-likeness, selectivity and non-estrogenicity. 
Phytoestrogens like coumestrol (1) and gossypol (2) derivatives are the first fairly active 
(IC50 values in the micromolar range) non-steroidal 17β-HSD1 inhibitors which have been 
described.84, 85 Their major drawback is that they suffer from a lack of selectivity, as they are 
also inhibitors of numerous other enzymes.85, 86 
Based on the knowledge they had gained in the steroid based inhibitors,83, 87-89 Sterix 
Limited synthesized a library of biphenyl ethanone derivatives90 as steroidomimetic of E1. The 
most active inhibitor (3) shows a moderate inhibition of 17β-HSD1 (IC50= 1.7 µM) and 
exhibits low selectivity over 17β-HSD2. 
More recently, thienopyrimidinones91, 92 have been developed as inhibitors of 17β-HSD1 
by Solvay Pharmaceuticals. The most potent compound of this series (4) appears to have an 
excellent inhibitory activity (IC50= 5 nM) in the cell free assay but its potency is significantly 
reduced (25 % inhibition at 1 µM)91 in the cell assay indicating poor bioavailability of these 
compounds.  
In the current year, 1-substituted hydroxyphenyl naphthols93-95 were found by our group to 
be highly selective and potent inhibitors of the enzyme. In addition to a high activity (5, IC50= 
20 nM), good selectivity over 17β-HSD2 and the ERs, the compound shows excellent 
pharmacokinetic properties in the rat (Figure 14). 
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Figure 14: described non-steroidal 17β-HSD1 inhibitors 
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2.  Outline of this thesis 
 
2.1  Scientific goal 
 
Estrogen target cells – i.e. cells expressing ERα and/or β - express to varying degrees 17β-
HSD1 and 17β-HSD2. The former one activates E1, the most prevalent estrogen in circulation, 
upon entering the cell into E2, which stimulates the cell proliferation.  
17β-HSD2 inactivates intracellular E2 by oxidizing it to E1 and thus protects the cell from too 
strong stimulation. As 17β-HSD1 is very often strongly overexpressed in breast cancer or 
endometriosis, this enzyme is discussed to be a promising target for the treatment of these 
diseases.  
This therapeutical concept might offer a softer approach compared to the existing therapies: 
fewer side effects can be expected as only the last step of the E2 biosynthesis will be inhibited. 
Recently the in vivo efficacy of 17β-HSD1 inhibitors to reduce E1 stimulated tumour growth 
on two different mouse models has been demonstrated,41, 69, 70 highlighting the fact that the 
inhibition of 17β-HSD1 is a suitable concept for the treatment of estrogen-dependent 
pathologies.  
Accordingly, the aim of the present thesis was to develop highly potent and selective 
inhibitors of 17β-HSD1 which are applicable in vivo in order to provide scientific tools for the 
elucidation of intracellular estrogen regulation and lead compounds for a novel strategy to treat 
hormone-dependent diseases. 
To achieve this goal, novel 17β-HSD1 inhibitors have been designed using a combination 
of a structure and a ligand based approach. Regarding the therapeutical concept it is important 
that inhibitors of 17β-HSD1 are selective toward: 1. 17β-HSD2, which inactivates E2 to E1, 
thus acting contra-productive to the type 1 enzyme; 2. the estrogen receptors α and β to avoid 
intrinsic estrogenic effects. 
 
2.2  Working strategy 
 
In the design process, it was decided that steroidal structures should be avoided to limit the 
side effects due to interaction with steroid hormone receptors. However, the compounds should 
be capable of mimicking E1. 
Based on the X-ray structure analysis of the enzyme active site (PDB-ID: 1FDT), our group 
established a pharmacophore model for non-steroidal inhibitors of 17β-HSD1. It contains two 
polar points A and B, which could be hydrogen bond donor or acceptor, mimicking the steroid 
O-3 and O-17 positions, respectively. A distance of about 11 Å, in the same range as observed 
for the steroid, should be optimum. Another polar group, C, equidistant to A and B could also 
be considered for interaction as two polar amino acids Ser222 and Tyr218 were identified in 
the X-ray structure. These three points A, B and C should be connected to a non polar core. 
Upon identification of the most appropriate core structure, a substituent R could be introduced 
on the hydrophobic scaffold to increase activity and selectivity. 
From the previously established pharmacophore model, a tricyclic core structure was 
derived. The compounds consist of two hydroxyphenyl or two methoxyphenyl moieties, which 
could imitate the A-ring (interaction with His221 and Glu282) and the D-ring (Ser142 and 
Tyr155) of the steroid. To keep a planar shape, similar to E1, the two hydroxyphenyl moieties 
should be linked via an aromatic ring. Furthermore, different position isomers of the hydroxy 
groups at the phenyl ring (para-/meta-, meta-/para- and para-/para-) should be investigated in 
order to find out the one which fits best to 17β-HSD1. 
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Figure 15: proposed pharmacophore model and derived core structure 
 
In the first project of the present work (Paper I), different azoles containing nitrogen and/or 
oxygen were considered as central aromatic rings (the nitrogen and/or the oxygen might be 
able to establish additional interactions with the amino acids Tyr218 and/or Ser222). Position, 
number and nature of the heteroatoms in the heterocycle as well as the location of the OH 
groups on the hydroxyphenyl moieties were varied to determine which “molecular geometry” 
(combination of heteroatoms and most suitable OH-OH substitution pattern) is in correlation 
with a high 17β-HSD1 inhibitory activity (Figure 16). The results of these investigations are 
presented in chapter 3.I.  
 
To obtain further insight into the impact of an additional nitrogen atom, and on the 
distribution of the nitrogen atoms in the central ring on inhibitory activity, a small study was 
performed with bis(hydroxyphenyl) triazoles (Paper II, chapter 3.II, Figure 16). Furthermore, it 
was investigated, whether an additional substituent on the heterocycle might be able to increase 
the potency of the inhibitors. 
 
In the third part of this thesis (Paper III, chapter 3.III), the significance of the OH groups 
was further evaluated on other five-membered heterocycles, especially sulfur containing ones. 
Moreover it was evaluated, whether aromatic six-membered rings were also appropriate to 
connect the two hydroxyphenyl moieties (Figure 16). 
 
From the previous subproject, 2,5-disubstituted thiophenes, thiazoles and 1,4-disubstituted 
benzenes proved to be highly potent inhibitors of 17β-HSD1 (IC50 in the nanomolar range) and 
therefore especially suitable hits for the introduction of further substituents. 
Aiming to increase activity and selectivity of this class of compounds, a series of molecules 
bearing various substituents either on the central aromatic ring or on the hydroxyphenyl 
moieties have been synthesized and their biological properties evaluated (Paper IV, chapter 
3.IV, Figure 16). 
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Figure 16: structure overview of the molecules described in this thesis 
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3. Results  
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Paper I 
 
abstract: The 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyses the reduction 
of the weakly active estrone (E1) into the most potent estrogen, 17β-estradiol (E2). E2 
stimulates the growth of hormone-dependent diseases via activation of the estrogen receptors 
(ERs). 17β-HSD1 is often over-expressed in breast cancer cells. Thus, it is an attractive target 
for the treatment of mammary tumors. The combination of a ligand- and a structure-based drug 
design approach led to the identification of bis(hydroxyphenyl) azoles as potential inhibitors of 
17β-HSD1. Different azoles and hydroxy substitution patterns were investigated. The 
compounds were evaluated for activity and selectivity with regard to 17β-HSD2, ERα and 
ERβ. The most potent compound is 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol (18, IC50= 
0.31 µM), showing very good selectivity, high cell permeability and medium CaCo-2 
permeability. 
 
 
Introduction 
 
The naturally occurring steroidal hormones, estrone (E1) and 17β-estradiol (E2) are 
responsible for the development and differentiation of estrogen-sensitive tissues. It is well 
known, however, that E2, the most active estrogen, also plays a pivotal role in the growth of 
estrogen-dependent breast cancer1 and is involved in the pathophysiology of endometriosis.2 
Until now three endocrine therapies have been established for the treatment of breast cancer.3,4 
SERMs (Selective Estrogen Receptor Modulators) and pure antiestrogens5 like fulvestrant 
block the estrogen action at the receptor level while aromatase inhibitors and GnRH-analogues 
restrain the formation of estrogens. This strong reduction of systemic estrogen action is a rather 
radical approach. A softer therapy could be the inhibition of the enzyme catalysing the last step 
of the E2 biosynthesis: 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). 
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17β-HSD1 is a member of the 17β-hydroxysteroid dehydrogenase family which is responsible 
for the intracellular regulation of steroidal sex hormones activities.6,7 Until now, fourteen 
members of this enzyme class are known.8 In humans, eleven of them regulate the 
concentration of active androgens and estrogens in a tissue-specific manner.8,9  
17β-HSD1 (EC1.1.1.62) is a cytosolic enzyme, which converts the weakly active estrone (E1) 
into the highly potent E2 using NAD(P)H as cofactor (Chart 1). The enzyme is expressed in 
different organs like ovaries, placenta, breast, endometrium10 and often overexpressed in many 
breast cancer tissues.11-14 Inhibition of 17β-HSD1 should be a good strategy to selectively 
reduce the E2 level in diseased tissues and might therefore be a new therapeutic approach with 
probably less side effects for the treatment of estrogen dependent diseases. 
As a biological counterpart the membrane-bound 17β-hydroxysteroid dehydrogenase type 2 
(17β-HSD2) catalyses the NAD+-dependent oxidation of E2 to E1 (Chart 1). This enzyme 
should not be affected by potential inhibitors of 17β-HSD1, as it might protect the cell from 
excessively high concentrations of active estrogen.15 Nor should 17β-HSD1 inhibitors show 
affinity to the estrogen receptors α and β (ERα and ERβ) to avoid intrinsic estrogenic effects. 
 
Chart 1: interconversion of estrone (E1) to 17β-estradiol (E2) 
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Over the last decade, several groups have reported on 17β-HSD1 inhibitors, most of them 
showing steroidal structures.6, 16-30 Until now, only three classes of non-steroidal compounds 
have been described.31-34 
In the following we will report on the design, synthesis and biological evaluation of potent and 
selective non-steroidal inhibitors of 17β-HSD1 that are appropriate for drug development. 
 
Design of the inhibitors 
 
Characterisation of the binding site 
 
Sixteen crystal structures35-43 with different steroidal ligands are available from the Protein 
Data Bank.44 The three dimensional architecture of the enzyme was investigated using the 
ternary complex of 17β-HSD1 with E2 and NADP+ (PDB-ID: 1FDT).35 A substrate binding 
site, a cofactor binding pocket and an entry channel can be defined. The former is a narrow 
hydrophobic tunnel showing a high degree of complementarity to the steroid. Two polar 
regions can be identified at each extremity of the substrate binding site corresponding to the 
binding positions of the 3- and 17-hydroxy group of E2. Both of them establish four hydrogen 
bonds with His221/Glu282 and Ser142/Tyr155, respectively. This area also contains a mainly 
apolar region, corresponding to the B/C ring of the steroid (Leu149, Val225, Phe226, Phe259). 
Interestingly, two polar amino acids (Tyr218, Ser222) are located in the same domain (Figure 
1). 
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Figure 1: schematic presentation of the active site of 17β-HSD1 containing E2 (PDB-code: 
1FDT). Orange labels denote polar amino acids and white labels stand for lipophilic amino 
acids. Hydrogen bonds are marked in red and cofactor in purple. 
 
 
 
The catalytic centre of the enzyme is formed by a tetrad of amino acids45 (Asn114, Ser142, 
Tyr155 and Lys159) which stabilises the steroid and the nicotinamide moiety during hydride 
transfer. The active site is limited by a flexible loop (amino acids 188-201) which is not well 
resolved in all of the X-ray structures.  
 
Design of steroidomimetics 
 
In the design process, the substrate binding site was defined as a binding region for the 
potential inhibitors as a lack of selectivity is expected for the compounds targeting only the 
cofactor binding pocket: this area consists of Rossmann fold motifs which are highly conserved 
in the majority of dehydrogenases. We focused on non-steroidal structures as it is known that 
steroidal compounds often show side effects which are caused by agonistic or antagonistic 
effects at steroid receptors. As the compounds have to mimic the steroidal substrate, they 
should contain two hydroxyphenyl (or two methoxyphenyl) moieties to imitate the A-ring 
(interaction with His221/Glu282) and the D-ring (interaction with Ser142/Tyr155) of the 
steroid. Additionally, the O-O distance should be in the same range as observed for the steroid 
(d= 11 Å). Different substitution patterns concerning the position of the phenolic OH groups 
were therefore investigated to find out the one which fits best into the active site (Chart 2). To 
mimic the flat shape of the substrate, the two substituted benzenes should be linked by an 
additional aromatic ring. The five-membered heterocycles imidazole, triazole, pyrazole, 
isoxazole and oxazole seemed to be especially suitable as their heteroatoms might be able to 
establish additional interactions with the amino acids Tyr218 and/or Ser222, which are located 
close to the C6 position of the steroidal B-ring. Position, number and nature of the heteroatoms 
in the five-membered ring were varied in order to identify the most appropriate heterocycle. 
1,2- and 1,3-bis(hydroxyphenyl) and tris(hydroxyphenyl) azoles have been described by Fink 
et al.46 as novel ER ligands. The fact that the compounds bearing two hydroxyphenyl moieties 
did not show any binding affinity to the ERs46 is supportive of our design concept. In the 
following we describe the synthesis of compounds 1 to 19 (Chart 2) and their biological 
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evaluation using human 17β-HSD1, 17β-HSD2, ERα and ERβ as well as T-47D and CaCo2- 
cell lines. 
 
Chart 2: title compounds 
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compound X Y Z R1 R2 
1 SH C  4-OH 3-OH 
2 SH C  4-OH 4-OH 
3 SH C  3-OH 4-OH 
4 H C  4-OH 3-OH 
5 H C  4-OH 4-OH 
6 H C  3-OH 4-OH 
7  N  4-OH 3-OH 
8  N  3-OH 4-OH 
9 N NH CH 4-OH 3-OH 
10 N NH CH 4-OH 4-OH 
11 N NH CH 3-OH 4-OH 
12 NH CH N 4-OH 3-OH 
13 NH CH N 4-OH 4-OH 
14 O CH N 4-OH 3-OH 
15 O CH N 4-OH 4-OH 
16 O CH N 3-OH 4-OH 
17 N O CH 4-OH 4-OH 
18 N O CH 3-OH 4-OH 
19 O N CH 3-OH 4-OH 
 
 
Chemistry 
 
 
The synthesis of the title compounds is depicted in Schemes 1 to 4. 1,4-Bis(hydroxyphenyl) 
imidazoles were synthesised according to the route presented in Scheme 1. Intermediates 1i to 
3i were prepared by nucleophilic substitution followed by cyclisation with potassium 
thiocyanate as described by Prakash et al.47 The sulfur removal (4i to 6i) was performed under 
strong acidic conditions according to Dodson and Ross.48 Compounds 1i to 6i were submitted 
to ether cleavage with boron trifluoride dimethyl sulfide complex46 as reagent. 
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Scheme 1: synthesis of compounds 1 to 6a 
 
O
Br
NH2 N
NR
N
NR
+
R = SH 1i to 3i
R = H 4i to 6i
R = SH 1 to 3
R = H 4 to 6
a, b d
 
3
4
R1
R2
R2
R1
HO
OH
c
 
 
 
 
 
 
 
 
 
 
aReagents and conditions: a.: NEt3, DMF, rt, 7 h; b.: KSCN, cat. HCl, MeOH, reflux, 18 h; c.: HNO3, NaNO2, 
glacial acetic acid, 0° C, 20 min; d.: BF3·SMe2, CH2Cl2, rt, 20 h. 
 
 
Synthesis of the 1,2,3-triazoles 7 and 8 was performed according to the synthetic pathway 
shown in Scheme 2. Aromatic nucleophilic substitution of iodophenol derivatives by sodium 
azide led to intermediates 7i and 8ii. The resulting azides were converted to compounds 7 and 
8i in the presence of the corresponding phenyl acetylene derivative using the method of 
Sharpless.49 The methoxy group of 8i was cleaved with boron trifluoride dimethyl sulfide 
complex. 
 
 
Scheme 2: synthesis of compounds 7 and 8a 
HO
N
NN
OH
+
a
c
b
8: 3-OH, R2= 4-OH
7i: 4-OH


8ii: 3-OH 7: 4-OH, R2= 3-OH


8i:3-OH, R2= 4-OMe
R2
R2
N3
I
HO
 
 
aReagents and conditions: a.: NaN3, CuI, L-Proline, NaOH, DMSO, 60 °C, 10 h; b.: Na-ascorbate, CuSO4, 
H2O/t-BuOH (1:1) , 60 °C, 24 h; c.: BF3·SMe2, CH2Cl2, rt, 20 h. 
 
 
The synthesis of the 2,5-bis(hydroxyphenyl) imidazoles and 2,5-bis(hydroxyphenyl) oxazoles 
is presented in Scheme 3. The commercially available amine derivatives were N-acylated with 
two different acid chlorides to build the key intermediates 9ii to 11ii. The latter were cyclised 
to the 2,4-disubstituted imidazoles (9i to 11i) according to Suzuki et al.50 and to the 2,5-
disubstituted oxazoles (17i and 18i) following Nicolaou et al.51 Ether cleavage was successful 
with boron trifluoride dimethyl sulfide complex for the imidazole compounds 9 to 11, 
pyridinium hydrochloride for 17 and boron tribromide for 18. 
compound R1 R2 
1i 4-OMe 3-OMe 
2i 4-OMe 4-OMe 
3i 3-OMe 4-OMe 
4i 4-OMe 3-OMe 
5i 4-OMe 4-OMe 
6i 3-OMe 4-OMe 
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Scheme 3: synthesis of compounds 9 to 11, 17 and 18a 
O
NH2 Cl
O
O
N
H
O
N
N
H
N
O
N
X
R1
R1
R2
R2
R1
R1
R2
R2
HO
OH
9ii to 11ii
9i to 11i
17i and 18i
X = NH 9 to 11
X= O 17 and 18
a
b
c
d
e
 
 
 
 
 
 
 
 
 
aReagents and conditions: a.: NEt3, rt, 30 min.; b.: NH4OAc, AcOH, reflux, 2 h; c.: POCl3, pyridine, reflux, 8 h; 
d.: BF3·SMe2, CH2Cl2, rt, 20 h; e.: for 17i: Pyridinium hydrochloride, 220 °C, 18h, for 18i: BBr3, CH2Cl2, -78 °C 
to rt, 20 h. 
 
 
The pyrazoles 12 and 13, the isoxazoles 14 and 16 were synthesised according to the route 
shown in Scheme 4. Key intermediates 12ii, 13ii and 16ii were prepared via Claisen 
condensation of the commercially available methoxylated acetophenone derivatives with the 
appropriate benzaldehydes under strongly basic conditions. The cyclisation step for the 
pyrazoles52 12i and 13i was carried out with hydrazine monohydrate (Method A). For 
compounds 14i to 16i, the α,β-unsaturated ketones 12ii, 13ii and 16ii were first activated with 
bromine and cyclised to isoxazole with hydroxylamine hydrochloride (Method B). Ether 
cleavage was performed with boron tribromide to yield 12 to 16.  
 
Scheme 4: synthesis of compounds 12 to 16a 
O
H
O
O NX NX
OH
HO
R1
R1
R1
R2
R2 R2
a
b c
12ii and 13ii
16ii
X = NH 12i and 13i
X = O 14i to 16i
X = NH 12 and 13
X = O 14 to 16
 
 
 
compound R1 R2 compound R1 R2 
9ii 4-OMe 3-OMe 9i 4-OMe 3-OMe 
10ii 4-OMe 4-OMe 10i 4-OMe 4-OMe 
11ii 3-OMe 4-OMe 11i 3-OMe 4-OMe 
   17i 4-OMe 4-OMe 
   18i 3-OMe 4-OMe 
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aReagents and conditions: a.: EtOH, Na, rt, 30 min; b.: Method A: hydrazine monohydrate, AcOH, EtOH, reflux, 
24 h; Method B: bromine, diethylether, 0 °C, 1 h, hydroxylamine hydrochloride, abs. EtOH, reflux 24 h; c: BBr3, 
CH2Cl2, -78 °C to rt, 20 h. 
 
Compound 19 was prepared in a one pot synthesis following the procedure of Lee et al.53 
Briefly, 4-methoxyacetophenone, [hydroxy(2,4-dinitrobenzensulfonyloxy)iodo]benzene and 3-
methoxybenzamide were heated under reflux in acetonitrile for 10 h to yield the intermediate 
19i. The ether groups of 19i were cleaved with boron tribromide. 
 
Biological results 
 
Inhibition of human 17β-HSD1 
 
Placental enzyme was isolated following a described procedure.54 Tritiated E1 was incubated 
with 17β-HSD1, cofactor and inhibitor. The amount of formed E2 was quantified by HPLC. 
All methoxy compounds and para-para di-hydroxylated derivatives are inactive (data not 
shown). In contrast, some of the unsymmetrically substituted compounds were active (Table 
1). Interestingly the para-meta di-substituted isoxazole 14 is inactive while its meta-para 
analogue 16 (IC50= 1.61 µM) shows inhibitory activity. This exemplifies the importance of the 
positions of the OH groups. The triazole 7, isoxazole 16 and 2,4-disubstituted oxazole 19 are 
only weak inhibitors of 17β-HSD1 while derivatives 8 and 18 show IC50 values in the 
nanomolar range. The 2,5-disubstituted oxazole 18 was the most potent compound identified 
with an IC50 value of 0.31 µM. 
 
Table 1: inhibition of human 17β-HSD1 and 17β-HSD2 by selected inhibitors  
 
compound structure IC50 (µM)
a
 selectivity 
factord 17β-HSD1b 17β-HSD2c 
7 
NN
N
HO
OH
 
1.32 8.12 6 
8 
N N
N
HO
OH
 
0.84 7.28 9 
16 
N O
HO
OH
 
1.61 0.27 0.1 
18 O
N
HO
OH
 
0.31 17.5 56 
19 N
O
HO
OH
 
1.85 0.25 0.1 
 
aMean value of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate E1, 500 nM, cofactor NADH, 500 µM; cHuman placenta, microsomal fraction, substrate E2, 500 nM, 
cofactor NAD+, 1500 µM; dIC50 HSD2/IC50 HSD1. 
 
compound R1 R2 method 
12i 4-OMe 3-OMe A 
13i 4-OMe 4-OMe A 
14i 4-OMe 3-OMe B 
15i 4-OMe 4-OMe B 
16i 3-OMe 4-OMe B 
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It is striking that only compounds containing a heterocycle which can function as a hydrogen 
bond acceptor (nitrogen and/or oxygen) are active. The position of the heteroatoms in the 
heterocyclic skeleton is also a decisive criterion for inhibitory activity. The 2,5-disubstituted 
oxazole (18, IC50= 0.31 µM) showed a stronger inhibition of the enzyme as its 2,4-
disubstituted oxazole (19, IC50= 1.85 µM) and 3,5-disubstituted isoxazole (16, IC50= 1.61 µM) 
analogues.  
 
Selectivity 
 
Since 17β-HSD2 catalyses the inactivation of E2 to E1, inhibitory activity toward this enzyme 
must be avoided. The 17β-HSD2 inhibition was determined using an assay similar to the 17β-
HSD1 test. Placental microsomes were incubated with tritiated E2 in the presence of NAD+ 
and inhibitor. Quantification of labelled product (E1) was performed by HPLC and following 
radio detection. IC50 values and selectivity factors (IC50 HSD2/ IC50 HSD1) are presented in 
Table 1.  
Compound 18 is only a weak inhibitor of the type 2 enzyme (IC50= 17.5 µM) with a selectivity 
factor of 56, while the isoxazole 16 (IC50= 0.27 µM) and the oxazole 19 (IC50= 0.25 µM) 
isomers show stronger inhibition for the type 2 versus type 1 enzyme (selectivity factors: 0.1). 
Furthermore, as 17β-HSD1 inhibitors should have no or low affinity to ERα and ERβ, binding 
affinity was measured for selected compounds. Using recombinant human protein, a 
competition assay applying tritium labelled E2 (RBA= 100 %) and hydroxyapatite was 
performed. The triazoles 7 and 8, isoxazole 16 and oxazole 19 show very low binding affinity 
to both ERs, whereas for the most interesting compound, the 2,5-disubstituted oxazole 18, a 
very low affinity to ERα (0.01< RBA(%)< 0.1) and a marginally higher (RBA= 0.5 %, Table 
2) affinity to ERβ is observed.  
 
Table 2: binding affinities for the estrogen receptors α and β by selected compounds 
 
compound structure RBA
a
 (%) 
ERα ERβ 
7 
NN
N
HO
OH
 
<0.01 <0.01 
8 
N N
N
HO
OH
 
0.01< RBA< 0.1 0.01< RBA< 0.1 
16 
N O
HO
OH
 
0.01< RBA< 0.1 <0.01 
18 O
N
HO
OH
 
0.01< RBA< 0.1 0.5 
19 N
O
HO
OH
 
0.01< RBA< 0.1 0.01< RBA< 0.1 
 
aRBA: relative binding affinity, E2: 100 %, mean value of three determinations, standard deviation less than 10 %. 
 
Further biological evaluation of compound 18 using T-47D and CaCo-2 cell lines. 
 
The most promising inhibitor of this series, compound 18 was evaluated for estrogenic effects 
on the ER-positive, mammary tumor T-47D cell line. No agonistic, i.e. stimulatory effect was 
observed after application of compound 18 even at a concentration 1000 fold higher compared 
to E2. 
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Compound 18 was additionally evaluated using the same cell line which expresses both 17β-
HSD1 and 17β-HSD2. The oxazole 18 inhibits the formation of E2 after incubation with 
labelled E1 exhibiting an IC50 value of 0.38 µM. As this value is very similar to the one 
observed in the cell free assay (0.31 µM, see Table 1) it can be concluded that the compound is 
capable of unfolding its activity in intact cells. 
Further investigations were performed using CaCo-2 cells. These cells exhibit morphological 
and physiological properties of the human small intestine55 and are generally accepted to be an 
appropriate model for the prediction of peroral absorption. Depending on the Papp data 
obtained, compounds are usually classified as low (Papp (10-6 cm/sec) < 1), medium (1 < Papp < 
10) or highly permeable (Papp > 10). Compound 18, showing a Papp value of 7.9·10-6 cm/sec, is 
a medium cell permeator like for example acetyl salicylic acid. 
 
Molecular Modeling 
 
In order to get a better insight into the molecular interactions between the most potent 
steroidomimetic 18 and 17β-HSD1, the compound was docked into the active site of the 
protein (PDB: 1FDT, E2 removed) using the docking software Gold 3.0 (rigid protein, flexible 
ligand).  
Two different binding modes can be expected because of the pseudo-symmetry of our 
steroidomimetic: each hydroxyphenyl group could mimic the A-ring of the steroid. The 
energetically most favourable pose is depicted in Figure 2. The para hydroxyphenyl substituent 
and the heterocycle are in the same plane while the meta hydroxyphenyl moiety is rotated 32° 
out of this plane. This conformation allows the inhibitor to establish hydrogen bond 
interactions with His221/Glu282 (para hydroxyphenyl moiety) and Ser142/Tyr155 (meta 
hydroxyphenyl substituent). Interestingly, the Noxazole-OTyr218 distance is 2.89 Ǻ making an 
additional hydrogen bond interaction very likely. On the other hand an interaction with the 
OSer222 cannot be observed as in the rigid protein structure the CH2OH moiety is turned away 
from the heterocycle. However, it cannot be excluded that there is a conformational change in 
that functional group after binding of this ligand. Additionally, it is likely that hydrophobic 
interactions (Van der Waals and pi−pi stacking) are also involved in the binding of 18 into the 
active site. 
 
Figure 2: 17β-HSD1 binding pocket (green amino acids) with docked compound 18 (yellow). 
Hydrogen bonding interactions are marked by violet lines. All distances are expressed in Å. 
For clarity, only selected amino acids are represented. 
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Discussion and Conclusion 
 
Looking at the SARs of the synthesised compounds, it becomes apparent that the positions of 
the OH groups at the hydroxyphenyl moieties are crucial for the activities of the corresponding 
derivatives: all para-para substituted compounds are inactive, while several of the meta-para 
/para-meta isomers are active. This suggests that 17β-HSD1 is not as flexible to adjust its 
geometry to the two OH groups as it is reported for the ERs56 and is in agreement with the non-
flexibility already observed for 17β-HSD1 inhibitors in the class of 6-
(hydroxyphenyl)naphthalenes.34 The fact that not all meta-para /para-meta bis-hydroxyphenyl 
derivatives (with O-O distances comparable to E2) are active, indicates that the nature of the 
heterocycle is also playing an important role for the inhibitory potencies of the compounds. 
Obviously hydrogen bond donors are unfavourable for activity (e.g. imidazoles 9 to 11, 
pyrazoles 12 and 13) while several compounds with only hydrogen bond acceptor groups show 
reasonable activities (e.g. triazoles 7 and 8, isoxazole 16, oxazoles 18 and 19).  
It is interesting to have a closer look at the inactive isoxazole 14 (para-meta) and its highly 
active isomer, the oxazole 18 (para-meta). Provided that both compounds interact with the 
active site in the same manner, e.g. the para-hydroxyphenyl moiety establishes hydrogen bond 
contacts with His221/Glu282, the structure of the inhibitors only differ by the position of the 
oxygen on the heterocycle. It has been described57 that only the nitrogen of isoxazole and 
oxazole (and not the oxygen) is able to establish hydrogen bond interaction. The position of the 
oxygen on the azole structure seems to be determinant for the ability of the compound for 
forming hydrogen bonds involving the nitrogen: in case of the isoxazole, the electronic density 
on the nitrogen is reduced compared to the oxazole. This is obviously due to the 
electronegative effect of the oxygen. It can therefore be assumed that only in case of compound 
18 hydrogen bond interactions with Tyr218 and Ser222 (Figure 2) are possible making the 
latter compound a potent inhibitor. These explanations are supported by the fact that the 
oxazole 19 shows a weak inhibitory activity. 
The insertion of a third nitrogen (triazoles 7 and 8) in the heterocycle increases the inhibitory 
potency of the correspondingly substituted imidazoles 4, 6 and imidazoles-2-thiol 1, 3 which 
are inactive. Obviously, this nitrogen plays the same role for the interaction with the amino 
acid residues in the binding site as observed for compound 18. 
 
The most interesting compound of the present study is 18 showing a high 17β-HSD1 inhibition 
and a good selectivity toward 17β-HSD2. In addition, compound 18 exhibits very low affinity 
to ERα and ERβ. It is striking that the high binding affinity of similar ER ligands like the 
tris(hydroxyphenyl) pyrazoles described by Katzenellenbogen’s group46, 58-60 depends on the 
presence of three hydroxyphenyl moieties. No polar amino acids in the B/C ring region of E2 
can be identified in the X-ray structures of the ERs as groups to establish interactions with the 
heterocycle. Obviously, the pyrazole is playing a passive role in this class of ER ligands. In 
case of our bis(hydroxyphenyl) substituted azoles the combination of at least two parameters is 
implicated in the 17β-HSD1 inhibitory potency: an optimal OH substitution pattern and an 
appropriate heterocycle. 
Activation of the ERs would be detrimental for the treatment of estrogen-dependent diseases. 
Therefore agonism must be avoided. Antagonistic activity would be less critical. The diseased 
cells certainly could benefit from compounds with dual activity. However, antiestrogens would 
also exert systemic effects in other healthy steroidogenic tissues leading to unwanted effects. 
Consequently, we focussed on the discovery of compounds without affinity to the ERs.  
The fact that the 2,5-disubstituted oxazole 18 inhibits the cellular formation of E2 with an IC50 
value in the nanomolar range, shows that this compound is able to enter the cell and to be 
active at the target enzyme. The fact that the inhibitor shows a good permeation is supported by 
the CaCo-2 data. These results are indicative of a sufficient intestinal absorption. 
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Compound 18 might therefore be a good lead compound for the development of a clinically 
applicable therapeutic for the treatment of estrogen-dependent diseases. 
 
Experimental section 
 
Chemical Methods 
 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, 
Lancaster, Roth, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 µm) coated with silica, preparative 
thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel). 
Melting points were measured on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded on a Bruker Vector 33 spectrometer (neat sample). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in δ (parts per million: ppm), by reference to the hydrogenated residues of 
deuteriated solvent as internal standard (CDCl3: δ = 7.24 ppm (1H-NMR) and δ = 77 ppm (13C-NMR), 
CD3OD: δ = 3.35 ppm (1H-NMR) and δ = 49.3 ppm (13C-NMR), CD3COCD3: δ = 2.05 ppm (1H-NMR) 
and δ = 29.9 ppm (13C-NMR), CD3SOCD3 δ = 2.50 ppm (1H-NMR) and δ = 39.5 ppm (13C-NMR). 
Signals are described as s, d, t, dd, m, dt, q for singlet, doublet, triplet, doublet of doublets, multiplet, 
doublet of triplets and quadruplet respectively. All coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI and APCI) were recorded on a TSQ Quantum (Thermo Finnigan) instrument. 
Elemental analyses were performed at the Department of Instrumental Analysis and Bioanalysis, 
Saarland University. 
 
The following compounds were prepared according to previously described procedures: 1,4-bis-(4-
methoxyphenyl)-1H-imidazol-2-thiol (2i),47 4-(3-methoxyphenyl)-1-(4-methoxyphenyl)-1H-imidazole 
(4i),61 1,4-bis-(4-methoxyphenyl)-1H-imidazole (5i),62 4-azidophenol (7i),63 3-[1-(4-hydroxyphenyl)-
1H-1,2,3-triazol-4-yl]phenol (7),63 3-azidophenol (8ii),63 3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-
yl]phenol (8),63 3-methoxy-N-[2-(4-methoxyphenyl)-2-oxo-ethyl]-benzamide (9ii),64 4-methoxy-N-[2-
(4-methoxyphenyl)-2-oxo-ethyl]benzamide (10ii),65 2,5-bis-(4-methoxyphenyl)-1H-imidazole (10i),66 
3-methoxy-N-[2-(4-methoxyphenyl)-2-oxo-ethyl]-benzamide (11ii),67 (2E)-1-(3-methoxyphenyl)-3-(4-
methoxyphenyl)prop-2-en-1-one (12ii),68 (2E)-1,3-bis(4-methoxyphenyl)prop-2-en-1-one (13ii),68 3,5-
bis-(4-methoxyphenyl)-1H-pyrazole (13i),69 4,4'-(1H-pyrazol-3,5-diyl)diphenol (13),46 3-(3-
methoxyphenyl)-5-(4-methoxyphenyl)isoxazole (14i),70 3-[5-(4-hydroxyphenyl)isoxazol-3-yl]phenol 
(14),71 3,5-bis-(4-methoxyphenyl)isoxazole (15i),71 4,4’-(isoxazol-3,5-diyl)diphenol (15),71 (2E)-3-(3-
methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (16ii),72 3-[3-(4-hydroxyphenyl)isoxazol-5-
yl]phenol (16),71 2,5-bis-(4-methoxyphenyl)-oxazole (17i).64 
 
General synthesis procedure for compounds 1i to 3i. A mixture of methoxyaniline (1 eq), 
methoxyphenacyl bromide (1 eq) and triethylamine (1 eq) were stirred at rt in 2 mL DMF for 7 h. The 
crude material was poured into ice water. The resulting precipitate was filtered, dried overnight in a 
desiccator. To a stirred solution of the precipitate (1 eq) in 20 mL methanol, potassium thiocyanate (1 
eq) and 60 µL concentrated chlorhydric acid were added. The resulting mixture was refluxed for 18 h. 
After cooling to rt, the precipitate was filtered off, dried overnight in a desiccator. The crude product 
was purified by CC. 
 
4-(3-Methoxyphenyl)-1-(4-methoxyphenyl)-1H-imidazol-2-thiol (1i). The title compound was 
prepared by reaction of para-methoxyaniline (751 mg, 6.11 mmol), 3-methoxyphenacyl bromide (1.38 
g, 6.11 mmol), triethylamine (0.89 mL, 6.11 mmol) and potassium thiocyanate (593 mg, 6.11 mmol) 
according to the procedure reported above. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 28 % (500 mg); yellow powder; mp: 248 °C; 1H NMR (CDCl3): 7.36 (d, J = 9.40 Hz, 2H), 7.30-
7.26 (m, 2H), 7.10 (d, J = 7.80 Hz, 2H), 6.84 (m, 1H), 6.81 (d, J = 8.80 Hz, 2H), 3.82 (s, 3H, OMe), 
3.72 (s, 3H, OMe); 13C NMR (CDCl3): 175.45, 160.05, 159.65, 129.70, 127.55, 117.45, 114.15 (2C), 
113.95, 110.00, 55.45, 55.40. IR: 1626, 1514, 1222, 1037, 824 cm-1; MS (APCI): 313 (M+H)+. 
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1-(3-Methoxyphenyl)-4-(4-methoxyphenyl)-1H-imidazol-2-thiol (3i). The title compound was 
prepared by reaction of meta-methoxyaniline (356 mg, 2.90 mmol), 4-methoxyphenacyl bromide (658 
mg, 2.90 mmol) and triethylamine (0.37 mL, 2.90 mmol), potassium thiocyanate (282 mg, 2.90 mmol) 
according to the procedure reported above. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 16 % (140 mg); white powder; mp: 250 °C; 1H NMR (CDCl3): 7.51 (d, J = 8.50 Hz, 2H), 7.38 (t, 
J = 7.80 Hz, 1H), 7.27 (s, 1H), 7.18 (d, J = 7.80 Hz, 1H), 7.02 (m, 1H), 6.97 (dd, J = 2.50 Hz and J = 
8.50 Hz, 1H), 6.89 (d, J = 8.50 Hz, 2H), 3.84 (s, 3H, OMe), 3.79 (s, 3H, OMe); 13C NMR (CDCl3): 
188.00, 160.00, 129.95, 126.50, 118.00, 114.65 (2C), 111.80, 55.60, 55.35; IR: 3055, 1601, 1455, 1181, 
825 cm-1; MS (ESI): 313 (M+H)+. 
 
4-(4-Methoxyphenyl)-1-(3-methoxyphenyl)-1H-imidazole (6i). The title compound was prepared by 
reaction of sodium nitrite (11 mg, 0.16 mmol, 1 eq), nitric acid (152 µL, 87 µmol, 0.5 eq) and 1-(3-
methoxyphenyl)-4-(4-methoxyphenyl)-1H-imidazol-2-thiol (3i) (150 mg, 0.48 mmol, 3 eq) mixed in 
glacial acetic acid (15 mL) at 0 °C and stirred for 20 min. The reaction was quenched with ammonium 
hydroxide (20 mL) and the resulting precipitate was filtered, dried overnight in a desiccator. The crude 
product was purified by CC (ethyl acetate/methanol 98:2); yield: 48 % (22 mg); yellow powder; mp: 
246 °C; 1H NMR (CDCl3): 8.90 (s, 1H) 7.60 (s, 1H), 7.53 (s, 1H), 7.48 (m, 3H), 7.32 (t, J = 7.80 Hz, 
1H), 7.02 (d, J = 8.50 Hz, 2H), 6.99 (dd, J = 1.80 Hz and J = 8.20 Hz, 1H), 3.95 (s, 3H, OMe), 3.85 (s, 
3H, OMe); 13C NMR (CDCl3): 161.15, 160.55, 136.15, 133.10, 130.20, 127.20, 123.85, 117.90, 117.15, 
115.85, 110.50, 56.25, 55.60; IR: 3200, 2966, 1520, 1255, 855 cm-1; MS (ESI): 281 (M+H)+. 
 
3-[4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl]phenol (8i). 3-Azidophenol (8ii) (500 mg, 3.70 mmol, 
1 eq), 1-ethynyl-4-methoxybenzene (489 mg, 3.70 mmol, 1 eq) were stirred in a mixture of water/t-
butanol (1:1, 20 mL) for 2 min. Copper(II)sulfate (9.24 mg, 0.04 mmol, 0.01 eq) was suspended in a 
freshly prepared solution of sodium ascorbate (1 M, 73.7 mg, 0.37 mmol, 0.1 eq) and added dropwise to 
the latter mixture. The reaction mixture was stirred at 60 °C for 24 h. After cooling to rt, the mixture 
was washed with water and the aqueous layer washed with ethyl acetate. The combined organic layers 
were dried over sodium sulfate and solvent was removed under reduced pressure. The crude product 
was purified by CC (ethyl acetate/methanol 9:1); yield: 37 % (350 mg); yellow powder; 1H NMR 
(CD3COCD3): 8.80 (s, 1H) 7.91 (d, J = 8.80 Hz, 2H), 7.46 (s, 1H), 7.41 (d, J = 7.90 Hz, 2H), 7.04 (d, J 
= 8.80 Hz, 2H), 6.96 (m, 1H), 3.85 (s, 3H, OMe); 13C NMR (CD3COCD3): 170.90, 159.45, 131.60, 
127.80 (2C), 118.50, 116.30, 115.10 (2C), 111.80, 108.10, 55.65; IR: 3148, 2928, 1614, 1499, 1257, 
833 cm-1. 
 
General synthesis procedure for compounds 9i to 11i. Benzamides 9ii to 11ii (1 eq) were refluxed in 
acetic acid (10 mL) with ammonium acetate (8 eq) for 2 h. Solvent was evaporated under reduced 
pressure and the crude product was suspended in a mixture of ethanol/water/dichloromethane (1:1:1). 
The dichloromethane layer was separated, washed with brine, dried over magnesium sulfate, evaporated 
under reduced pressure and purified by CC. 
 
2-(4-Methoxyphenyl)-5-(3-methoxyphenyl)-1H-imidazole (9i). The title compound was prepared by 
reaction of 3-methoxy-N-[2-(4-methoxyphenyl)-2-oxo-ethyl]-benzamide (9ii) (917 mg, 3.20 mmol) and 
ammonium acetate (1.90 g, 25.6 mmol) according to the procedure reported above. The product was 
purified by CC (hexane/ethyl acetate 5:5); yield: 25 % (224 mg); white powder; mp: 198 °C; 1H NMR 
(CD3SOCD3): 8.07 (d, J = 2.50 Hz, 1H), 7.98 (d, J = 8.50 Hz, 2H), 7.78 (d, J = 8.50 Hz, 1H), 7.57 (s, 
1H), 7.37 (s, 1H), 7.12-7.08 (m, 2H), 6.75 (s, 1H), 3.83 (s, 3H, OMe), 3.82 (s, 3H, OMe); 13C NMR 
(CD3SOCD3): 162.10, 160.85, 151.40, 137.50, 128.65 (2C), 127.25, 125.40, 123.35, 120.75, 115.75 
(2C), 113.70, 56.80, 56.50; IR: 3070, 2950, 1578, 1242, 742 cm-1; MS (ESI): 281 (M+H)+. 
 
2-(3-Methoxyphenyl)-5-(4-methoxyphenyl)-1H-imidazole (11i). The title compound was prepared by 
reaction of 3-methoxy-N-[2-(4-methoxyphenyl)-2-oxo-ethyl]-benzamide (11ii) (917 mg, 3.20 mmol) 
and ammonium acetate (1.90 g, 25.6 mmol) according to the procedure reported above. The product 
was purified by CC (hexane/ethyl acetate 5:5); yield: 6 % (54 mg); white powder; mp: 202 °C; 1H NMR 
(CDCl3): 8.04 (s, 1H), 7.85 (d, J = 8.20 Hz, 2H), 7.28-7.24 (m, 3H), 6.88 (d, J = 8.20 Hz, 2H), 6.78 (dq, 
J = 1.50 Hz and J = 7.60 Hz, 1H), 3.79 (s, 3H, OMe), 3.77 (s, 3H, OMe); 13C NMR (CDCl3): 164.00, 
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132.35 (2C), 130.15, 120.60, 119.85, 113.75, 112.65, 55.60, 55.50; IR: 3077, 2965, 1678, 1468, 1240, 
1031, 742 cm-1; MS (ESI): 281 (M+H).+. 
 
5-(4-Methoxyphenyl)-2-(3-methoxyphenyl)-oxazole (18i). The title compound was prepared by 
reaction of 3-methoxy-N-[2-(4-methoxyphenyl)-2-oxo-ethyl]-benzamide (9ii) (347 mg, 1.16 mmol, 1 
eq) and phosphorous oxychloride (12 mL, 0.89 mmol, 0.8 eq) in pyridine (20 mL) and refluxed for 8 h. 
After cooling to rt, ethyl acetate (40 mL) was added and the crude material was poured into a saturated 
sodium hydrogencarbonate solution. The aqueous layer was extracted two times with ethyl acetate. The 
combined organic layers were washed with brine, dried over magnesium sulfate, evaporated under 
reduced pressure and purified by CC (hexane/ethyl acetate 5:5); yield: 36 % (117 mg); yellow oil; 1H 
NMR (CD3COCD3): 7.79 (d, J = 8.80 Hz, 2H), 7.70 (dt, J = 1.00 Hz and J = 8.80 Hz, 1H), 7.64 (q, J = 
1.00 Hz, 1H), 7.53 (s, 1H, H-oxazole), 7.44 (t, J = 7.90 Hz, 1H), 7.08 (m, 3H), 3.90 (s, 3H, OMe), 3.86 
(s, 3H, OMe); 13C NMR (CD3COCD3): 161.05, 160.95, 152.40, 130.95, 129.85, 126.65, 123.15, 121.65, 
119.15, 116.95, 115.40, 111.85, 55.75, 55.70; IR: 2937, 1612, 1253, 1010, 872 cm-1. 
 
General synthesis procedure for compounds 12i and 13i (method A). A solution of hydrazine 
monohydrate (4 eq) in glacial acetic acid (4 eq) was added dropwise to the propenone intermediate 12ii 
and 13ii (1 eq). The reaction mixture was heated at reflux for 24 h. After cooling to rt, the precipitate 
was filtered off. A mixture of water/ethyl acetate (1:1) was added to the filtrate. The combined organic 
layers were washed with brine, dried over magnesium sulfate, evaporated under reduced pressure and 
purified by CC. 
 
3-(4-Methoxyphenyl)-5-(3-methoxyphenyl)-pyrazole (12i). The title compound was prepared by 
reaction of (2E)-1-(3-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (12ii) (250 mg, 0.93 
mmol) and hydrazine monohydrate (212 µL, 3.72.mmol) according to described method A. The product 
was purified by CC (hexane/ethyl acetate 5:5) followed by preparative TLC (dichloromethane/methanol 
99:1); yield: 25 % (60 mg); yellow oil; 1H NMR (CDCl3): 7.55 (d, J = 8.80 Hz, 2H), 7.21-7.19 (m, 2H), 
7.18 (t, J = 7.80 Hz, 1H), 6.78-6.75 (m, 3H), 6.62 (s, 1H), 3.74 (s, 3H, OMe), 3.62 (s, 3H, OMe); 13C 
NMR (CDCl3): 159.85, 159.55, 129.70, 126.85, 126.85, 118.10, 114.15 (2C), 114.10, 110.50, 99.35, 
55.20, 55.05; IR: 2933, 2837, 1601, 1439, 1250, 1033, 834 cm-1. 
 
General synthesis procedure for compounds 14i to 16i (method B): Propenone intermediate (12ii, 
13ii and 16ii, 1 eq) was stirred at 0 °C in 5 mL dry diethylether and bromine (1 eq) was added 
dropwise. After 1 h at 0 °C, the reaction was warmed up to rt, precipitate was filtered and washed with 
diethylether. The resulting di-brominated propenone was obtained in quantitative yield and used 
without further purification. The latter (1 eq) was refluxed in 10 mL absolute ethanol with 1 eq 
hydroxylamine hydrochloride and 1 eq potassium hydroxide for 24 h. After cooling to rt, the mixture 
was poured into a cold water solution. The resulting precipitate was filtered, washed with cold water, 
dried overnight in a desiccator and purified by CC. 
 
5-(3-Methoxyphenyl)-3-(4-methoxyphenyl)-isoxazole (16i). The title compound was prepared by 
reaction of (2E)-3-(3-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (16ii) (275 mg, 1.03 
mmol), bromine (52 µL, 1.03 mmol), hydroxylamine hydrochloride (71.6 mg, 1.03.mmol) and 
potassium hydroxide (57.8 mg, 1.03 mmol) according to method B. The product was purified by CC 
(hexane/ethyl acetate 9:1) followed by preparative TLC (dichloromethane/methanol 1%); yield: 45 % 
(130 mg); yellow powder; mp: 161 °C; 1H NMR (CDCl3): 7.20 (m, 2H), 6.75 (dd, J = 2.00 Hz and J = 
7.50 Hz, 1H), 6.80 (d, J = 7.50 Hz, 1H), 6.76 (s, 1H), 6.74 (s, 1H), 6.70 (m, 1H), 6.45 (d, J = 7.50 Hz, 
2H), 3.72 (s, 3H, OMe), 3.56 (s, 3H, OMe); 13C NMR (CDCl3): 171.65, 164.15, 162.40, 161.25, 131.80, 
131.20, 128.70 (2C), 121.60, 120.60, 117.35, 115.70, 113.00, 97.50; IR: 2925, 2853, 1602, 1248, 746 
cm-1. 
 
4-(4-Methoxyphenyl)-2-(3-methoxyphenyl)oxazole (19i). 4-Methoxy-acetophenone (500 mg, 3.33 
mmol, 1 eq) was refluxed for 2 h together with [hydroxy(2,4-dinitrobenzensulfonyloxy)-iodo]benzene 
(1.88 g, 3.99 mmol, 1.2 eq) in acetonitrile (20 mL). After cooling to rt, 3-methoxybenzamide (1.52 g, 
9.99 mmol, 3 eq) was added and the reaction mixture was refluxed for 10 h. Acetonitrile was 
evaporated under reduced pressure. The crude product was suspended in dichloromethane. The 
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resulting organic layer was washed with a saturated sodium bicarbonate solution and dried over 
magnesium sulfate. Solvent was removed under reduced pressure and the product was purified by CC 
(hexane/ethyl acetate 7:3); yield 50 % (465 mg); white powder; mp: 165 °C; 1H NMR (CD3COCD3): 
8.23 (s, 1H, H-oxazole), 7.90 (d, J = 9.20 Hz, 2H), 7.32 (m, 2H), 7.20 (t, J = 7.50 Hz, 1H), 6.93 (d, J = 
9.20 Hz, 2H), 6.76 (m, 1H), 3.73 (s, 3H, OMe), 3.70 (s, 3H, OMe); IR: 3015, 2925, 1625, 789 cm-1. 
 
Ether cleavage - general procedure for compounds 1 to 6 and 9 to 11: To a solution of bis-
methoxyphenyl derivative (1 eq) in dry dichloromethane was added dropwise boron trifluoride dimethyl 
sulfide complex (75 eq). The reaction mixture was stirred at rt for 20 h. To quench the reaction water 
was added and the aqueous layer was washed with ethyl acetate. The combined organic layers were 
washed with brine, dried over sodium sulfate, evaporated under reduced pressure and purified by 
preparative TLC.  
 
3-[1-(4-Hydroxyphenyl)-2-sulfanyl-1H-imidazol-4-yl]phenol (1). The title compound was prepared 
by reaction of 4-(3-methoxyphenyl)-1-(4-methoxyphenyl)-1H-imidazol-2-thiol (1i) (100 mg, 0.32 
mmol) according to the procedure reported above. The product was purified by preparative TLC (ethyl 
acetate); yield: 61 % (55 mg); orange powder; mp: 265 °C; 1H NMR (CD3SOCD3): 12.76 (s, 1H, SH), 
7.64 (s, 1H), 7.39 (d, J = 8.50 Hz, 2H), 7.19-7.15 (m, 2H), 7.09 (s, 1H), 6.84 (d, J = 8.50 Hz, 2H), 6.71-
6.69 (m, 1H); 13C NMR (CD3SOCD3): 162.30, 157.60, 156.85, 129.90, 129.20, 128.95, 127.15, 116.15, 
115.10 (2C), 114.85, 111.10; IR: 3214, 1604, 1514, 1395, 1101, 833, 750 cm-1; MS (APCI): 284 (M)+; 
Anal. calcd C15H12N2O2S C. 63.36; H, 4.25; N, 9.85. Found C, 63.20; H, 3.99; N, 9.80. 
 
4,4'-(2-Sulfanyl-1H-imidazol-1,4-diyl)diphenol (2). The title compound was prepared by reaction of 
1,4-bis-(4-methoxyphenyl)-1H-imidazol-2-thiol (2i) (100 mg, 0.32 mmol) according to the procedure 
reported above. The product was purified by preparative TLC (ethyl acetate); yield: 36 % (35 mg); 
white powder; mp: 268 °C; 1H NMR (CD3OD): 7.49 (d, J = 8.80 Hz, 2H) 7.42 (d, J = 8.80 Hz, 2H), 
7.34 (s, 1H), 6.92 (d, J = 8.80 Hz, 2H), 6.87 (d, J = 8.80 Hz, 2H); 13C NMR (CD3OD): 162.00, 159.05, 
158.80, 131.20, 131.10, 131.00, 128.55, 127.30, 120.55, 116.90, 116.50, 115.95; IR: 3135, 2469, 2072, 
1511, 1116, 973, 836 cm-1; MS (APCI): 284 (M)+, 285 (M+H)+; Anal. calcd C15H12N2O2S. C, 63.36; H, 
4.25; N, 9.85. Found C, 63.40; H, 4.24; N, 9.95. 
 
3-[4-(4-Hydroxyphenyl)-2-sulfanyl-1H-imidazol-1-yl]phenol (3). The title compound was prepared 
by reaction of 1-(3-methoxyphenyl)-4-(4-methoxyphenyl)-1H-imidazol-2-thiol (3i) (100 mg, 0.32 
mmol) according to the procedure reported above. The product was purified by preparative TLC (ethyl 
acetate); yield: 37 % (40 mg); yellow powder; 1H NMR (CD3SOCD3): 12.75 (s, 1H, SH), 7.62 (s, 1H), 
7.40 (d, J = 8.50 Hz, 2H), 7.18-7.13 (m, 2H), 7.07 (s, 1H), 6.83 (d, J = 8.50 Hz, 2H), 6.69-6.66 (m, 1H); 
13C NMR (CD3SOCD3): 162.35, 157.65, 156.95, 129.85, 129.00, 128.90, 127.20, 116.20 (2C), 115.05, 
114.90, 111.25; IR: 3213, 1600, 1514, 1392, 1100, 845, 750 cm-1; MS (APCI): 284 (M)+; Anal. calcd 
C15H12N2O2S. C, 63.36; H, 4.25; N, 9.85. Found C, 63.12; H, 4.22; N, 9.84. 
 
3-[1-(4-Hydroxyphenyl)-1H-imidazol-4-yl]phenol (4). The title compound was prepared by reaction 
of 4-(3-methoxyphenyl)-1-(4-methoxyphenyl)-1H-imidazole (4i) (100 mg, 0.36 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (ethyl acetate); yield: 28 % (25 
mg); yellow oil; 1H NMR (CD3COCD3): 9.32 (d, J = 1.20 Hz, 1H), 8.33 (d, J = 1.20 Hz, 1H), 7.70 (dd, 
J = 2.20 Hz and J = 8.80 Hz, 2H), 7.36-7.33 (m, 2H), 7.29 (t, J = 1.90 Hz, 1H), 7.06 (dd, J = 2.20 Hz 
and J = 8.80 Hz, 2H), 6.99 (m, 1H); 13C NMR (CD3COCD3): 159.70, 158.95, 134.95, 131.60, 129.10, 
128.10, 124.95, 118.25, 117.95, 117.80, 117.35, 113.35; IR: 3563, 1684, 1629, 1048, 836 cm-1; MS 
(ESI): 253 (M+H)+; Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 71.11; H, 4.62; N, 
11.01. 
 
4,4’-bis-(1H-Imidazol-1,4diyl)-diphenol (5). The title compound was prepared by reaction of 1,4-bis-
(4-methoxyphenyl)-1H-imidazole (5i) (100 mg, 0.36 mmol) according to the procedure reported above. 
The product was purified by preparative TLC (ethyl acetate), yield: 26 % (24 mg); yellow powder; 1H 
NMR (CD3COCD3): 9.43 (d, J = 1.50 Hz, 1H), 8.32 (d, J = 1.50 Hz, 1H), 7.74 (dd, J = 2.20 Hz and J = 
8.80 Hz, 2H), 7.71 (dd, J = 2.20 Hz and J = 8.80 Hz, 2H), 7.10 (dd, J = 2.20 Hz and J = 8.80 Hz, 2H), 
7.08 (dd, J = 2.20 Hz and J = 8.80 Hz, 2H); 13C NMR (CD3COCD3): 160.40, 128.70 (2C), 125.30, 
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117.70 (2C), 117.45 (2C), 117.25; IR: 3563, 3155, 1684, 1048, 931, 836 cm-1; MS (ESI): 253 (M+H)+; 
Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 71.43; H, 4.85; N, 11.11. 
 
3-[4-(4-Hydroxyphenyl)-1H-imidazol-4-yl]phenol (6). The title compound was prepared by reaction 
of 4-(4-methoxyphenyl)-1-(3-methoxyphenyl)-1H-imidazole (6i) (100 mg, 0.36 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (ethyl acetate); yield: 26 % (24 
mg); yellow oil; 1H NMR (CD3COCD3): 9.50 (d, J = 1.50 Hz, 1H), 8.40 (d, J = 1.50 Hz, 1H), 7.77 (m, 
2H), 7.50 (t, J = 8.20 Hz, 1H), 7.36-7.34 (m, 2H), 7.16 (dd, J = 2.20 Hz and J = 8.80 Hz, 1H), 7.04 (dt, 
J = 2.20 Hz and J = 8.20 Hz, 2H); 13C NMR (CD3COCD3): 137.45, 132.50, 128.80 (2C), 118.35, 
117.50, 114.35, 110.70; IR: 3542, 3160, 2955, 1699, 1630, 1062, 841 cm-1; MS (ESI): 253 (M+H)+; 
Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 71.59; H, 4.92; N, 10.97. 
 
3-[2-(4-Hydroxyphenyl)-1H-imidazol-5-yl]phenol (9). The title compound was prepared by reaction 
of 2-(4-methoxyphenyl)-5-(3-methoxyphenyl)-1H-imidazole (9i) (40 mg, 0.14 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 45 % (15 mg); yellow powder; 1H NMR (CD3COCD3): 8.58 (s, 1H), 7.42 (t, J = 7.80 Hz, 2H), 
7.40 (m, 1H), 7.33 (m, 1H), 7.27 (t, J = 7.80 Hz, 2H), 7.05 (dd, J = 0.90 Hz and J = 1.50 Hz, 1H), 6.90 
(dd, J = 0.90 Hz and J = 1.50 Hz, 1H), 6.47 (s, 1H, N-H); 13C NMR (CD3COCD3): 168.95, 168.90, 
158.25, 137.90, 136.95, 130.10 (2C), 119.40, 119.10, 118.70, 115.25; IR: 3450, 2950, 1604, 1580, 785 
cm-1. MS (ESI): 253 (M+H)+; Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 71.23; H, 
4.64; N, 10.98. 
 
4,4'-(1H-Imidazol-2,5-diyl)diphenol (10). The title compound was prepared by reaction of 2,5-bis-(4-
methoxyphenyl)-1H-imidazole (10i) (82 mg, 0.29 mmol) according to the procedure reported above. 
The product was purified by preparative TLC (dichloromethane/methanol 99:1); yield: 17 % (12 mg); 
yellow powder; 1H NMR (CD3OD): 7.83 (d, J = 8.70 Hz, 2H), 7.62 (d, J = 8.70 Hz, 2H), 7.60 (s, 1H), 
7.03 (d, J = 8.70 Hz, 2H), 6.92 (d, J = 8.70 Hz, 2H); 13C NMR (CD3OD): 131.30, 129.15, 120.15 (2C), 
119.80 (2C), 115.55 (2C), 114.75 (2C), 114.30; IR: 2590, 1645, 1488, 1114, 841 cm-1; MS (ESI): 253 
(M+H)+; Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 71.30; H, 4.52; N, 11.00. 
 
3-[5-(4-Hydroxyphenyl)-1H-imidazol-2-yl]phenol (11). The title compound was prepared by reaction 
of 2-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1H-imidazole (11i) (40 mg, 0.14 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 45 % (15 mg); yellow powder; 1H NMR (CD3COCD3): 8.56 (s, 1H), 7.40 (t, J = 7.80 Hz, 2H), 
7.39 (m, 1H), 7.37 (m, 1H), 7.25 (t, J = 7.80 Hz, 2H), 6.99 (dd, J = 0.90 Hz and J = 1.50 Hz, 1H), 6.97 
(dd, J = 0.90 Hz and J = 1.50 Hz, 1H), 6.47 (s, 1H, NH); 13C NMR (CD3COCD3): 168.95, 168.90, 
158.25, 137.95, 136.90, 130.15 (2C), 119.30 (2C), 118.95, 115.40; IR: 3350, 3045, 2922, 1664, 1582, 
760 cm-1; MS (ESI): 253 (M+H)+; Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 
71.42; H, 4.89; N, 11.08. 
 
Ether cleavage – general synthesis for compounds 12, 18 and 19: To a solution of 
bis(methoxyphenyl) derivative (1 eq) in dry dichloromethane at -78°C (dry ice /acetone bath), boron 
tribromide (1 M in dichloromethane, 6 eq) were added dropwise and the reaction mixture was stirred for 
20 h. To quench the reaction, water was added and the aqueous layer was washed with ethyl acetate. 
The combined organic layers were washed with brine, dried over sodium sulfate, evaporated under 
reduced pressure and purified by preparative TLC. 
 
3-[3-(4-Hydroxyphenyl)-1H-pyrazol-5-yl]phenol (12). The title compound was prepared by reaction 
of 3-(4-methoxyphenyl)-5-(3-methoxyphenyl)-pyrazole (12i) (82 mg, 0.29 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (dichloromethane/methanol 
92:8); yield: 55 % (40 mg); orange powder; mp: 262 °C; 1H NMR (CD3OD): 7.65 (d, J = 8.50 Hz, 2H), 
7.22 (m, 1H), 6.83 (d, J = 8.50 Hz, 2H), 6.81 (s, 1H), 6.72-6.74 (m, 3H); 13C NMR (CD3OD): 160.50, 
131.85, 122.10, 122.10, 117.05, 116.80, 116.00, 113.30 (2C), 102.15; IR: 3500, 2935, 1620, 790 cm-1; 
MS (ESI): 253 (M+H)+; Anal. calcd C15H12N2O2. C, 71.42; H, 4.79; N, 11.10. Found C, 71.38; H, 4.71; 
N, 11.25. 
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3-[5-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol (18). The title compound was prepared by reaction of 
5-(4-methoxyphenyl)-2-(3-methoxyphenyl)-oxazole (18i) (100 mg, 0.35 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 65 % (59 mg); yellow powder; 1H NMR (CD3COCD3): 8.80 (s, 1H, OH), 8.75 (s, 1H, OH), 7.69 
(d, J = 8.20 Hz, 2H), 7.60 (m, 2H), 7.46 (s, 1H, H-oxazole), 7.35 (t, J = 8.20 Hz, 1H), 6.98-6.95 (m, 
3H); 13C NMR (CD3COCD3): 160.90, 158.95, 158.75, 152.55, 130.95, 129.80, 126.80, 122.50, 120.65, 
118.25 (2C), 118.15, 116.85, 115.40, 113.55; IR: 3480, 1602, 1510, 852 cm-1; MS (ESI): 254 (M+H)+; 
Anal. calcd C15H11NO3. C, 71.14; H, 4.38; N, 5.53. Found C, 70.92; H, 4.35; N, 5.60. 
 
3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol (19). The title compound was prepared by reaction of 
4-(4-methoxyphenyl)-2-(3-methoxyphenyl)oxazole (19i) (100 mg, 0.36 mmol) according to the 
procedure reported above. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 82 % (74 mg); yellow powder; 1H NMR (CD3COCD3): 8.27 (s, 1H, H-oxazole), 7.93 (d, J = 8.50 
Hz, 2H), 7.37 (s, 1H), 7.33 (d, J = 7.60 Hz, 1H), 7.20 (t, J = 7.60 Hz, 1H), 6.97 (d, J = 8.50 Hz, 2H), 
6.79 (m, 1H); 13C NMR (CD3COCD3): 161.80, 159.70, 157.75, 141.55, 133.70, 132.90, 129.70, 128.05, 
119.25, 116.70, 115.75, 114.90, 112.35; IR: 3300, 1595, 1259, 804 cm-1; MS (ESI): 252 (M-H)-; Anal. 
calcd C15H11NO3. C, 71.14; H, 4.38; N, 5.53. Found C, 71.00; H, 4.48; N, 5.58. 
 
4,4'-(1,3-Oxazol-2,5-diyl)diphenol (17). The title compound was prepared by reaction of 2,5-bis-(4-
methoxyphenyl)-oxazole (17i) (260 mg, 0.90 mmol, 1 eq) and pyridinium hydrochloride (2.90 g, 25.7 
mmoles, 37 eq) heated to 220 °C for 18 h. After cooling to rt, water (10 mL) and ethyl acetate (20 mL) 
were added. The aqueous layer was washed with ethyl acetate. The combined organic layers were dried 
over sodium sulfate, filtered, evaporated under reduced pressure and purified by preparative TLC 
(hexane/ethyl acetate 5/5); yield: 82 % (186 mg), yellow powder; mp: 163 °C; 1H NMR (CD3OD): 7.89 
(d, J = 7.80 Hz, 2H), 7.60 (d, J = 8.80 Hz, 2H), 7.32 (s, 1H), 6.91-6.86 (m, 4H); 13C NMR (CD3OD): 
162.35, 161.30, 159.35, 152.78, 132.80, 129.00 (2C), 126.80 (2C), 125.80 (2C), 116.90 (2C); IR: 3387, 
1611, 1506, 1170, 834 cm-1; MS (ESI): 254 (M+H)+; Anal. calcd C15H11NO3. C, 71.14; H, 4.38; N, 
5.53. Found C, 71.02; H, 4.18; N, 5.63. 
 
Biological Methods 
 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described 
procedures.40, 73 Fresh human placenta was homogenised and the enzymes were separated by 
centrifugation. For the purification of 17β-HSD1, the cytosolic fraction was precipitated with 
ammonium sulfate. 17β-HSD2 was obtained from the microsomal fraction. 
 
1. Inhibition of 17β-HSD1 
 
Inhibitory activities were evaluated by an established method with minor modifications.54, 74, 75 Briefly, 
the enzyme preparation was incubated with NADH [500µM] in the presence of potential inhibitors at 
37 °C in a phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA 1mM. Inhibitor 
stock solutions were prepared in DMSO. The final concentration of DMSO was adjusted to 1 % in all 
samples. The enzymatic reaction was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]-
E1 (final concentration: 500 nM, 0.15 µCi). After 10 min, the incubation was stopped with HgCl2 and 
the mixture was extracted with diethylether. After evaporation, the steroids were dissolved in 
acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse 
phase chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a 
HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of 
the steroids were performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The 
conversion rate was calculated after analysis of the resulting chromatograms according to following 
equation: 100)1()2(
)2(% ×
+
=
EAUCEAUC
EAUC
conversion . Each value was calculated from at least 
three independent experiments.  
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2. Inhibition of 17β-HSD2 
 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal 
fraction was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 
7-3H]-E2 (final concentration: 500 nM, 0.11 µCi) for 20 min at 37°C. Further treatment of the samples 
and HPLC separation was carried out as mentioned above. 
The conversion rate was calculated after analysis of the resulting chromatograms according to following 
equation: 100)2()1(
)1(% ×
+
=
EAUCEAUC
EAUC
conversion . 
 
3. ER affinity 
 
The binding affinity of select compounds to the ERα and ERβ was determined according to 
Zimmermann et al.76 Briefly, 0.25 pmol of ERα or ERβ, respectively, were incubated with [2, 4, 6, 7-
3H]-E2 (10 nM) and test compound for 1 h at room temperature. The potential inhibitors were dissolved 
in DMSO (5 % final concentration). Non-specific-binding was performed with diethylstilbestrol (10 
µM). After incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 
mL TE-buffer). The complex formed was separated, washed and resuspended in ethanol. For 
radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and 
samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). For 
determination of the relative binding affinity (RBA), inhibitor and E2 concentrations required to 
displace 50 % of the receptor bound labelled E2 were determined. RBA values were calculated 
according to the following equation: [ ] ( )( ) 100
2%
50
50
×=
compoundIC
EICRBA . The RBA value for E2 was 
arbitrarily set at 100 %. 
 
4. T-47D cell assays 
 
4.1  Evaluation of the estrogenic activity 
 
Phenol red-free medium was supplemented with sodium bicarbonate (2 g/L), streptomycin (100 
µg/mL), insuline zinc salt (10 µg/mL), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 
U/mL) and DCC-FCS 5% (vol/vol). RPMI 1640 (without phenol red) was used for the experiments. 
Cells (7500 cells/96-wellplate) were grown for 48 h in phenol red-free medium. Compound 18 was 
added at a final concentration of 100 nM. Inhibitors and E2 were diluted in ethanol (final ethanol 
concentration was adjusted to 1%). As a positive control E2 was added at a final concentration of 0.1 
nM. Ethanol was used as negative control. Medium was changed every two to three days and 
supplemented with the respective additive. After eight days of incubation, the cell viability was 
evaluated measuring the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide 
(MTT). The cleavage of MTT to a blue formazan by mitochondrial succinat-dehydrogenase was 
quantified spectrophotometrically at 590 nm as described by Denizot and Lang77 with minor 
modifications. The control proliferation was arbitrarily set at 1 and the stimulation induced by the 
inhibitor was calculated according to following equation: 
( )[ ]
( )[ ] %10012
1% ×
−−
−−
=
inducedEionproliferat
inducedcompoundionproliferat
nstimulatio . Each value is calculated as a 
mean value of at least three independent experiments.  
 
4.2  Evaluation of the 17β-HSD1 activity 
 
A stock culture of T-47D cells was grown in RPMI 1640 medium supplemented with 10 % FCS, L-
glutamine (2 mM), penicillin (100 IU/mL), streptomycin (100 µg/mL), insulin-zinc-salt (10 µg/mL) and 
sodium pyruvate (1 mM) at 37 °C under 5 % CO2 humidified atmosphere. 
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The cells were seeded into a 24-well plate at 1x106 cells/well in DMEM medium with FCS, L-
glutamine and the antibiotics added in the same concentrations as mentioned above. After 24 h the 
medium was changed for fresh serum free DMEM and a solution of test compound in DMSO was 
added. Final concentration of DMSO was adjusted to 1 % in all samples. After a pre-incubation of 30 
min at 37°C with 5 % CO2, the incubation was started by addition of a mixture of unlabelled- and [2, 4, 
6, 7-3H]- E1 (final concentration : 50 nM, 0.15 µCi). After 2.5 h incubation, the enzymatic reaction was 
stopped by removing of the supernatant medium. The steroids were extracted into diethylether. Further 
treatment of the samples was carried out as mentioned for the 17β-HSD1 assay. 
 
5. CaCo-2 assay 
 
CaCo-2 cell culture and transport experiments were performed according to Yee78 with small 
modifications. Cell culture time was reduced from 21 to 10 days by increasing seeding density from 
6.3·104 to 1.65·105 cells per well. Four reference compounds (atenolol, testosterone, ketoprofen, 
erythromycin) were used in each assay for validation. The compounds were applied to the cells as a 
mixture (cassette dosing) to increase the throughput. The initial concentration of the compounds in the 
donor compartment was 50 µM (0.2 M MES, pH: 6.5, containing either 1 % ethanol or DMSO). 
Samples were taken from the acceptor side after 0 min, 60, 120 and 180 min and from the donor side 
after 0 and 180 min. Each experiment was run in triplicate. The integrity of the monolayers was 
checked by measuring the transepithelial electrical resistance (TEER) before the transport experiments 
and by measuring lucifer yellow permeability after each assay. All samples of the CaCo-2 transport 
experiments were analysed by LC/MS/MS after dilution with buffer of the opposite transwell chamber 
(1:1, containing 2 % acetic acid). The apparent permeability coefficients (Papp) were calculated using 
equation
0
app P
dtAc
dQ
= , where 
dt
dQ
 is the appearance rate of mass in the acceptor compartment, A the 
surface area of the transwell membrane, and c0 the initial concentration in the donor compartment. 
 
Molecular Modeling 
 
The X-ray structure of 17β-HSD1 (PDB-code: 1FDT) was obtained from the Protein Data Bank.44 
Water molecules, E2 and sulfate ions were removed from the PDB file and hydrogen atoms and neutral 
end groups were added. Close contacts were fixed (Arg37) and correct atom types were set.  
Docking of inhibitors into the substrate binding site was performed by the automated docking program 
GOLD 3.0.79 
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Paper II 
 
 
abstract: 17β Hydroxysteroid dehydrogenase type 1 (17β-HSD1) is responsible for the 
catalytic reduction of the weak estrogen estrone (E1) into the highly potent 17β-estradiol (E2). 
As 17β-HSD1 is often overexpressed in mammary tumors and endometriosis, the selective 
inhibition of this enzyme is discussed as a promising approach for the treatment of estrogen-
dependent diseases. Recently, we reported on bis(hydroxyphenyl)azoles as a new class of 
potent inhibitors of 17β-HSD1. In this paper, we focused on bis(hydroxyphenyl)triazoles. The 
influence of nitrogens on the potency as well as the space available around the heterocycle was 
investigated. Substituents were introduced on the triazole core in order to establish additional 
interactions with the enzyme active site. The compounds were evaluated for activity towards 
17β-HSD1 and selectivity with regard to 17β-HSD2, the enzyme which is responsible for the 
deactivation of E2 into E1. 3-[4-(4-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl]phenol (3) was the 
most active compound discovered in this study with an IC50 value of 840 nM and a reasonable 
selectivity toward 17β-HSD2. 
 
Introduction 
 
Estrogens are responsible for the development and differentiation of estrogen-sensitive tissues. 
Furthermore, it is well known that 17β-estradiol (E2), the most active estrogen, also plays a 
crucial role in the growth of estrogen-dependent mammary tumors1 and is involved in the 
pathophysiology of endometriosis.2 
The potency of steroidal sex hormones like E2 is modulated by enzymes of the 17β-
hydroxysteroid dehydrogenase (17β-HSD) family,3 especially 17β-HSD1 and 17β-HSD2, 
which catalyze the activation of E2 from estrone (E1) or the deactivation of E2 into E1, 
respectively (Chart 1). 17β-HSD1 is a cytosolic enzyme present in different organs like 
ovaries, placenta, breast, endometrium4 which is often overexpressed in breast cancer tissues5-8 
and endometriosis.9 Consequently, selective inhibition of 17β-HSD1 is discussed to be a good 
strategy to reduce the intracellular E2 levels and regarded as a new therapeutic approach for the 
treatment of estrogen-dependent diseases. As a biological counterpart, 17β-HSD2 should not 
be affected by potential inhibitors of 17β-HSD1, as it protects the cell from excessively high 
concentrations of active estrogens.10  
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Chart 1: interconversion of estrone (E1) to 17β-estradiol (E2) 
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Until now, several groups have reported on 17β-HSD1 inhibitors, most of them showing 
steroidal structures.11,12 Concerning the non-steroidal cores, only four compound classes have 
been described so far: thienopyrimidinones,13, 14 biphenyl ethanones,15 from our group 6-
(hydroxyphenyl) naphthols16,17 and recently, we reported on bis(hydroxyphenyl) azoles19 as 
potent and selective inhibitors of 17β-HSD1. Different core structures were investigated (Chart 
2): imidazoles like compounds A and B, pyrazoles like compound C and oxazoles like 
compound D. The most active was compound D with an IC50 value of 310 nM and a selectivity 
factor of 56 against 17β-HSD2. 
 
Chart 2: described bis(hydroxyphenyl) azoles 
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In the following, we will report on the design, synthesis and biological evaluation of a new 
family of azoles: bis(hydroxyphenyl) triazoles (Chart 3). 
 
Chart 3: title compounds 
 
N
N
N
N
N N
R1
R2
1-3 R1
R2
4-9
R
 
 
compound R R1 R2 
1  3-OH 3-OH 
2  4-OH 3-OH 
3  3-OH 4-OH 
4 CH3 3-OH 3-OH 
5 CH3 4-OH 3-OH 
6 CH3 3-OH 4-OH 
7 Ph 3-OH 3-OH 
8 Ph 4-OH 3-OH 
9 Ph 3-OH 4-OH 
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Design of the inhibitors 
 
The analysis of the available ternary complex of 17β-HSD1 with E2 and NADP+ (PDB-ID: 
1FDT;18 provided useful informations about the architecture of the active site of the enzyme. A 
substrate binding site and a cofactor binding pocket can be defined. The former is a narrow 
hydrophobic tunnel containing two polar areas at each end. His221/Glu282 are located on the 
one side and Ser142/Tyr155 on the other side, corresponding to the binding oxygens in 3- and 
17-hydroxy group of E2. Interestingly, close to the hydrophobic B/C region of the estrogen two 
polar amino acids, Tyr218 and Ser222, can be found which do not interact with the steroid. 
In our design concept, we focused on non-steroidal structures to avoid binding to other steroid 
receptors. The compounds should be able to mimic the substrate of the enzyme. We have 
previously reported on the importance of the two hydroxyphenyl moieties present in our 
steroidomimetics.19 The positions of the OH substituents on the phenyl groups is decisive for 
the inhibitory potency of the compounds: only inhibitors bearing a meta-para di-OH 
substitution pattern (O-O distance in the same range as observed for the steroid, d= 11 Å) were 
active probably due to the establishment of hydrogen bond interactions with His221/Glu282 
and Ser142/Tyr155. Meta-meta disubstituted compounds which were not investigated so far 
might also show a favorable geometry to establish these interactions. 
Furthermore, the nature of the heterocycle present between the two hydroxyphenyl moieties 
also influences the activity of the compounds. Heterocycles like oxazole D which can act as 
hydrogen bond acceptors were active while inhibitors bearing a H-bond donator function (NH) 
like 2,4-disubstituted imidazoles (e.g. compound B) and 3,5-disubstituted pyrazoles (e.g. 
compound C) were devoid of activity. It was hypothesized that the activity of compound D 
was linked to its ability to establish hydrogen bond interaction with Tyr218 and/or Ser222.19  
It is striking that 1,4-disubstituted imidazoles like compound A, although pure hydrogen bond 
acceptors, were inactive. To obtain an insight into the impact of an additional nitrogen atom 
and on distribution of the nitrogen atoms in the central ring on inhibitory activity, 1,2,3-
triazoles 1-3 and 1,2,4-triazoles 4-9 were designed. 
In addition, a non polar substituent was introduced on the heterocycle, anticipating 
supplementary hydrophobic interactions with amino acid residues of the substrate binding site. 
Compounds 4-9 bearing a methyl or a phenyl on the triazole core could give additional 
informations on the feasibility of these interactions (π-stacking interactions with Tyr218 for 
example in case of compounds 7-9) as well as on the space available around the heterocycle.  
 
Chemistry 
 
1,2,3-Triazoles 1-3 were obtained according to the synthetic pathway previously described by 
Bey et al.19 
 
The synthesis of 1,2,4-triazoles 4-9 is presented in Scheme 1. Starting from the N-acylimidates 
4b-6b prepared according to the method described by Kelarev et al.,21 the dimethoxylated 
1,2,4-triazoles 4a-9a were synthesized by nucleophilic addition of methylhydrazine for 
compounds 4a-6a and phenylhydrazine for compounds 7a-9a. The deprotection of the 
methoxy groups of compounds 4a-9a was performed with borontrifluoride dimethyl sulfide 
complex.19 
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Scheme 1a: synthesis of compounds 4-9 
 
Cl
O
NH
OEt
N
O OEt
N
NN
R
N
NN
R
+
R1
R2
a
R1
R2
b
OH
R1
R2
c
HO
4a: R1= 3-OMe, R2= 3-OMe
5a: R1= 4-OMe, R2= 3-OMe
6a: R1= 3-OMe, R2= 4-OMe
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9a: R1= 3-OMe, R2= 4-OMe
4b-6b 4a-9a 4-6 R= CH3
7-9 R= Ph
 
 
aReagents and conditions: (a) CH2Cl2, NEt3, 30-40 °C, 6 h; (b) for compounds 4a-6a H3CNHNH2 and for 
compounds 7a-9a PhNHNH2, CH2Cl2, 30-40 °C, 4 h; (c) BF3·SMe2, CH2Cl2, rt , 20 h. 
 
Inhibition of human 17β-HSD1 and 17β-HSD2 
 
The 17β-HSD1 and 17β-HSD2 inhibition assays were carried out following a previously 
described procedure.19 Briefly, the cytosolic (17β-HSD1) or microsomal (17β-HSD2) fraction 
of human placental was incubated with tritiated substrate, cofactor and inhibitor at 37 °C. After 
HPLC separation of substrate and product, the amount of radiolabeled E2 (17β-HSD1) or E1 
(17β-HSD2) formed was quantified. The inhibition values of compounds 1-9 are shown in 
Table 1.  
The meta-meta disubstituted 1,2,3-triazole 1 is a weak inhibitor of 17β-HSD1 (17 % inhibition 
at 1 µM). Shifting one group from the meta to the para position (compounds 2 and 3) leads to 
an increase in activity, compound 3 being the most active one (IC50= 0.84 µM and 1.32 µM for 
3 and 2, respectively). Concerning selectivity, the 1,2,3-triazoles 2 and 3 are very weak 
inhibitors of the type 2 enzyme (IC50= 8.12 µM and 7.28 µM, respectively). 
None of the 1,2,4-triazoles (compounds 4-9) shows inhibition of 17β-HSD1. Surprisingly, the 
N-1 phenyl substituted 1,2,4-triazoles (compounds 7 and 8) are selective inhibitors of 17β-
HSD2 (44 % and 41 % inhibition at 1 µM, respectively). 
The introduction of an additional nitrogen into the inactive imidazole core structure (compound 
A) enhances inhibition of 17β-HSD1 strongly (compound 2, IC50= 1.32 µM) whereas a 
supplementary substituent (methyl for compounds 4-6 and phenyl for compounds 7-9) is 
obviously not tolerated by the enzyme. 
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Table 1: inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 1-9 
N
N
N
N
N N
R1
R2
1-3 R1
R2
4-9
R
 
compound R R1 R2 
IC50 value (µM)a 
17β-HSD1b 17β-HSD2c 
1  3-OH 3-OH 17d ni 
2  4-OH 3-OH 1.32 8.12 
3  3-OH 4-OH 0.84 7.28 
4 CH3 3-OH 3-OH ni ni 
5 CH3 4-OH 3-OH ni 20d 
6 CH3 3-OH 4-OH ni 21d 
7 Ph 3-OH 3-OH ni 41d 
8 Ph 4-OH 3-OH ni 44d 
9 Ph 3-OH 4-OH ni ni 
 
aMean values of three determinations, standard deviation less than 18 %; bHuman placental, cytosolic fraction, 
substrate [3H]-E1 + E1 [500 nM], cofactor NADH [500 µM]; cHuman placental, microsomal fraction, substrate 
[3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 µM]; d% inhibition at 1 µM; ni: no inhibition (<10 % inhibition at 1 
µM). 
 
Discussion and conclusion 
 
As already mentioned in a previous report,19 the OH substitution pattern on the phenyl ring is a 
decisive criterion for inhibitory activity. The distance between the meta-meta hydroxy group 
(compound 1) which is shorter compared to the para-meta (compound 2) and the meta-para 
(compound 3) might be one explanation for the lower activity of compound 1.  
Varying the heterocycle, two active 1,2,3-triazoles 2 and 3 have been identified. They differ 
from the inactive 1,4-disubstituted imidazole (compound A) by the presence of an additional 
nitrogen in position 2. It is interesting that the introduction of this supplementary heteroatom 
leads to a strong increase in activity (A: inactive, IC50= 1.32 µM for 2 and 0.84 µM for 3, 
respectively). It can be concluded that this nitrogen in position 2 is stabilizing the molecule in 
the active site via additional interactions. A hydrogen bond interaction between the nitrogen of 
the heterocycle and the OH of Tyr218 might be responsible for this gain in activity. 
We also wanted to investigate whether an additional substituent on the heterocycle might be 
able to increase the potency of the inhibitor by establishing supplementary interactions. 1,2,4-
Triazole was chosen as core structure as none of the nitrogen of the 1,2,3-triazoles can be 
substituted in an appropriate position where space is available. 
The 1,2,4-triazoles are structurally related to the 2,4-disubstituted imidazoles like compound B 
and to the 3,5-disubstituted pyrazoles like compound C which are both inactive. It was 
previously hypothesized that this lack of activity was due to the presence of a hydrogen bond 
donator (NH). Introduction of a methyl or phenyl group in this position will remove the 
hydrogen bond donating function of the heteroatom and was hypothesized to increase the 
ability of the inhibitors to induce hydrophobic interactions with the enzyme active site. The 
fact that all 1,2,4-triazoles (compounds 4-9) are inactive indicates that either the nitrogen in the 
vertex position on the heterocycle and/or the supplementary substituent are not tolerated by the 
enzyme. The introduction of a phenyl moiety into the 1,2,4-triazole core (compounds 7-9) 
induces conformational constraints: to adopt a stable conformation the hydroxyphenyl moiety 
close to the phenyl substituent and/or the phenyl itself will rotate out of the heterocyclic plane. 
This conformational change disturbs the flatness of the inhibitor considerably. The 
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hydroxyphenyl moieties might therefore not be able to adopt an appropriate conformation to 
establish hydrogen bond interactions with His221/Glu282 and Ser142/Tyr155, thus leading to 
compounds devoid of 17β-HSD1 inhibitory activity. The loss of planarity, however, is 
correlated with an increase of 17β-HSD2 inhibition. This finding is in agreement with the 
structures of previously described inhibitors of this enzyme21 which also lack planarity.  
In this study, the 1,2,3-triazoles (compounds 2 and 3) have been identified as a new class of 
potent and selective inhibitors of 17β-HSD1. The hydroxy substitution pattern (meta-para and 
para-meta) of the most active compounds confirms the reduced flexibility of the enzyme active 
site already observed. The introduction of an additional nitrogen in the inactive 1,4-
disubstituted imidazole core structure leads to a highly active inhibitor of 17β-HSD1. In 
contrast introduction of a substituent on the heterocycle is not tolerated by this enzyme but in 
case of a phenyl moiety results in fairly potent 17β-HSD2 inhibitors. They might be considered 
as leads for further structural optimizations in the development of selective 17β-HSD2 
inhibitors. 
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Paper III 
 
 
abstract: 17β-Estradiol (E2), the most potent female sex hormone, stimulates the growth of 
mammary tumours and endometriosis via activation of the estrogen receptor α (ERα). 
17β−Hydroxysteroid dehydrogenase type 1 (17β-HSD1), which is responsible for the catalytic 
reduction of the weakly active estrogen estrone (E1) into E2, is therefore discussed as a novel 
drug target. Recently, we have discovered a 2,5-bis(hydroxyphenyl) oxazole to be a potent 
inhibitor of 17β-HSD1. In this paper, further structural optimizations were performed: 39 
bis(hydroxyphenyl) azoles, thiophenes, benzenes and aza-benzenes were synthesized and their 
biological properties were evaluated. The most promising compounds of this study show 
enhanced IC50 values in the low nanomolar range, a high selectivity toward 17β-HSD2, a low 
binding affinity to ERα, a good metabolic stability in rat liver microsomes and a reasonable 
pharmacokinetic profile after peroral application. Calculation of the molecular electrostatic 
potentials revealed a correlation between 17β-HSD1 inhibition and the electron density 
distribution.  
 
Introduction 
 
Estrogens, the most potent one being 17β-estradiol (E2), act as female sex hormones and are 
predominantly produced before menopause by the ovaries. They unfold their activity by 
stimulation of the estrogen receptors (ERs) α and β. Besides their physiological effects, they 
are, however, also involved in the initiation and progression of estrogen-dependent diseases 
like mammary tumor1 and endometriosis.2 Presently, the three main endocrine therapies for the 
treatment of breast cancer are:3,4 inhibition of estrogen biosynthesis by aromatase inhibitors or 
GnRH agonists or antagonists and interference with the estrogen action at the receptor level by 
selective estrogen receptor modulators (SERMs) or pure antiestrogens.5 Besides specific 
disadvantages of each therapeutic concept, all of these strategies have in common that they 
reduce estrogen levels systemically leading to the corresponding side effects. 
A softer approach could be inhibition of the enzyme involved in the last step of the E2 
biosynthesis: 17β-hydroxysteroid dehydrogenase (17β-HSD) which is able to convert estrone 
(E1) into E2. There are three subtypes (1, 7 and 12) described, the most important of which is 
17β-HSD1. The primary function of 17β-HSD7 and 17β-HSD12 is supposed to be in the 
cholesterol synthesis6 and in the regulation of the lipid biosynthesis,7 respectively. Moreover, 
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Day et al.8 showed that 17β-HSD12, although highly expressed in breast cancer cell lines, is 
inefficient in E2 formation.  
17β-HSD1 is NAD(P)H-dependent and intracellularly converts the weak estrogen E1 into the 
strong estrogen E2. As it is often over-expressed in breast cancer cells9-12 and endometriosis,13 
17β-HSD1 is regarded as a promising novel target for the treatment of estrogen-dependent 
diseases. Appropriate inhibitors of this enzyme should exhibit less side effects compared to the 
current treatments as they should selectively reduce the concentration of active E2 in the 
diseased tissues.14 
As a biological counterpart, 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyzes 
the deactivation of E2 into E1. It protects the cell from excessively high concentrations of 
active estrogens15 and should therefore not be affected by inhibitors of 17β-HSD1. In addition 
17β-HSD1 inhibitors should not show affinity to the ERs to avoid intrinsic estrogenic effects. 
 
17β-HSD1 was crystallized with different steroidal ligands.16-24 The published X-ray structures 
provide insight into the active site, a narrow hydrophobic tunnel with polar contacts at each 
end. On one side His221/Glu282 are located, on the other Ser142/Tyr155 (two members of the 
catalytic tetrad).25 Surprisingly, close to the hydrophobic B/C region of the steroid two polar 
amino acids, Tyr218 and Ser222, can be found which do not interact with E2.  
Several steroidal and non-steroidal inhibitors of 17β-HSD1 have been described. The first 
report on steroidal compounds by Penning26 was as early as 1996. In the last few years several 
articles of other groups followed.27 Regarding the non-steroidal inhibitors, only four compound 
classes have been described so far, all of them very recently: thienopyrimidinones A,28,29 
biphenyl ethanones B,30 and from our group 6-(hydroxyphenyl) naphthols C31,32 and 
bis(hydroxyphenyl) azoles D33 (Chart 1).  
 
Chart 1: non-steroidal 17β-HSD1 inhibitors 
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The most promising compound in the latter series was the 2,5-bis(hydroxyphenyl) oxazole E 
with an IC50 of 310 nM and a selectivity factor of 56 against 17β-HSD2. In general it was 
discovered that the inhibitory activity of these compounds depends on the existence of hydroxy 
rather than methoxy groups on the phenyl substituents and on the OH substitution pattern, 
meta-para and para-meta substituted compounds being more active than para-para substituted 
ones. Furthermore it became apparent that inhibition also depends on the nature of the 
heterocycle. Hydrogen bond donor functions turned out to be inappropriate, whereas in several 
compounds H-bond acceptor atoms were favorable. This finding led to the hypothesis that 
active compounds are capable of interacting with Tyr218 or Ser222 via H-bonds.33 
In order to enhance activity and selectivity and to get a better insight into the interaction of 
these compounds with the active site of 17β-HSD1, the significance of the OH groups will be 
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further evaluated and other five-membered heterocycles, especially sulfur containing ones, will 
be investigated. Furthermore it will be evaluated, whether six-membered rings are also 
appropriate to connect the two hydroxyphenyl moieties. 
In the following we describe the synthesis of 39 bis(hydroxyphenyl) azoles, thiophenes, 
benzenes and aza-benzenes (Chart 2) as well as the determination of their 17β-HSD1 inhibitory 
activity and selectivity toward 17β-HSD2, ERα and ERβ. Furthermore, cell permeability using 
CaCo-2 cells, metabolic stability in rat liver microsomes, inhibition of the most important 
hepatic CYP enzymes and pharmacokinetic properties in the rat of selected compounds are 
determined. For a better understanding of the SARs molecular electrostatic potentials (MEPs) 
were calculated. 
 
Chart 2: title compounds 
 
Chemistry 
 
Starting from the commercially available dibrominated heterocycles and methoxylated benzene 
boronic acids, compounds 1 to 8, 19 to 28, 31 and 32 were prepared via two successive Suzuki 
reactions34 followed by a demethylation step using borontribromide35 as reagent. The Suzuki 
cross-coupling was carried out using three different methods. Intermediates 1ii to 8ii, 18ii to 
27ii and 1i to 8i were prepared following Method A (aq. sodium carbonate, toluene, Pd(PPh3)4, 
reflux, 4 h) and compounds 31ii, 32ii, 19i to 28i, 31i and 32i were synthesized using Method B 
(sodium carbonate, THF/water (1:1), Pd(PPh3)4, reflux, 20 h). During the first cross coupling 
reaction leading to the mono(methoxyphenyl) substituted derivatives 1ii-8ii, 18ii-27ii, 31ii, 
32ii no disubstituted compounds were obtained indicating that the (methoxyphenyl)bromo 
azoles and thiophenes are less reactive than their dibromo aryl precursors. The bromo 
intermediate 18ii was treated with n-BuLi in anhydrous THF and subsequently hydrolyzed 
with water to yield the mono methoxylated thiophene 18i. The methoxy groups of 1i to 8i, 18i 
to 28i, 31i and 32i were cleaved with boron tribromide (Method E: BBr3, CH2Cl2, -78 °C to rt, 
18 h, Scheme 1). 
RESULTS  - 48 - 
Scheme 1a: synthesis of compounds 1 to 8, 18 to 28, 31 and 32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aReagents and conditions: a. for compounds 1ii to 8ii, 18ii to 27ii and 1i to 8i: Method A: aq. Na2CO3, toluene, 
Pd(PPh3)4, reflux, 4 h; for compounds 31ii, 31i, 32ii, 32i and 19i to 28i: Method B: Na2CO3, THF/water (1:1), 
Pd(PPh3)4, reflux, 20 h; b. 1. n-BuLi, THF dry, -78 °C, 15 min, 2. water; c. Method E: BBr3, CH2Cl2, -78 °C to rt, 
18 h. 
 
The 1,3,4-thiadiazole 9 was prepared in a three step synthetic pathway based on the method 
described by Gierczyk and Zalas.36 The 3-methoxybenzoyl chloride was treated with hydrazine 
monohydrate to give the resulting 3-methoxy-N’-(3-methoxybenzoyl)benzohydrazide, which 
was cyclized into the corresponding thiadiazole using Lawesson reagent in DME under 
microwave assisted conditions. In a last step, the methoxy substituents were cleaved with 
boron tribromide (Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h). 
 
The synthesis of the 1,2,4-thiadiazoles 10 and 11 is shown in Scheme 2. The commercially 
available 4-methoxybenzonitrile and 3-hydroxybenzonitrile were converted into the thioamide 
intermediates 10ii and 11i, respectively, using aqueous ammonium sulfide under microwave 
assisted reaction.37 These thioamides were submitted to strong acidic conditions resulting in a 
mixture of the thiadiazoles 10i and 11 which were separated by column chromatography. The 
bis(methoxyphenyl) compound could not be isolated. Compound 10i was demethylated with 
boron tribromide (Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h, Scheme 2). 
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Scheme 2a: synthesis of compounds 10 and 11 
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aReagents and conditions: a. conc. HCl, 38 °C, 8 h; b. Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h. 
 
The synthesis of compounds 12 to 15 is presented in Scheme 3. The dimethoxylated-1,2,4-
triazoles 12i to 15i were synthesized by reaction of the N-acylimidates38 12ii to 15ii with 
methylhydrazine (Method D: MeNHNH2, CH2Cl2, 30-40 °C, 4 h). The methoxy groups of 
compounds 12i to 15i were cleaved with borontrifluoride dimethyl sulfide complex35 (Method 
F: BF3ּSMe2, CH2Cl2, rt, 20 h, Scheme 3). 
 
Scheme 3a: synthesis of compounds 12 to 15 
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aReagents and conditions: a. CH2Cl2, NEt3, 30-40 °C, 6 h; b. Method D: MeNHNH2, CH2Cl2, 30-40 °C, 4 h; c. 
Method F: BF3ּSMe2, CH2Cl2, rt, 20 h. 
 
Compound 16 was prepared according to Sharpless39 using 3-azidophenol and 3-
hydroxyphenyl acetylene. 
 
Compounds 17, 29, 30, 37 and 38 were obtained, under microwave assisted conditions, in a 
one pot synthesis (Method C: DME/EtOH/water (1:1:1), Cs2CO3, Pd(PPh3)4, MW (150 W, 150 
°C, 15 bar, 15 min)) with benzene boronic acid for 17, hydroxylated benzene boronic acid for 
29, 30, 37 and 38 and the corresponding dibrominated heterocycle.  
 
The synthesis of compounds 33 to 36 is depicted in Scheme 4. Starting from the commercially 
available dibrominated benzene and methoxylated benzene boronic acids, compounds 33 to 36 
were prepared via two successive Suzuki reactions following the conditions of Method A. In 
the first reaction only the mono substituted compounds 33ii and 35ii were obtained due to the 
fact that the (methoxyphenyl)bromobenzenes are less reactive than the dibromobenzenes. 
Consequently, longer reaction times were required for the second cross coupling reaction (20 
versus 4 h). The methoxy groups of compounds 33i-36i were cleaved using boron tribromide 
(Method E: BBr3, CH2Cl2, -78 °C to rt, 18 h, Scheme 4). 
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Scheme 4a: synthesis of compounds 33 to 36 
Br
OMe
OMe
OMe
B(OH)2
OMe
B(OH)2
OMe
Br
Br
a
OH
OH
a
+ +
3-Br, 4-OMe: 33ii
4-Br, 3-OMe: 35ii  33i-36i  33-36
b
 
 
aReagents and conditions: a. Method A: Na2CO3 10 % in water, toluene, Pd(PPh3)4, reflux, 4 h; b. Method E: 
BBr3, CH2Cl2, -78 °C to rt, 18 h. 
 
1,2,4,5-Tetrazine 39 was synthesized following the procedure described by Guither et al.40 
Briefly, 3-hydroxybenzonitrile was refluxed with hydrazine monohydrate and sulfur. 
Treatment with sodium nitrite led to cyclization resulting in 3,3'-(1,2,4,5-tetrazine-3,6-
diyl)diphenol 39. 
 
Biological results 
 
Activity: inhibition of human 17β-HSD1 
 
Placental enzyme was partially purified following a described procedure.41 Tritiated E1 was 
incubated with 17β-HSD1, cofactor and inhibitor. The amount of labelled E2 formed was 
quantified by HPLC. Compounds showing less than 10 % inhibition at 1 µM were considered 
to be inactive.  
The inhibition values of the test compounds are shown in Table 1. It becomes apparent that 
eleven compounds are more active than the previously described oxazole E98 (IC50= 310 nM). 
All methoxy compounds (data not shown) and para-para dihydroxylated derivatives are 
inactive except phenylene 34 which is a weak inhibitor (IC50> 1000 nM). The shift of one 
hydroxy substituent from the para- into the meta- position leads to highly active compounds 
except for thiazoles 1, 7 (IC50 values> 1000 nM) and 5 (IC50> 5000 nM) which have a weak 
inhibitory activity and triazoles 12 and 14 which are inactive. Moving the second OH 
substituent also in meta position (meta-meta derivatives) results in potent compounds except 
for triazole 16 which is a weak inhibitor (IC50> 5000 nM) and selenophene 30 and triazole 15 
which are inactive. 
The exchange of the para-OH group of the highly active thiophene 22 (IC50= 69 nM) with 
hydrogen reduces activity (compound 19, IC50= 342 nM). More dramatically, the replacement 
of the meta-OH function of compound 22 with hydrogen results in the inactive compound 20. 
Similarly, the exchange of the meta-hydroxyphenyl moiety as well as the two hydroxy groups 
of 22 with hydrogens leads to the inactive compounds 17 and 18. This exemplifies the 
importance of the existence of two OH substituents and their positions at the phenyl moieties 
with at least one being in the meta position. 
The synthesized thiazoles 1 to 8 show lower activities than the thiophene analogues 17 to 28 
except compound 3 (IC50= 50 nM) which exhibits similar inhibition as 22 (IC50= 69 nM) and 
27 (IC50= 77 nM). The introduction of a second nitrogen (compounds 9 to 11) in the 
heterocyclic scaffold of these potent inhibitors does not strongly reduce activity (9, IC50= 336 
nM; 11, IC50= 169 nM). For meta-meta disubstituted compounds the introduction of nitrogen in 
compound 4 decreases activity slightly (9, IC50= 336 vs 243 nM), whereas introduction in 
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compound 8 increases activity (11, IC50= 169 vs 455 nM), as it is observed for the meta-para 
disubstituted compound 7 (10, IC50= 413 vs >1000 nM).  
Moving the hydroxyphenyl moiety of the highly active thiophene 22 (IC50= 69 nM) from 
position 5 to the 3 position decreases activity dramatically (32, IC50> 1000 nM). Exchange of 
the sulfur atom of the potent thiophene 23 (IC50= 173 nM) with selenium results in the inactive 
compound 30. 
In case of the six-membered rings, benzene and some of its aza-analogues were investigated. 
The 1,3-bis(hydroxyphenyl) substituted phenylenes were not active, whereas the 1,4-
disubstituted compounds showed some activity, the most active benzene compound being the 
meta-meta derivative 35 (IC50= 173 nM). The introduction of one or more nitrogens into the 
central benzene ring of 35 (compounds 37 to 39) results in an increase (pyridine 37, IC50= 101 
nM), no change (tetrazine 39, IC50= 201 nM) and a decrease of inhibitory activity (pyrazine 38, 
IC50= 1000 nM). 
Furthermore in Table 1, the angles between the two phenyl moieties are presented as a 
structural parameter. No correlation to the activities of the corresponding compounds can be 
observed. 
 
Table 1: inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 1-39, O-O distances 
and phenyl-het-phenyl angles 
 
 
 
 
 
 
 
 
compound Het R1 R2 d(Å)a αb 
IC50 (nM)c 
selectivity 
factorf 17β-HSD1d 
17β-
HSD2e 
1 
S
N
 
4-OH 3-OH 11.9< d< 12.7 
153 
>1000 nt  
2 4-OH 4-OH 13.6 ni nt  
3 3-OH 4-OH 11.9< d< 12.7 50 4004 80 
4 3-OH 3-OH 10.1< d< 11.7 243 2500 10 
 
        
5 S
N
 
4-OH 3-OH 10.5< d< 12.0 
130 
>5000 nt  
6 4-OH 4-OH 12.5 ni nt  
7 3-OH 4-OH 10.5< d< 12.0 >1000 nt  
8 3-OH 3-OH 9.0< d< 11.2 455 2220 5 
 
        
9 
S
NN
 
3-OH 3-OH 9.9< d< 11.5 157 336 nt  
 
        
10 S N
N
 
3-OH 4-OH 9.7< d< 11.9 128 413 2194 5 11 3-OH 3-OH 8.5< d< 11.2 169 602 3 
 
S H
OH
1-17 
19-32 33-39
R1
18
α
α
R2
Het
Het
R1
R2
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Table 1 continued 
compound Het R1 R2 d(Å)a αb 
IC50 (nM)c 
selectivity 
factorf 17β-HSD1d 
17β-
HSD2e 
12 
N N
N
 
4-OH 3-OH 10.2< d< 11.9 
145 
ni nt  
13 4-OH 4-OH 12.4 ni nt  
14 3-OH 4-OH 10.2< d< 11.9 ni nt  
15 3-OH 3-OH 8.7< d< 11.4 ni nt  
         
16 
N N
N
 
3-OH 3-OH 8.7< d< 11.2 147 >5000 nt  
17 
S
 
H H 
 
147 
ni nt  
18   ni nt  
19 3-OH H 342 2337 7 
20 4-OH H ni nt  
21 4-OH 4-OH 13.5 ni nt  
22 3-OH 4-OH 11.8< d< 12.8 69 1953 28 
23 3-OH 3-OH 9.8< d< 11.8 173 745 4 
 
        
24 
S
 
3-OH H  
136 
>5000 nt  
25 4-OH 3-OH 10.4< d< 12.0 151 1690 11 
26 4-OH 4-OH 12.3 ni nt  
27 3-OH 4-OH 10.4< d< 12.0 77 1271 16 
28 3-OH 3-OH 8.5< d< 11.4 185 559 3 
 
        
29 
Se
 
4-OH 4-OH 13.8 
162 ni nt  30 3-OH 3-OH 10.4< d< 11.3 ni nt  
 
        
31 
S
 
4-OH 4-OH 8.1 
69 
ni nt  
32 3-OH 4-OH 6.2< d< 8.9 >1000 nt  
 
        
33 
 
4-OH 3-OH 9.3< d< 12.1 
120 
>1000 nt  
34 4-OH 4-OH 12.3 >1000 nt  
 
        
35 
 
3-OH 3-OH 11.4< d< 12.4 
180 
173 2259 13 
36 3-OH 4-OH 13.1 471 4509 9 
 
        
37 
N
 
3-OH 3-OH 11.6< d< 12.3 180 101 3399 34 
38 
N
N
 
3-OH 3-OH 11.4< d< 12.2 180 1000 5502 5 
 
        
39 
N
N
N
N
 
3-OH 3-OH 11.3< d< 12.2 180 201 5102 25 
aO-O distance between the hydroxy substituents, for E2 d= 11.0 Å; bAngle between the two phenyl moieties in °; 
cMean values of three determinations, standard deviation less than 12 % except 3: 18 % for 17β-HSD1; dHuman 
placenta, cytosolic fraction, substrate [3H]-E1 + E1 [500 nM], cofactor NADH [500 µM]; eHuman placenta, 
microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 µM], fIC50 (17β-HSD2)/ IC50 (17β-
HSD1); ni: no inhibition, nt: not tested. 
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Selectivity: inhibition of human 17β-HSD2 and affinities for ERα and ERβ  
 
Since 17β-HSD2 catalyzes the inactivation of E2 to E1, inhibitory activity toward this enzyme 
must be avoided. The 17β-HSD2 inhibition was determined using an assay similar to the 17β-
HSD1 test. Placental microsomes were incubated with tritiated E2 in the presence of NAD+ 
and inhibitor. Separation and quantification of labelled product (E1) was performed by HPLC 
using radio detection. A selection of the most potent 17β-HSD1 inhibitors was tested for 
inhibition of 17β-HSD2. IC50 values and selectivity factors (IC50 HSD2 / IC50 HSD1) are 
presented in Table 1. 
It is striking that most meta-meta bis(hydroxyphenyl) substituted inhibitors present only poor 
selectivity except for compounds 37 and 39 which show high selectivity factors of 34 and 25, 
respectively. The meta-para/para-meta disubstituted inhibitors mostly show higher selectivity 
with compound 3 exhibiting the highest selectivity factor of 80. 
 
A further prerequisite for 17β-HSD1 inhibitors to be used as potential drugs is that these 
compounds do not show affinity for ERα and ERβ, or only a marginal one, since binding to 
these receptors could counteract the therapeutic efficacy. The binding affinities of selected 
compounds were determined using recombinant human protein in a competition assay applying 
[3H]-E2 and hydroxyapatite (Table 2). All tested compounds show very marginal or marginal 
affinity to the ERs. 
  
Table 2: binding affinities for the human estrogen receptors α and β of selected compounds 
 
compound RBA
a
 (%) 
ERαb ERβb 
3 <0.01 0.01< RBA< 0.1 
22 0.1< RBA< 1 1.5 
25 0.01< RBA< 0.1 0.1< RBA< 1 
27 0.01< RBA< 0.1 0.1< RBA< 1 
35 <0.001 0.01< RBA< 0.1 
37 0.01< RBA< 0.1 <0.01 
 
aRBA (relative binding affinity), E2: 100 %, mean values of three determinations, standard deviations less than 10 
%; bHuman recombinant protein, incubation with 10 nM [3H]-E2 and inhibitor for 1 h. 
 
Further biological evaluation  
 
The intrinsic estrogenic activity of a representative compound of each class was determined 
using the ER-positive mammary tumor T-47D cell line. No agonistic, i.e. no stimulatory effect 
was observed after application of the inhibitors even at a concentration 1000 fold higher than 
E2 (data not shown). 
 
A selection of active and selective compounds was investigated for permeation of CaCo-2 
cells. These cells exhibit morphological and physiological properties of the human small 
intestine42 and are a generally accepted model for the prediction of peroral absorption. 
Depending on the Papp data obtained, compounds can be classified as low (Papp (·10-6 cm/sec) < 
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1), medium (1 < Papp < 10) or highly permeable (Papp > 10)). Thiazole 3 shows medium cell 
permeation while thiophenes 22, 25 and phenylene 35 exhibit high cell permeability (Table 3). 
 
Table 3: CaCo-2 cell permeation of highly active 17β-HSD1 inhibitors 
 
compound Papp(·10-6 cm/s)a,b classification 
3 7.8 medium 
22 22.0 high 
25 14.4 high 
35 12.5 high 
atenolol 0.1 low 
testosterone 9.4 medium 
ketoprofene 25.7 high 
 
aPermeability of reference compounds similar to the values described [atenolol,71 testosterone,67 ketoprofene72]; 
bPapp: apparent permeability coefficient, mean values of three determinations, standard deviations less than 10 %. 
 
A representative compound of the thiazole, thiophene and phenylene class (compounds 4, 25 
and 35) was evaluated for their phase 1 metabolic stability using rat liver microsomes. Samples 
were taken at defined time points and the remaining percentage of parent compound was 
determined by LC-MS/MS. Half-life and intrinsic clearance were evaluated and compared to 
the two reference compounds diazepam and diphenhydramine (Table 4). All tested compounds 
show longer half lives than the antihistaminic drug diphenhydramine (values in the range 
between 12.6 and 22.7 min vs 6.8 min). 
 
Table 4: half-lives and intrinsic clearances of compounds 4, 25 and 35 in rat liver microsomesa 
 
compound half-life (min) 
CLintb 
(µL /min 
/mg protein) 
4 12.6 367.2 
25 18.6 248.5 
35 22.7 203.4 
diazepamc 40.8 113.3 
diphenhydraminec 6.8 679.6 
 
a0.33 mg/mL protein, NADP+-regenerating system, [inhibitor]: 1 µM, incubation at 37 °C, samples taken at 0, 15, 
30 and 60 min, determination of parent compound by MS; bCLint: intrinsic body clearance; cvalues of reference 
compounds similar to described values. 
 
The same compounds (4, 25 and 35) were further investigated for inhibition of the six most 
important human hepatic enzymes: CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4. All compounds 
show very low inhibition of CYP1A2, 2B6, 2C19 and 2D6 (IC50> 4 µM). In case of CYP2C9 
and CYP3A4 (4: 2.1 and 0.8, 25: 0.8 and 1.9, 35: 1.9 and 2.1 µM, respectively) inhibition was 
higher, but still clearly below the IC50 values of 17β-HSD1 inhibition. These results indicate a 
low risk of drug-drug interaction caused by CYP-inhibition. 
RESULTS  - 55 - 
The pharmacokinetic profiles of the most active and selective azole compound 3 and one of the 
six-membered ring compounds (39) were determined in rats after oral administration in a 
cassette. The most potent six-membered ring compound 37 was not chosen as it was unstable 
in buffer over 24 h. Each group consisted of 4 male rats and the compounds were administered 
in doses of 10 mg/kg. Plasma samples were collected over 24 h and plasma concentrations 
were determined by HPLC-MS/MS. The pharmacokinetic parameters are presented in Table 5. 
Maximal plasma concentration (Cmax) and AUC value are much higher for compound 39 
compared to compound 3. 
 
Table 5: pharmacokinetic parameters of compound 3 and 39 in male rats after oral application 
of 10 mg/kg 
 
parameters compound 3 39 
Cmax obs (ng/mL)a 7.8 106.0 
Cz (ng/mL)b 6.6 54.0 
tmax obs (h)c 8.0 3.0 
tz (h)d 10.0 10.0 
t1/2z (h)e 1.5 1.2 
AUC0-tz (ng/mL)f 99.2 1204.0 
 
aCmax obs: maximal measured concentration; bCz: last analytical quantifiable concentration; ctmax obs: time to reach 
the maximum measured concentration; dtz: time of the last sample which has an analytically quantifiable 
concentration; et1/2z: half-life of the terminal slope of a concentration time curve; fAUC0-tz: area under the 
concentration time curve up to the time tz of the last sample. 
 
Computational Chemistry 
To obtain an insight which physicochemical parameter might influence biological activity, the 
charge density distribution was considered and the molecular electrostatic potentials (MEPs) of 
selected compounds were determined. The geometry of the compounds had been fully 
optimized in the gas phase at the B3LYP/6-311++G (d,p) level of density functional theory 
(DFT). MEPs were plotted for every compound on its electron density with GaussView 3.09. 
The electrostatic potential distribution of the charge density is presented by a color code 
ranging from –3.1 ·10-2 to 4.5 ·10-2 Hartree (Figures 1 and 2 and Supporting Information). For 
better comparison, the MEPs of different compounds were divided into 3 regions 
corresponding to each aromatic system. 
 
In Figure 1, the MEPS of five-membered heterocyclic compounds are arranged based on their 
increasing inhibitory potency. While the positions of the hydroxyphenyl moieties are fixed, the 
nature of the heterocycle is varied. It becomes apparent that the heterocycle influences the ESP 
distribution of the whole molecule. In order to rationalise these MEPs, the ESP distribution 
ranges (C1), the mean values of the distribution ranges (C2) and the ∆ of ESP (C3) were 
analyzed: negative ESP values (red/orange/yellow) in region I and II and less negative to 
almost neutral ESP values (green/yellow) in region III are obviously an important factor for 
high inhibitory potency. Trying to establish a semi-quantitative MEP-activity relationship 
(“semi-QMAR”) optimal ESP ranges for areas I, II and III for potent inhibition were identified 
(hydrogens and the OH groups were not considered): for region I ESP from –1.7 to –1.2 ·10-2, 
for region II –1.6 to –0.9 ·10-2 and for region III –1.2 to –0.5 ·10-2 Hartree. Similarly, the 
optimal ∆ values of ESP for each region were determined: 0.5, 0.7 and 0.7 Hartree, 
respectively. Both the shift of a certain ESP distribution range on the scale and the change of 
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the ∆ value result in a decrease of inhibitory activity. The combination of these two criteria is 
substantiated with +, – and 0 in Figure 1.D indicating favorable, unfavorable and neutral 
impact on activity. 
 
 
Figure 1. (A) structure and 17β-HSD1 inhibitory activity of F,33 E,33 and compounds 1, 3, 17 
ordered by increasing activity; (B) MEP maps, dorsal and ventral view; (C1) ESP distribution 
range (Hartree; ·10-2); (C2) mean value of distribution range (Hartree, ·10-2); (C3) ∆ of ESP; (D) 
“semi-QMAR”. MEP surfaces were plotted with GaussView 3.09. 
 
Compound F33 exhibits a polarization between top and bottom sides of the molecule: the 
vertex-side (NH) has positive ESP values, while on the opposite side (N-C) negative to neutral 
values are predominant. This polarization (∆= 7.2 ·10-2 Hartree) results in an inactive 
compound, indicating that the ESP of the central heterocycle is crucial for 17β-HSD1 
inhibitory activity. 
A good example for the change in activity is well demonstrated by the ESP distribution in 
region III for thiazoles 1 and 3 (Figure 1 C1 and C2). The dramatic loss of activity of 
compound 1 (IC50> 1000 nM) in comparison to 3 (IC50= 50 nM) is due to a non optimal 
electron density distribution.  
 
The MEP maps of the six-membered ring compounds are depicted in Figure 2. A similar 
charge density distribution was observed except for the only planar compound of this series, 
tetrazine 33, which showed no polarization between top and bottom side of the molecule. It 
remains to be clarified whether this is the reason for the reasonable activity of compound 33.  
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Figure 2. (A) structure and 17β-HSD1 inhibitory activity of compounds 29 and 31 to 33 
ordered by increasing activity; (B) MEP maps, dorsal and ventral view; (C1) ESP distribution 
range (Hartree;·10-2); (C2) mean value of distribution range (Hartree,·10-2); (C3) ∆ of ESP; (D) 
“semi-QMAR”. MEP surfaces were plotted with GaussView 3.09. 
 
Discussion and conclusion 
 
The present paper shows that compound E from a previous study33 could be optimized. The 
most active and selective thiazole 3 shows an IC50 value of 50 nM and a selectivity factor of 80 
(compound E, IC50= 310 nM, selectivity factor: 56). 
The biological results obtained confirm similar findings described in our previous article:33 the 
OH substitution pattern of our compounds is decisive for inhibitory activity. Comparison of the 
mono hydroxylated thiophenes 19 and 20 (meta- and para-, respectively) shows that the meta-
hydroxy group is crucial for activity. The inactivity of compound 18 indicates that the phenyl 
moiety of the meta-hydroxyphenyl thiophene 19 is also important for potency. The 
replacement of the meta-hydroxy group of 19 with hydrogen leading to the inactive compound 
17 demonstrates the importance of the hydrogen bond interaction for activity. 
As observed for the previously described bis(hydroxyphenyl) derivatives,33 the distance 
between the two oxygens obviously has to be close to the value observed for the substrate (d= 
11 Å). The para-para disubstituted compounds show distances longer than 12.5 Å. They are all 
inactive. Concerning the meta-para and meta-meta disubstituted compounds, which have O-O 
distances between 8.5 and 12.8 Ǻ, medium to high inhibitory activities are observed for most 
compounds. They could be able to establish hydrogen bond interactions with His221/Glu282 
and Ser142/Tyr155. However, the inactivity of thiazoles 1, 5, 7 and triazoles 12 to 16, which 
are all meta-para and meta-meta disubstituted, indicates that this distance is not the only 
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decisive criterion for activity. The heterocycle also influences the inhibitory potencies of the 
compounds.  
In the five-membered ring series, the potency of 1,2,3-triazoles described previously98 led us to 
further investigate this class of compounds. The inactivity of compounds 12 to 15 shows that 
either the nitrogen distribution in the ring or the methyl group are not tolerated by the enzyme. 
The replacement of the N-Me moiety of 14 with sulfur (compound 10) leading to a fairly 
potent compound indicates that S in this position has a positive influence. To further 
investigate the role of the nitrogen in the ring, thiazoles 1 to 8 and thiophenes 21 to 28, 31 and 
32 were investigated. The fact that thiazole 3 and thiophene 22 exhibit almost identical 
potencies shows that the nitrogen does not contribute to binding, i.e. that there is obviously no 
hydrogen bond interaction.  
In this report, we could also show that six-membered rings are appropriate for the design of 
highly active 17β-HSD1 inhibitors. Comparison of the almost equipotent phenylene 35, 
pyridine 37 and tetrazine 39 confirms the hypothesis that nitrogens are tolerated in the ring but 
do not contribute to a specific interaction. 
The role of the angle between the two hydroxyphenyl moieties was also investigated in order to 
find out whether there is a correlation between this parameter and the inhibitory potency. The 
broad range of angles calculated (128° for 11 to 180° for 37, two highly active compounds) 
could not be correlated with high or low inhibitory potency indicating that the enzyme presents 
some flexibility for ligand binding. Interestingly, for smaller angles between the two 
hydroxyphenyl groups, as in case of compounds 10 and 11 (N atom at the vertex), the meta-
meta substitution results in a higher activity, while for larger angles, in presence of a sulfur 
atom at the vertex of the five-membered heterocycle (2,5-disubstituted thiazoles and 2,5-
disubstituted thiophenes), the optimal substitution pattern is meta-para/para-meta. This 
phenomenon will be further investigated. 
Our finding that there exists a correlation between the MEPs and the biological activities of the 
compounds (semi-QMAR) might be exploited for further structure optimization underlining 
the relevance of this descriptor for biological activity. Furthermore, the MEPs could be used to 
investigate how these inhibitors approach and bind to the enzyme as it is described for 
genistein and the estrogen receptor.99 
 
Interestingly the exchange of a CH in the thiophene 22 by a N leading to the thiazole 3 
increases selectivity toward 17β-HSD2 dramatically (IC50 17β-HSD2 / IC50 17β-HSD1, 28 vs 
80). In general, the most potent compounds exhibit a really low affinity for the ERα and 
ERβ and show no stimulation of cell proliferation (agonistic effect) in the ER-positive T-47D 
cell line. It is worth mentioning that 3 in spite of its good CaCo-2 permeability shows a really 
low bioavailability compared to 39. Glucuronidation and/or sulfatation might be responsible 
for the low plasma levels of the parent compounds.  
In the present report, we described the synthesis of bis(hydroxyphenyl) azoles, thiophenes, 
benzenes, aza-benzenes and the evaluation of their biological properties. The most promising 
compounds of this study, 3, 22 and 39, show a high selectivity toward 17β-HSD2, a low 
binding affinity to the ERα, a high CaCo-2 permeability and a reasonable pharmacokinetic 
profile after peroral application. These new compounds should be useful tools to further 
investigate in vivo 17β-HSD1 as a target for the treatment of estrogen-dependent diseases. 
RESULTS  - 59 - 
Experimental section 
 
Chemical methods 
 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, 
Lancaster, Roth, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 µm) coated with silica, preparative 
thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel).  
Melting points were measured on a Mettler FP1 melting point apparatus and are uncorrected. 
IR spectra were recorded on a Bruker Vector 33 spectrometer (neat sample). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in δ (parts per million: ppm), by reference to the hydrogenated residues of 
deuteriated solvent as internal standard (CDCl3: δ = 7.24 ppm (1H NMR) and δ = 77 ppm (13C NMR), 
CD3OD: δ = 3.35 ppm (1H NMR) and δ = 49.3 ppm (13C NMR), CD3COCD3: δ = 2.05 ppm (1H NMR) 
and δ = 29.9 ppm (13C NMR), CD3SOCD3: δ = 2.50 ppm (1H NMR) and δ = 39.5 ppm (13C NMR). 
Signals are described as s, d, t, dd, m, dt for singlet, doublet, triplet, doublet of doublets, multiplet and 
doublet of triplets, respectively. All coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were recorded on a TSQ Quantum (Thermo/Fischer) instrument. Elemental analyses 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University. 
 
5-Bromo-2-(4-methoxyphenyl)-1,3-thiazole (1ii),10044 4-methoxythiobenzamide (10ii),45 3-bromo-2-(4-
methoxyphenyl)thiophene (31ii),46 3-bromo-4'-methoxybiphenyl (33ii),47 4'-bromo-3-methoxybiphenyl 
(35ii),48 2-(4-methoxyphenyl)-5-(3-methoxyphenyl)-1,3-thiazole (1i),49 2,5-bis(4-methoxyphenyl)-1,3-
thiazole (2i),50 2,4-bis(4-methoxyphenyl)-1,3-thiazole (6i),35 3-hydroxythiobenzamide (11i),16 2,5-bis(4-
methoxyphenyl)thiophene (21i),51 2,4-bis(4-methoxyphenyl)thiophene (26i),52 2,3-bis(4-
methoxyphenyl)thiophene (31i),53 3,4''-dimethoxy-1,1':3',1''-terphenyl (33i),54 4,4''-dimethoxy-1,1':3',1''-
terphenyl (34i),54 4,4'-(1,3-thiazole-2,5-diyl)diphenol (2),55 4,4'-(1,3-thiazole-2,4-diyl)diphenol (6),35 
3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol (11),56 3,3'-(1H-1,2,3-triazole-1,4-diyl)diphenol (16)101,57 2,5-
diphenylthiophene (17),58 4,4'-thiene-2,5-diyldiphenol (21),51 4,4'-thiene-2,4-diyldiphenol (26),55 
1,1':3',1''-terphenyl-3,4''-diol (33),59 1,1':3',1''-terphenyl-4,4''-diol (34),60 1,1':4',1''-terphenyl-3,3''-diol 
(35)102,59 1,1':4',1''-terphenyl-3,4''-diol (36)102,59 3,3'-pyrazine-2,5-diyldiphenol (38),61 3,3'-(1,2,4,5-
tetrazine-3,6-diyl)diphenol (39)40 were prepared following described procedures. 
 
General procedure for Suzuki coupling 
Method A: 
A mixture of arylbromide (1 eq), methoxybenzene boronic acid (1 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.005 eq) in an oxygen free toluene/water (1:1) solution was 
stirred at 100 °C for 4 h under nitrogen. The reaction mixture was cooled to rt. The aqueous layer was 
extracted with ethyl acetate. The combined organic layers were washed with brine, dried over 
magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC. 
 
Method B: 
A mixture of arylbromide (1 eq), methoxybenzene boronic acid (1.2 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.005 eq) in an oxygen free tetrahydrofurane/water (1:1) 
solution was stirred at 100 °C for 20 h under nitrogen. The reaction mixture was cooled to rt. The 
aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC. 
 
Method C: 
A mixture of aryl dibromide (1 eq), methoxybenzene boronic acid (2.4 eq), caesium carbonate (4 eq) 
and tetrakis(triphenylphosphine) palladium (0.001 eq) was suspended in an oxygen free 
DME/EtOH/water (1:1:1) solution. The reaction mixture was exposed to microwave irradiation (15 
min, 150 W, 150 °C, 15 bar). After reaching rt, water was added and the aqueous layer was extracted 
with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, 
filtered and concentrated to dryness. The product was purified by preparative TLC. 
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Method D: General procedure for synthesis of 1,2,4-triazoles: 
A solution of acyl chloride (1 eq) in dichloromethane was added dropwise to a mixture of ethyl imino 
ester (1 eq) and dry triethylamine (1 eq) in 20 mL dichloromethane and heated to 30-35 °C for 6 h. 
After cooling to rt, the mixture was poured into 3 % NaHCO3 solution (25 mL). The layers were 
separated and the organic layer was washed with water, dried over sodium sulfate and evaporated to 
dryness under reduced pressure. The resulting N-acylimino esters 12ii to 15ii were heated to 30-35°C 
with methyl hydrazine (2 eq) in CH2Cl2 for 4 h. The solvent was removed under reduced pressure and 
the 1,2,4-triazoles 12i to 15i were crystallized from CH2Cl2/ Et2O. 
 
General procedure for ether cleavage 
Method E: 
To a solution of methoxybenzene derivative (1 eq) in dry dichloromethane at -78 °C (dry ice/acetone 
bath), boron tribromide in dichloromethane (1 M, 3 eq per methoxy function) was added dropwise. The 
reaction mixture was stirred for 20 h at rt under nitrogen. Water was added to quench the reaction, and 
the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with 
brine, dried over sodium sulfate, evaporated to dryness under reduced pressure and purified by 
preparative TLC. 
 
Method F:  
To a solution of bis(methoxyphenyl) derivative (1 eq) in dry dichloromethane, borontrifluoride 
dimethyl sulfide complex (75 eq) was added dropwise at rt. The reaction mixture was stirred for 20 h. 
Water was added to quench the reaction and the aqueous layer was extracted with ethyl acetate. The 
combined organic layers were washed with brine, dried over sodium sulfate, evaporated to dryness 
under reduced pressure and purified by preparative TLC. 
 
3-[2-(4-Hydroxyphenyl)-1,3-thiazol-5-yl]phenol (1). The title compound was prepared by reaction of 
5-(3-methoxyphenyl)-2-(4-methoxyphenyl)-1,3-thiazole (1i) (40 mg, 0.13 mmol) and boron tribromide 
(0.81 mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl 
acetate 5:5); yield: 77 % (28 mg); MS (ESI): 270 (M+H)+; Anal. (C15H11NO2S) C, H, N. 
 
5-Bromo-2-(3-methoxyphenyl)-1,3-thiazole (3ii). The title compound was prepared by reaction of 2,5-
dibromo-1,3-thiazole (500 mg, 2.06 mmol), 3-methoxybenzeneboronic acid (376 mg, 2.47 mmol), 
sodium carbonate (437 mg, 4.12 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 10 µmol) 
according to method A. The product was purified by CC (dichloromethane/methanol 95:5); yield: 50 % 
(278 mg). 
 
2-(3-Methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (3i). The title compound was prepared by 
reaction of 5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (3ii) (250 mg, 0.93 mmol), 4-
methoxybenzeneboronic acid (170 mg, 1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and 
tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 58 % (160 mg). 
 
3-[5-(4-Hydroxyphenyl)-1,3-thiazol-2-yl]phenol (3). The title compound was prepared by reaction of 
2-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (3i) (40 mg, 0.13 mmol) and boron tribromide 
(0.81 mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl 
acetate 5:5); yield: 80 % (50 mg); MS (ESI): 270 (M+H)+; Anal. (C15H11NO2S) C, H, N. 
 
2,5-Bis(3-methoxyphenyl)-1,3-thiazole (4i). The title compound was prepared by reaction of 5-bromo-
2-(3-methoxyphenyl)-1,3-thiazole (3ii) (250 mg, 0.93 mmol), 3-methoxybenzeneboronic acid (170 mg, 
1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 
mg, 4.6 µmol) according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 40 % (111 mg). 
 
3,3'-(1,3-Thiazole-2,5-diyl)diphenol (4). The title compound was prepared by reaction of 2,5-bis(3-
methoxyphenyl)-1,3-thiazole (4i) (100 mg, 0.36 mmol) and boron tribromide (2.02 mmol) according to 
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method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 85 % (82 
mg); MS (ESI): 270 (M+H)+; Anal. (C15H11NO2S) C, H, N. 
 
4-Bromo-2-(4-methoxyphenyl)-1,3-thiazole (5ii). The title compound was prepared by reaction of 2,4-
dibromo-1,3-thiazole (500 mg, 2.06 mmol), 4-methoxybenzeneboronic acid (376 mg, 2.47 mmol), 
sodium carbonate (437 mg, 4.12 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 10 µmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 55 % (305 
mg). 
 
2-(4-Methoxyphenyl)-4-(3-methoxyphenyl)-1,3-thiazole (5i). The title compound was prepared by 
reaction of 4-bromo-2-(4-methoxyphenyl)-1,3-thiazole (5ii) (250 mg, 0.93 mmol), 3-
methoxybenzeneboronic acid (170 mg, 1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and 
tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 52 % (143 mg). 
 
3-[2-(4-Hydroxyphenyl)-1,3-thiazol-4-yl]phenol (5). The title compound was prepared by reaction of 
2-(4-methoxyphenyl)-4-(3-methoxyphenyl)-1,3-thiazole (5i) (70 mg, 0.24 mmol) and boron tribromide 
(1.44 mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl 
acetate 5:5); yield: 78 % (50 mg); MS (ESI): 268 (M-H)-; Anal. (C15H11NO2S) C, H, N. 
 
4-Bromo-2-(3-methoxyphenyl)-1,3-thiazole (7ii). The title compound was prepared by reaction of 2,4-
dibromo-1,3-thiazole (500 mg, 2.06 mmol), 3-methoxybenzeneboronic acid (376 mg, 2.47 mmol), 
sodium carbonate (437 mg, 4.12 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 10 µmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 50 % (270 
mg). 
 
2-(3-Methoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazole (7i). The title compound was prepared by 
reaction of 4-bromo-2-(3-methoxyphenyl)-1,3-thiazole (7ii) (250 mg, 0.93 mmol), 4-
methoxybenzeneboronic acid (170 mg, 1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and 
tetrakis(triphenylphosphine) palladium (5.4 mg, 4.6 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 79 % (218 mg). 
 
3-[4-(4-Hydroxyphenyl)-1,3-thiazol-2-yl]phenol (7). The title compound was prepared by reaction of 
2-(3-methoxyphenyl)-4-(4-methoxyphenyl)-1,3-thiazole (7i) (70 mg, 0.24 mmol) and boron tribromide 
(1.44 mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl 
acetate 5:5); yield: 80 % (52 mg); MS (ESI): 268 (M-H)-; Anal. (C15H11NO2S) C, H, N. 
 
2,4-Bis(3-methoxyphenyl)-1,3-thiazole (8i). The title compound was prepared by reaction of 4-bromo-
2-(3-methoxyphenyl)-1,3-thiazole (7ii) (250 mg, 0.93 mmol), 3-methoxybenzeneboronic acid (170 mg, 
1.11 mmol), sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (5.4 
mg, 4.6 µmol) according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 18 % (50 mg). 
 
3,3'-(1,3-Thiazol-2,4-diyl)diphenol (8). The title compound was prepared by reaction of 2,4-bis(3-
methoxyphenyl)-1,3-thiazole (8i) (70 mg, 0.24 mmol) and boron tribromide (1.44 mmol) according to 
method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 78 % (50 
mg); MS (ESI): 268 (M-H)-; Anal. (C15H11NO2S) C, H, N. 
 
3,3’-(1,2,4-Thiadiazol-2,5-diyl)diphenol (9). A solution of 3-hydroxythiobenzamide (100 mg, 0.17 
mmol, 2 eq) in DMSO (10 ml) was stirred for 5 h at rt with 3 ml concentrated chlorhydric acid. The 
crude mixture was poured into water and the resulting precipitate was filtered, washed with water and 
dried overnight in a desiccator; yield: 92 % (41 mg); MS (ESI): 269 (M-H)-. Anal. (C14H10N2O2S) C, H, 
N. 
 
3-[3-(4-Methoxyphenyl)-1,2,4-thiadiazol-5-yl]phenol (10i). A solution of 4-methoxythiobenzamide 
(10ii) (318 mg, 1.90 mmol, 1 eq) in DMSO was heated for 8 h at 38 °C with 3-hydroxythiobenzamide 
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(11i) (290 mg, 1.90 mmol, 1 eq) and concentrated hydrochloric acid (193 µL, 1.90 mmol, 1 eq). After 
cooling to rt, the crude mixture was poured into water and the resulting precipitate was collected by 
filtration. The mixture of 10i and 11 was separated by CC (hexane/ethyl acetate 8:2); yield: 30 % (70 
mg) for 10i and 42 % (215 mg) for 11. 
 
3-[3-(4-Hydroxyphenyl)-1,2,4-thiadiazol-5-yl]phenol (10). The title compound was prepared by 
reaction of 3-[3-(4-methoxyphenyl)-[1,2,4]-thiadiazol-5-yl]-phenol (10i) (150 mg, 0.53 mmol) and 
boron tribromide (1.59 mmol) according to method E. The product was purified by preparative TLC 
(hexane/ethyl acetate 5:5); yield: 91 % (130 mg); MS (ESI): 271 (M+H)+; Anal. (C14H10N2O2S) C, H, 
N. 
 
3-(3-Methoxyphenyl)-5-(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (12i). The title compound 
was prepared from para-anisoyl chloride (170 mg, 1.0 mmol), ethyl 3-methoxybenzimidate (179 mg, 
1.0 mmol) and methyl hydrazine (92 mg, 2.0 mmol) according to method D; yield: 85 % (250 mg); m.p. 
108-110 °C (CH2Cl2/ Et2O); MS (ESI): 296 (M+H)+. 
 
3-[5-(4-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (12). The title compound was 
prepared by reaction of 3-(3-methoxyphenyl)-5-(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (12i) 
(100 mg, 0.37 mmol) and borontrifluoride dimethyl sulfide complex (27.75 mmol) according to method 
F. The product was purified by preparative TLC (ethyl acetate); yield: 46 % (42 mg); MS (ESI): 268 
(M+H)+. 
 
3,5-Bis(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (13i). The title compound was prepared from 
para-anisoyl chloride (170 mg, 1.0 mmol), ethyl 4-methoxybenzimidate (179 mg, 1.0 mmol) and 
methyl hydrazine (92 mg, 2.0 mmol) according to method D; yield: 78 % (230 mg); m.p. 141-143 °C 
(CH2Cl2/ Et2O); MS (ESI): 296 (M+H)+. 
 
4-[5-(4-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (13). The title compound was 
prepared by reaction of  3,5-bis(4-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (13i) (100 mg, 0.37 
mmol) and borontrifluoride dimethyl sulfide complex (27.7 mmol) according to method F. The product 
was purified by preparative TLC (ethyl acetate); yield: 63 % (57 mg); MS (ESI): 268 (M+H)+. 
 
3-(4-Methoxyphenyl)-5-(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (14i). The title compound 
was prepared from meta-anisoyl chloride (170 mg, 1.0 mmol), ethyl 4-methoxybenzimidate (179 mg, 
1.0 mmol) and methyl hydrazine (92 mg, 2.0 mmol) according to method D; yield: 77 % (227 mg); m.p. 
114-116 °C (CH2Cl2/ Et2O); MS (ESI): 296 (M+H)+. 
 
4-[5-(3-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (14). The title compound was 
prepared by reaction of 3-(4-methoxyphenyl)-5-(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (14i) 
(100 mg, 0.37 mmol) and borontrifluoride dimethyl sulfide complex (27.7 mmol) according to method 
F. The product was purified by preparative TLC (ethyl acetate); yield: 53 % (48 mg); MS (ESI): 268 
(M+H)+. 
 
3,5-Bis(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (15i). The title compound was prepared from 
meta-anisoyl chloride (170 mg, 1.0 mmol), ethyl 3-methoxybenzimidate (179 mg, 1.0 mmol) and 
methyl hydrazine (92 mg, 2.0 mmol) according to method D; yield: 67 % (198 mg); m.p. 67-69 °C 
(CH2Cl2/ Et2O); MS (ESI): 296 (M+H)+. 
 
3-[5-(3-Hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol (15). The title compound was 
prepared by reaction of 3,5-bis(3-methoxyphenyl)-1-methyl-1H-1,2,4-triazole (15i) (100 mg, 0.37 
mmol) and borontrifluoride dimethyl sulfide complex (27.7 mmol) according to method F. The product 
was purified by preparative TLC (ethyl acetate); yield: 64 % (58 mg); MS (ESI): 268 (M+H)+. 
 
2-Bromo-5-(3-methoxyphenyl)thiophene (18ii). The title compound was prepared by reaction of 2,5-
dibromothiophene (465 µL, 4.13 mmol), 3-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium 
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carbonate (876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 µmol) according 
to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 41 % (445 mg). 
 
2-(3-Methoxyphenyl)thiophene (18i). To a solution of 2-bromo-5-(3-methoxyphenyl)thiophene (18ii) 
(100 mg, 0.37 mmol, 1 eq) in dry THF cooled to -78 °C for 5 min, n-BuLi (1.6 M in hexane, 0.28 mL, 
0.44 mmol, 1.2 eq) was added dropwise and stirred for 15 min at -78 °C. The crude mixture was 
carefully hydrolyzed by addition of water (10 ml) and layers were separated. The aqueous layer was 
extracted with ethyl acetate. The combined organic layers were washed with brine, dried over 
magnesium sulfate and evaporated to dryness under reduced pressure; yield: 98 % (69 mg). 
 
3-(2-Thienyl)phenol (18). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)thiophene (18i) (80 mg, 0.42 mmol) and boron tribromide (1.26 mmol) according to 
method E. The product was purified by preparative TLC (hexane/ethyl acetate 7:3); yield: 85 % (63 
mg); MS (ESI): 177 (M+H)+; Anal. (C10H8OS) C, H, N. 
 
2-(3-Methoxyphenyl)-5-phenylthiophene (19i). The title compound was prepared by reaction of 2-
bromo-5-(3-methoxyphenyl)thiophene (18ii) (400 mg, 1.52 mmol), benzeneboronic acid (223 mg, 1.82 
mmol), sodium carbonate (322 mg, 3.04 mmol) and tetrakis(triphenylphosphine) palladium (8.8 mg, 7.6 
µmol) according to method B. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 70 % 
(283 mg). 
 
3-(5-Phenyl-2-thienyl)phenol (19). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-5-phenylthiophene (19i) (100 mg, 0.37 mmol) and boron tribromide (2.22 mmol) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 
81 % (75 mg); MS (ESI): 253 (M+H)+; Anal. (C16H12OS) C, H, N. 
 
2-Bromo-5-(4-methoxyphenyl)thiophene (20ii). The title compound was prepared by reaction of 2,5-
dibromothiophene (V= 465 µL, 4.13 mmol), 4-methoxybenzeneboronic acid (753 mg, 4.95 mmol), 
sodium carbonate (876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 µmol) 
according to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 75 % (815 
mg). 
 
2-(4-Methoxyphenyl)-5-phenylthiophene (20i). The title compound was prepared by reaction of 2-
bromo-5-(4-methoxyphenyl)thiophene (20ii) (400 mg, 1.52 mmol), benzeneboronic acid (223 mg, 1.82 
mmol), sodium carbonate (322 mg, 3.04 mmol) and tetrakis(triphenylphosphine) palladium (8.8 mg, 7.6 
µmol) according to method B. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 75 % 
(303 mg). 
 
4-(5-Phenyl-2-thienyl)phenol (20). The title compound was prepared by reaction of 2-(4-
methoxyphenyl)-5-phenylthiophene (20i) (100 mg, 0.37 mmol) and boron tribromide (2.22 mmol) 
according to method E. The product was purified by preparative TLC (dichloromethane/methanol 99:1); 
yield: 95 % (89 mg); MS (ESI): 253 (M+H)+; Anal. (C16H12OS) C, H, N. 
 
2-(3-Methoxyphenyl)-5-(4-methoxyphenyl)thiophene (22i). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (18ii) (150 mg, 0.57 mmol), 4-
methoxybenzeneboronic acid (223 mg, 0.68 mmol), sodium carbonate (120 mg, 1.14 mmol) and 
tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 µmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 75 % (126 mg). 
 
3-[5-(4-Hydroxyphenyl)-2-thienyl]phenol (22). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-5-(4-methoxyphenyl)thiophene (22i) (150 mg, 0.51 mmol) and boron tribromide (3.06 
mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 93 % (127 mg); MS (ESI): 269 (M+H)+; Anal. (C16H12O2S) C, H, N. 
 
2,5-Bis(3-methoxyphenyl)thiophene (23i). The title compound was prepared by reaction of 2-bromo-
5-(3-methoxyphenyl)thiophene (18ii) (150 mg, 0.57 mmol), 3-methoxybenzeneboronic acid (223 mg, 
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0.68 mmol), sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 
mg, 2.8 µmol) according to method B. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 78 % (132 mg). 
 
3,3'-Thiene-2,5-diyldiphenol (23). The title compound was prepared by reaction of 2,5-bis(3-
methoxyphenyl)thiophene (23i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) according to 
method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 95 % (130 
mg); MS (ESI): 269 (M+H)+; Anal. (C16H12O2S) C, H, N. 
 
4-Bromo-2-(3-methoxyphenyl)thiophene (24ii). The title compound was prepared by reaction of 2,4-
dibromothiophene (1.00 g, 4.13 mmol), 3-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium 
carbonate (876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 µmol) according 
to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 72 % (782 mg). 
 
2-(3-Methoxyphenyl)-4-phenylthiophene (24i). The title compound was prepared by reaction of 4-
bromo-2-(3-methoxyphenyl)thiophene (24ii) (250 mg, 0.93 mmol), benzeneboronic acid (137 mg, 1.12 
mmol), sodium carbonate (197 mg, 1.86 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 4.64 
µmol) according to method B. The product was purified by CC (petroleum ether/ethyl acetate 7:3); 
yield: 91% (225 mg). 
 
3-(4-Phenyl-2-thienyl)phenol (24). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-4-phenylthiophene (24i) (225 mg, 0.85 mmol) and boron tribromide (3.6 mmol) 
according to method E. The product was purified by preparative TLC (dichloromethane/methanol 99:1); 
yield: 69 % (147 mg); MS (ESI): 253 (M+H)+. 
 
4-Bromo-2-(4-methoxyphenyl)thiophene (25ii). The title compound was prepared by reaction of 2,4-
dibromothiophene (1.00 g, 4.13 mmol), 4-methoxybenzeneboronic acid (753 mg, 4.95 mmol), sodium 
carbonate (876 mg, 8.26 mmol) and tetrakis(triphenylphosphine) palladium (24 mg, 20 µmol) according 
to method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 78 % (847 mg). 
 
2-(4-Methoxyphenyl)-4-(3-methoxyphenyl)thiophene (25i). The title compound was prepared by 
reaction of 4-bromo-2-(4-methoxyphenyl)thiophene (25ii) (150 mg, 0.57 mmol), 3-
methoxybenzeneboronic acid (223 mg, 0.68 mmol), sodium carbonate (120 mg, 1.14 mmol) and 
tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 µmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 70 % (118 mg). 
 
3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol (25). The title compound was prepared by reaction of 2-(4-
methoxyphenyl)-4-(3-methoxyphenyl)thiophene (25i) (150 mg, 0.51 mmol) and boron tribromide (3.06 
mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 80 % (109 mg); MS (ESI): 267 (M-H)-; Anal. (C16H12O2S) C, H, N. 
 
2-(3-Methoxyphenyl)-4-(4-methoxyphenyl)thiophene (27i). The title compound was prepared by 
reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (24ii) (150 mg, 0.57 mmol), 4-
methoxybenzeneboronic acid (223 mg, 0.68 mmol), sodium carbonate (120 mg, 1.14 mmol) and 
tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 µmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 70 % (118 mg). 
 
3-[4-(4-Hydroxyphenyl)-2-thienyl]phenol (27). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-4-(4-methoxyphenyl)thiophene (27i) (150 mg, 0.51 mmol) and boron tribromide 
solution (3.06 mmol) according to method E. The product was purified by preparative TLC 
(hexane/ethyl acetate 5:5); yield: 85 % (116 mg); MS (ESI): 267 (M-H)-; Anal. (C16H12O2S) C, H, N. 
 
2,4-Bis(3-methoxyphenyl)thiophene (28i). The title compound was prepared by reaction of 4-bromo-
2-(3-methoxyphenyl)thiophene (24ii) (150 mg, 0.57 mmol), 3-methoxybenzeneboronic acid (223 mg, 
0.68 mmol), sodium carbonate (120 mg, 1.14 mmol) and tetrakis(triphenylphosphine) palladium (3.2 
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mg, 2.8 µmol) according to method B. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 72 % (121 mg). 
 
3,3'-Thiene-2,4-diyldiphenol (28). The title compound was prepared by reaction of 2,4-bis(3-
methoxyphenyl)thiophene (28i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) according to 
method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 88 % (120 
mg); MS (ESI): 267 (M-H)-; Anal. (C16H12O2S) C, H, N. 
 
4,4’-(Seleniene-2,5-diyl)diphenol (29). The title compound was prepared by reaction of 2,5-
dibromoselenophene (150 mg, 0.52 mmol), 4-hydroxybenzeneboronic acid (172 mg, 1.25 mmol), 
caesium carbonate (679 mg, 2.08 mmol) and tetrakis(triphenylphosphine) palladium (6.0 mg, 5.2 µmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 
49 % (81 mg); MS (ESI): 317 (M+H)+; Anal. (C16H12O2Se) C, H, N. 
 
3,3’-(Seleniene-2,5-diyl)diphenol (30). The title compound was prepared by reaction of 2,5-
dibromoselenophene (150 mg, 0.52 mmol), 3-hydroxybenzeneboronic acid (172 mg, 1.25 mmol), 
caesium carbonate (679 mg, 2.08 mmol) and tetrakis(triphenylphosphine) palladium (6.0 mg, 5.2 µmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); yield: 
42 % (69 mg); MS (ESI): 317 (M+H)+; Anal. (C16H12O2Se) C, H, N. 
 
3-Bromo-2-(4-methoxyphenyl)thiophene (31ii). The title compound was prepared by reaction of 2,3-
dibromothiophene (234 µL, 2.1 mmol), 4-methoxybenzeneboronic acid (383 mg, 2.52 mmol), sodium 
carbonate (403 mg, 4.2 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 µmol) according 
to method B. The product was purified by CC (hexane); yield: 70 % (387 mg).  
 
4,4'-(Thiene-2,3-diyl)diphenol (31). The title compound was prepared by reaction of 2,3-bis(4-
methoxyphenyl)thiophene (31i) (150 mg, 0.51 mmol) and boron tribromide (3.06 mmol) according to 
method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); yield: 70 % (95 
mg); MS (ESI): 269 (M+H)+; Anal. (C16H12O2S) C, H, N. 
 
3-Bromo-2-(3-methoxyphenyl)thiophene (32ii). The title compound was prepared by reaction of 2,3-
dibromothiophene (234 µL, 2.1 mmol), 3-methoxybenzeneboronic acid (383 mg, 2.52 mmol), sodium 
carbonate (403 mg, 4.2 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 µmol) according 
to method B. The product was purified by CC (hexane); yield: 58 % (320 mg). 
 
2-(3-Methoxyphenyl)-3-(4-methoxyphenyl)-thiophene (32i). The title compound was prepared by 
reaction of 3-bromo-2-(3-methoxyphenyl)thiophene (32ii) (150 mg, 0.57 mmol), 4-
methoxybenzeneboronic acid (223 mg, 0.68 mmol), sodium carbonate (120 mg, 1.14 mmol) and 
tetrakis(triphenylphosphine) palladium (3.2 mg, 2.8 µmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield 40 % (68 mg). 
 
3-[3-(4-Hydroxyphenyl)-2-thienyl]phenol (32). The title compound was prepared by reaction of 2-(3-
methoxyphenyl)-3-(4-methoxyphenyl)thiophene (32i) (150 mg, 0.51 mmol) and boron tribromide (3.06 
mmol) according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 5:5); 
yield: 56 % (77 mg); MS (ESI): 269 (M+H)+; Anal. (C16H12O2S) C, H, N. 
 
3,3''-Dimethoxy-1,1':4',1''-terphenyl (35i). The title compound was prepared by reaction of 4'-bromo-
3-methoxybiphenyl (35ii) (500 mg, 1.90 mmol), 3-methoxybenzeneboronic acid (346 mg, 2.28 mmol), 
sodium carbonate (403 mg, 3.80 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 9.5 µmol) 
according to an adaptation of method A (heating the mixture 20 h instead of 4 h). The product was 
purified by CC (hexane/ethyl acetate 95:5); yield: 14 % (77 mg).  
 
3,4''-Dimethoxy-1,1':4',1''-terphenyl (36i). The title compound was prepared by reaction of 4'-bromo-
3-methoxybiphenyl (35ii) (500 mg, 1.90 mmol), 4-methoxybenzeneboronic acid (346 mg, 2.28 mmol), 
sodium carbonate (403 mg, 3.80 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 9.5 µmol) 
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according to an adaptation of method A (heating the mixture 20 h instead of 4 h). The product was 
purified by CC (hexane/ethyl acetate 95:5); yield: 90 % (496 mg). 
 
3,3'-Pyridine-2,5-diyldiphenol (37). The title compound was prepared by reaction of 2,5- dibromo 
pyridine (150 mg, 0.63 mmol), 3-hydroxybenzeneboronic acid (231 mg, 1.52 mmol), caesium carbonate 
(821 mg, 2.52 mmol) and tetrakis(triphenylphosphine) palladium (7.3 mg, 6.3 µmol) according to 
method C. The product was purified by preparative TLC (dichloromethane/methanol 98:2); yield: 67 % 
(111 mg); MS (ESI): 262 (M-H)-; Anal. (C17H13NO2) C, H, N. 
  
Biological Methods 
 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described 
procedures.22,62 Fresh human placenta was homogenized and centrifuged. The pellet fraction contains 
the microsomal 17β-HSD2, while 17β-HSD1 was obtained after precipitation with ammonium sulfate 
from the cytosolic fraction. 
 
1. Inhibition of 17β-HSD1  
 
Inhibitory activities were evaluated by a well established method with minor modifications.41, 63, 64 
Briefly, the enzyme preparation was incubated with NADH [500 µM] in the presence of potential 
inhibitors at 37 °C in a phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA 
1mM. Inhibitor stock solutions were prepared in DMSO. Final concentration of DMSO was adjusted to 
1 % in all samples. The enzymatic reaction was started by addition of a mixture of unlabelled- and [2, 4, 
6, 7-3H]- E1 (final concentration: 500 nM, 0.15 µCi). After 10 min, the incubation was stopped with 
HgCl2 and the mixture was extracted with ether. After evaporation, the steroids were dissolved in 
acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 rp 
chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a 
HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of 
the steroids were performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The 
conversion rate was calculated according to following equation: 100
1%2%
2%% ⋅
+
=
EE
E
conversion . 
Each value was calculated from at least three independent experiments.  
 
2. Inhibition of 17β-HSD2 
 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal 
fraction was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 
7-3H]-E2 (final concentration: 500 nM, 0.11 µCi) for 20 min at 37 °C. Further treatment of the samples 
and HPLC separation was carried out as mentioned above. 
 
3. ER affinity 
 
The binding affinity of select compounds to the ERα and ERβ was determined according to 
Zimmermann et al.65 Briefly, 0.25 pmol of ERα or ERβ, respectively, were incubated with [2, 4, 6, 7-
3H]-E2 (10 nM) and test compound for 1 h at rt. The potential inhibitors were dissolved in DMSO (5 % 
final concentration). Non-specific-binding was performed with diethylstilbestrol (10 µM). After 
incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 mL TE-
buffer). The formed complex was separated, washed and resuspended in ethanol. For radiodetection, 
scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were 
measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). For determination of 
the relative binding affinity (RBA), inhibitor and E2 concentrations required to displace 50 % of the 
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receptor bound labelled E2 were determined. RBA values were calculated according to the following 
equation: [ ] ( )( ) 100
2%
50
50
⋅=
compoundIC
EICRBA . The RBA value for E2 was arbitrarily set at 100 %. 
 
4. Evaluation of the estrogenic activity using T-47D cells 
 
Phenol red-free medium was supplemented with sodium bicarbonate (2 g/L), streptomycin (100 
µg/mL), insuline zinc salt (10 µg/mL), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 
U/mL) and DCC-FCS 5% (v/v). RPMI 1640 (without phenol red) was used for the experiments. Cells 
were grown for 48 h in phenol red-free medium. Compounds 4, 10, 22, 25, 35 and 36 were added at a 
final concentration of 100 nM. Inhibitors and E2 were diluted in ethanol (final ethanol concentration 
was adjusted to 1 %). As a positive control E2 was added at a final concentration of 0.1 nM. Ethanol 
was used as negative control. Medium was changed every two to three days and supplemented with the 
respective additive. After eight days of incubation, the cell viability was evaluated measuring the 
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT). The cleavage of 
MTT to a blue formazan by mitochondrial succinat-dehydrogenase was quantified 
spectrophotometrically at 590 nm as described by Denizot and Lang66 with minor modifications. The 
control proliferation was arbitrarily set at 1 and the stimulation induced by the inhibitor was calculated 
according to following equation: ( )[ ]( )[ ] %10012
1% ⋅
−−
−−
=
inducedEionproliferat
inducedcompoundionproliferat
nstimulatio . 
Each value is calculated as a mean value of at least three independent experiments 
 
5. Caco-2 transport experiments 
 
Caco-2 cell culture and transport experiments were performed according to Yee67 with small 
modifications. Cell culture time was reduced from 21 to 10 days by increasing seeding density from 
6.3·104 to 1.65·105 cells per well. Four reference compounds (atenolol, testosterone, ketoprofene, 
erythromycin) were used in each assay for validation. The compounds were applied to the cells as a 
mixture (cassette dosing) to increase the throughput. The initial concentration of the compounds in the 
donor compartment was 50 µM (0.2 M MES, pH: 6.5, containing either 1 % ethanol or DMSO). 
Samples were taken from the acceptor side after 0 min, 60, 120 and 180 min and from the donor side 
after 0 and 180 min. Each experiment was run in triplicate. The integrity of the monolayers was 
checked by measuring the transepithelial electrical resistance (TEER) before the transport experiments 
and by measuring lucifer yellow permeability after each assay. All samples of the CaCo-2 transport 
experiments were analyzed by LC/MS/MS after dilution with buffer of the opposite transwell chamber 
(1:1, containing 2 % acetic acid). The apparent permeability coefficients (Papp) were calculated using 
equation
0
app P
dtAc
dQ
= , where 
dt
dQ
 is the appearance rate of mass in the acceptor compartment, A the 
surface area of the transwell membrane, and c0 the initial concentration in the donor compartment. 
 
6. Metabolic stability assay 
 
The assay was performed with liver microsomes from male Sprague Dawley rats (BD Gentest, USA). 
Stock solutions (10 mM in acetonitrile) were diluted to give working solutions in 20 % acetonitrile. The 
incubation solutions consisted of a microsomal suspension of 0.33 mg/mL of protein in phosphate 
buffer 100 mM pH 7.4 and 90 µL NADP+-regenerating system (NADP+ 1 mM, glucose-6-phosphate 5 
mM, glucose–6-phosphate dehydrogenase 5 U/mL, MgCl2 5 mM).  
The reaction was initiated by the addition of test compound (final concentration 1µM) to the pre-
incubated microsomes/buffer mix at 37 °C. The samples were removed from the incubations after 0, 15, 
30, and 60 min and processed for acetonitrile precipitation. The samples were analyzed by LC-MS/MS. 
Two control groups were run in parallel: positive controls (PC; n= 1) using 7-ethoxycoumarin as 
reference compound to prove the quality of the microsomal enzymatic activity and negative controls 
(NC; n= 1), using boiled microsomes (boiling water bath, 25 min) without regenerating system to 
ensure that the potential apparent loss of parent compound in the assay incubation is due to metabolism. 
The amount of compound in the samples was expressed in percentage of remaining compound 
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compared to time point zero (= 100 %). These percentages were plotted against the corresponding time 
points and the half-life time was derived by a standard fit of the data. 
Intrinsic clearance (Clint) estimates were determined using the rate of parent disappearance. The slope (-
k) of the linear regression from log [test compound] versus time plot was determined as well as the 
elimination rate constant: k= ln2/t1/2. The equation expressing the microsomal Clint can be derived: 
Clint=k*V*fu [µl/min/mg protein], where fu is the unbound fraction. V gives a term for the volume of the 
incubation expressed in µL / mg protein. As fu is not known for the tested compound, the calculation 
was performed with fu =1 (V= incubation volume [µL]/microsomal protein[mg] = 6667). 
 
7. Inhibition of human hepatic CYPs 
 
The commercially available P450 inhibition kits from BD GentestTM (Heidelberg, Germany) were used 
according to the instructions of the manufacturer. Compounds 4, 25 and 35 were tested for inhibition of 
the following enzymes: CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4. Inhibitory potencies were determined 
as IC50-values. 
 
8. In-Vivo Pharmacokinetics 
 
Male Wistar rats weighing 300-330 g (Janvier France) were housed in a temperature- controlled room 
(20-22 °C) and maintained in a 12h light/12h dark cycle. Food and water were available ad libitum. 
They were anesthetized with a ketamine (135 mg/kg)/ xylyzine (10 mg/kg) mixture and cannulated with 
silicone tubing via the right jugular vein and attached to the skull with dental cement.68 Prior to the first 
blood sampling, animals were connected to a counterbalanced system and tubing to perform blood 
sampling in the freely moving rat.  
Compounds 3 and 39 were applied orally in a cassette dosing in 4 rats at the dose of 10 mg/kg body 
weight by using a feeding needle. The compounds were dissolved in a mixture labrasol/water (1:1) and 
given at a volume of 5mL/kg. Blood samples (0.2 mL) were taken at 0, 1, 2, 3, 4, 6, 8, 10 and 24 h 
postdose and collected in heparinised tubes. They were centrifuged at 3000g for 10 min, and plasma 
was harvested and kept at -20 °C until analyzed.  
HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor-HPLC-system 
coupled with a TSQ Quantum (Thermo/Fisher) triple quadrupole mass spectrometer equipped with an 
electrospray interface (ESI).  
 
Computational chemistry 
 
1. Distance and angle calculations 
 
All distances and angles were calculated after energy minimisation using Hyperchem v. 6.0. 
 
2. MEP 
 
For selected compounds ab initio geometry optimisations were performed gas phase at the B3LYP/6-
311**G (d,p) level of density functional theory (DFT) by means of the Gaussian03 software and the 
molecular electrostatics potential map (MEP) was plotted using GaussView 3.09, the 3D molecular 
graphics package of Gaussian.69 These electrostatic potential surfaces were generated by mapping 6-
311G** electrostatic potentials onto surfaces of molecular electron density (isovalue = 0.002e/Å). The 
MEP maps are color coded, where red stands for negative values (3.1*10-2 Hartree) and blue for 
positive ones (4.5*10-2 Hartree).103 
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Paper IV 
 
abstract: 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is responsible for the 
catalytic reduction of weakly active E1 to highly potent E2. E2 stimulates the proliferation of 
hormone-dependent diseases via activation of the estrogen receptor α (ERα). Due to the 
overexpression of 17β-HSD1 in mammary tumors, this enzyme should be an attractive target 
for the treatment of estrogen-dependent pathologies. Recently, we have reported on a series of 
potent 17β-HSD1 inhibitors: bis(hydroxyphenyl) azoles, thiophenes and benzenes. In this 
paper, different substituents were introduced into the core structure and the biological 
properties of the corresponding inhibitors were evaluated. Computational methods and analysis 
of different X-rays of 17β-HSD1 lead to identification of two different binding modes for these 
inhibitors. The fluorine compound 23 exhibits an IC50 values of 8 nM and is the most potent 
non-steroidal inhibitor described so far. It also shows a high selectivity (17β-HSD2, ERα) and 
excellent pharmacokinetic properties after peroral application to rats. 
 
Introduction 
 
Estrogens are involved in the regulation of the female reproduction system. However, it is also 
well known that 17β-estradiol (E2), the natural ligand of the estrogen receptors (ERs) α and β, 
plays a critical role in the development of several estrogen-dependent pathologies like breast 
cancer1 and endometriosis.2 
Until now, hormone-dependent breast cancers are treated using three different endocrine 
therapies:3,4 aromatase inhibitors and GnRH analogues disrupt the estrogen biosynthesis while 
selective estrogen receptor modulators (SERMs) or pure antiestrogens5 prevent E2 to unfold its 
action at the receptor level. Besides specific disadvantages of each therapeutic approach, all of 
these strategies have in common a rather radical reduction of estrogen levels in the whole body 
leading to significant side effects. 
A softer approach could be the inhibition of an enzyme of the 17β-hydroxysteroid 
dehydrogenase (17β-HSD) family, especially one which is responsible for the E2 formation 
from estrone (E1). Until now, three subtypes (1, 7 and 12) are able to catalyze this reaction, the 
most important being 17β-HSD1. The primary physiological role of 17β-HSD7 and 17β-
HSD12 is supposed to be in the cholesterol synthesis6,7 and in the regulation of the lipid 
biosynthesis,8 respectively. In addition, Day et al.9 recently, showed that 17β-HSD12, although 
highly expressed in breast cancer cell lines, is inefficient in E2 formation. 
17β-HSD1, which is responsible for the intracellular NAD(P)H-dependent conversion of the 
weak E1 into the highly potent estrogen E2, is often overexpressed in breast cancer cells10-13 
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and endometriosis.14 Inhibition of this enzyme is therefore regarded as a promising novel target 
for the treatment of estrogen-dependent diseases. 
Recently, two groups9, 15, 16 reported about the in-vivo efficacy of 17β-HSD1 inhibitors to 
reduce E1 induced tumour growth using two different mouse models and indicating that the 
17β-HSD1 enzyme is a suitable target for the treatment of breast cancer. 
In order to not counteract the therapeutic efficacy of 17β-HSD1 inhibitors, it is very important 
that the compounds are selective toward 17β-HSD2, the enzyme which catalyzes the 
deactivation of E2 into E1. Additionally, to avoid intrinsic estrogenic effects, the inhibitors 
should not show affinity to the estrogen receptors α and β.  
During the last decade, several groups reported on 17β-HSD1 inhibitors, most of them having 
steroidal structures.17-19 Recently non-steroidal cores have been published too. Until today four 
classes of compounds are described: thienopyrimidinones,20-21 biphenyl ethanones22 and from 
our group (hydroxyphenyl)naphthalenes23-25 and bis(hydroxyphenyl)azoles, thiophenes, 
benzenes and aza-benzenes.26-30 The most promising compounds of the latest series are 
thiophenes 1, 7 and 33, thiazole 36 and phenylene 40 exhibiting IC50 values toward 17β-HSD1 
in the nanomolar range and high selectivity toward 17β-HSD2 and the ERs (Chart 1).  
 
Chart 1: described bis(hydrophenyl)azoles, thiophenes, benzenes and aza-benzenes 
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In the following, we will report on structural optimizations which led to the discovery of new 
highly potent and selective 17β-HSD1 inhibitors.  
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Chart 2: title compounds 
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Design 
 
Up to now, several crystal structures of human 17β-HSD1 were resolved: as apoenzyme (i.e. 
PDB code: 1BHS31), as binary complex (enzyme-E2, i.e. PDB code: 1IOL32) or as ternary 
complex (enzyme-E2-NADP+: i.e. PDB code 1FDT;33 1A27;34 enzyme-HYC (hybride 
inhibitor): PDB code: 1I5R35).  
The analysis of the ternary complexes available from 17β-HSD1 provides useful knowledge 
about the architecture of the enzyme and important hints for structure based drug design: a 
substrate binding site (SUB) and a cofactor binding pocket (COF) can be identified as well as 
the most important amino acids responsible for substrate and cofactor anchoring. The SUB is a 
narrow hydrophobic tunnel containing two polar regions at each end: His221/Glu282 on the 
one side and Ser142/Tyr155 on the other side, corresponding to the binding oxygens in 3- and 
17-hydroxy group of E2. Additionally a flexible loop can be identified which is not well 
resolved in almost all the structures. 
From previous results obtained in the class of bis(hydroxyphenyl)azoles, thiophenes, benzenes 
and aza-benzenes,26, 27 a SAR study highlighted four structural features which are important for 
high 17β-HSD1 inhibitory activity: 1. one hydroxyphenyl moiety on the core structure is not 
sufficient for a high potency, 2. only the meta-para and meta-meta dihydroxy substitution 
pattern (O-O distance in the same range as observed for the steroid, d = 11 Å) are active, 3. the 
presence of the meta-hydroxy group is more important for inhibitory activity than the para-, 4. 
only central aromatic rings without hydrogen bond donor function like thiophene, thiazole, 
benzene exhibit inhibitory activity. It was also shown that a correlation seems to exist between 
the activity of the compounds and the electrostatic potential distribution of the molecules:27 to 
be active the ESP values of the different regions of the inhibitor has to be in an appropriate 
range. 
In the present report, we will present the structure optimization of this class of compounds 
leading to an increase in activity and in selectivity of these inhibitors. First, the influence of the 
bioisosteric exchange of one OH group on the enzyme activity will be determined. Secondly, 
the space availability around the inhibitors and the nature of the most appropriate substituent 
will be investigated by substitutions, either on the heterocycle, or on the hydroxyphenyl 
moieties. The nature of the substituent will be varied in order to investigate the possible 
interactions between the inhibitor and the enzyme. Thirdly, computational studies (docking 
studies and ESP calculations) will be performed in order to identify the most plausible binding 
mode for this class of compounds. Furthermore the selectivity toward 17β-HSD2 and the ERs 
α and β will be determined as well as the potency of the compounds in T-47D cells and 
inhibition of the two most important hepatic CYP enzymes. Finally, the pharmacokinetic 
profile of the two most promising candidates will be evaluated in rats after oral administration. 
 
Chemistry 
 
The synthesis of compounds 1 to 11, 21 to 25 and 32 is presented in Scheme 1. Starting from 
the mono-brominated key intermediate 1b and the appropriate commercially available boronic 
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acids, the preparation of compounds 1a to 11a, 21a to 25a and 32a was accomplished via 
Suzuki cross coupling reaction36 under microwave assisted conditions (Method A: Cs2CO3, 
DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min). The resulting 
disubstituted thiophenes were subsequently submitted to ether cleavage with borontribromide27 
(Method C: BBr3, CH2Cl2, -78 °C to rt, 18 h) leading to compounds 1 to 11, 21 to 25 and 32 
(Scheme 1). In case of intermediate 25a, the boronic acid 25b was prepared in a three step 
synthesis pathway: first, an iodine substituent was selectively introduced in position 2 of the 
para-bromoanisole (compound 25d) using (diacetoxyiodo) benzene.37 Then, a selective Suzuki 
reaction on the iodo-position of 25d under Method B (Na2CO3, toluene/water (1:1), Pd(PPh3)4, 
reflux, 20 h) led to the intermediate 25c and the corresponding boronic acid 25b was prepared 
using n-butyl lithium and triethyl borate followed by hydrolysis with diluted hydrochloric acid. 
 
Scheme 1a: synthesis of compounds 1 to 11, 21 to 25 and 32 
 
S
MeO
B(OH)2
S
OH
S
MeO
OMe
Br
OMe
Br
I
OMe
Br
Ph
OMe
B(OH)2
Ph
S
MeO
OMe
Ph
Br +
a b
b
1b R1
R2
R2
R1
1a-11a
21a-24a
32a
1-11
21-25
32
R1
R2
+ 1b
25a25b25c25d
d ec f
 
cmpd R1 R2 cmpd R1 R2 
1 OH H 9 H N
H
SO2
 
2 H H 10 H NH
SO2
 
3 F H 11 H NH
SO2
 
4 NH2 H 21 OH CH3 
5 SH H 22 OH OH 
6 CN H 23 OH F 
7 H OH 24 OH CF3 
8 H F 25 OH Ph 
 
  32 F F 
 
aReagents and conditions: (a) Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 
15 bars), 15 min; (b) BBr3, CH2Cl2, -78 °C to rt, 18 h; (c) PhI(OAc)2, I2, AcOEt, 60 °C, 5 h; (d) Ph-B(OH)2, 
Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h; (e) 1. n-BuLi, dry THF, 5 min, -78 °C, 2. 
B(OEt)3, 2 h -78°C to rt, 3. HCl 1N, rt; (f) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h. 
 
The preparation of compounds 31 and 33 to 42 is similar to the synthetic pathway presented in 
Scheme 1 for compounds 1 to 11. The first Suzuki coupling was carried out according to 
Method B with the corresponding dibrominated heterocycle and the methoxylated benzene 
boronic acid. The resulting mono substituted compounds 31b and 33b to 42b were submitted 
to a second cross coupling reaction under microwave assisted conditions following Method A. 
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The compounds were subsequently demethylated with boron tribromide to yield compounds 31 
and 33 to 42. 
 
The synthesis of compounds 12, 14 and 15 is depicted in Scheme 2. The key intermediate 
mono methoxylated dibromothiophene 12b was prepared following two successive Suzuki 
coupling reactions according to Method B (Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 
h) from 2,3,5-tribromothiophene and methoxybenzene boronic acid. The reaction time of both 
cross couplings was carefully controlled (restricted to 4 h) in order to get a selective bromine 
replacement each time. Intermediates 12a, 14a, and 15a were obtained via a third Suzuki 
coupling using Method B. The methoxy substituents were cleaved in a last step, using boron 
tribromide (Method C: BBr3, CH2Cl2, -78 °C to rt, 18 h).  
 
Scheme 2a: synthesis of compounds 12, 14 and 15 
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14a 3-OMe, R= H
15a 3-OMe, R= 3-OMe
12
14-15
a
 
aReagents and conditions: (a) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 h; (h) boronic acid, 
Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h; (d) BBr3, CH2Cl2, -78 °C to rt, 18 h. 
 
Compound 13 was synthesized under microwave assisted conditions in a one pot reaction using 
2,5-dibromo-3-methylthiophene and 3-hydroxyphenyl boronic acid following Method A 
(Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars)) for 15 min. 
 
The synthesis of the molecules bearing an additional substituent on the meta-hydroxyphenyl 
moiety of thiophene 1 (compounds 16 to 20) is shown in Scheme 3. Intermediate 16c was 
prepared via Suzuki reaction from the para-methoxylated benzene boronic acid and the 2,5-
dibromothiophene following Method B heating the reaction 4 h instead of 20 h in order to 
avoid any dicoupling reaction. Treatment of 16c with n-butyl lithium and triethyl borate 
afforded after hydrolysis with diluted hydrochloric acid the corresponding boronic acid 16b. 
The resulting compound was subjected to an additional cross coupling reaction which was 
carried out with the appropriate bromine derivative following Method A for compounds 17a to 
20a and Method B for compound 16a. The hydrolysis of the methoxy groups with boron 
tribromide (Method C) led to compounds 16 to 20. 
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Scheme 3a: synthesis of compounds 16 to 20 
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Reagents and conditions: (a) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 4 h; (b) 1.n-BuLi, 
anhydrous THF, -78 °C, 15 min, 2. B(OEt)3, THF, -78 °C to rt, 2 h, 3. HCl 1N; (c) Method A for 17a-20a 
(Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min); Method B for 16a 
(Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h); (d) BBr3, CH2Cl2, -78 °C to rt, 18 h. 
 
The synthesis of compounds 26 to 28 substituted in ortho-position of the para-OH group is 
depicted in Scheme 4. The preparation of the key intermediate 26b started from the 
commercially available 3-formyl-4-methoxyphenyl boronic acid. Reduction of the aldehyde 
function using sodium borohydride followed by a cross coupling reaction with 1b under 
microwave irradiation according to Method A (Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, 
MW (150 W, 150 °C, 15 bars), 15 min) afforded the disubstituted thiophene 26c. The alcohol 
function of 26c was subsequently oxidized with pyridinium chlorochromate to yield to the key 
aldehyde 26b. It was subjected to the Horner-Wadworths-Emmons conditions38 to introduce 
the acrylic ester moiety (intermediate 26a). Hydrolysis of the ester function using lithium 
hydroxide,24 amide bond formation with aniline, EDCI and HOBt39 afforded compound 27a 
The catalytic double bond hydrogenation of 27a was performed using Perlman’s catalyst.40 The 
ether functions of 26a, 27a and 28a were deprotected using boron tribromide (Method C) to 
give the desired compounds 26 to 28.  
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Scheme 4a: synthesis of compounds 26 to 28  
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aReagents and conditions: (a) NaBH4, THF/EtOH (1:1), 0 °C to rt, 2 h; (b) Method A: Cs2CO3, 
DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min; (c) PCC, CH2Cl2, rt, 30 min; (d) 
NaH, THF dry, rt, 4 h; (e) BBr3, CH2Cl2, -78 °C to rt, 18 h; (f) 1. LiOH, THF/H2O (2:1), reflux, 20 h, 2. aniline, 
EDCI, HOBt, CH2Cl2, reflux, 20 h; (g) Pd(OH)2, THF/EtOH (1:1), H2, rt, 20 h. 
 
 
The synthesis of the difluorinated thiophenes 29 and 30 is presented in Scheme 5. These 
compounds were obtained after two successive cross coupling reactions: in a first step 2,5-
dibromothiophene reacted with 3-fluoro-4-methoxyphenyl boronic acid following Method B 
(Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h). In a second step, the resulting mono 
substituted thiophene 29b was subsequently submitted to a second cross coupling reaction 
under microwave irradiation (Method A: Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW 
(150 W, 150 °C, 15 bars), 15 min) to yield the intermediates 29a and 30a. Ether cleavage with 
boron tribromide led to the final compounds 29 and 30. 
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Scheme 5a: synthesis of compounds 29 to 30 
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aReagents and conditions: (a) Method B: Na2CO3, toluene/water (1:1), Pd(PPh3)4, reflux, 20 h ; (b) Method A: 
Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bars), 15 min; (c) BBr3, CH2Cl2, -78 °C to 
rt, 18 h. 
 
Biological Results 
 
Activity: inhibition of human 17β-HSD1 
 
Placental enzyme was partially purified following a described procedure.26, 27 Tritiated E1 was 
incubated with 17β-HSD1, cofactor and inhibitor. After HPLC separation of substrate and 
product, the amount of labelled E2 formed was quantified. The inhibition values of the test 
compounds are shown in Tables 1 to 5. Thiophenes 1, 2, 7 and 29, thiazole 33 and phenylenes 
35 and 37, identified in our previous article,27 were used as reference compounds. 
It was first investigated whether one of the two hydrophenyl moieties could be exchanged by 
another functional group having similar properties. Previous results27 showed that the meta-
hydroxy group is highly important for activity and was therefore maintained in the core 
structure. The exchange of the para-hydroxy group on the meta-para disubstituted thiophene 
(1, IC50= 69 nM) by a bioisosteric function (F, NH2, SH) resulted in moderate (3, IC50= 717 
nM) or weak inhibitors (4 and 5, IC50> 5000 nM) of 17β-HSD1 (Table 1). Moving the F atom 
from the para- (compound 3) to the meta-position (compound 8) led to a small increase in 
activity (8, IC50= 535 nM vs. 3, IC50= 717 nM). Replacement of the meta-fluorine for a 
methylsulfonamide moiety (9) did not improve the activity (9, IC50= 523 nM vs. 8, IC50= 535 
nM), while a compound bearing a bulky substituent like tolylsulfonamide (11, IC50= 350 nM) 
showed comparable activity to the mono hydroxylated thiophene (2, IC50= 342 nM) indicating 
that there is some space in this region of the enzyme for substitution but it is unlikely that 
specific interactions between the tolylsulfonamide moiety and amino acids of the active site 
take place. The insertion of a C1-linker between the phenyl moiety and the methylsulfonamide 
group was detrimental for the activity (9, IC50= 523 nM vs. 10, IC50> 1000 nM). It can be 
therefore concluded that the two hydroxy functions are necessary for high activity and the 
para-hydroxy group can not be replaced by a bioisoteric group. 
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Table 1: effect of the exchange of one OH substituent for other functional groups on human 
17β-HSD1 and 17β-HSD2 inhibitory activities. 
 
S
OH R
S
OH
R
1-6 2
7-11
 
cmpd R 
IC50 (nM)a 
selectivity 
factord cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
17β- 
HSD1b 
17β- 
HSD2c 
1 OH 69 1950 28 7 OH 173 745 4 
2 H 342 2337 7 2 H 342 2337 7 
3 F 717 3655 5 8 F 535 1824 3 
4 NH2 >5000 nt  9 N
H
SO2
 
523 1575 3 
5 SH >5000 nt  10 NH
SO2
 
>1000 nt  
6 CN >1000 nt  11 NH
SO2
 
350 276 1 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
In order to improve the activity and the selectivity of our inhibitors, substituents capable to 
establish further interactions with the enzyme were added either on the heterocycle or on the 
hydroxyphenyl moieties. Additional functional groups were introduced in both of the meta-
para 2,5-bis(hydroxyphenyl)thiophene 1 (IC50 = 69 nM) and the meta-meta 2,5-disubstituted 
derivative 7 (IC50 = 216 nM). 
 
Concerning substitution on the heterocycle, two kinds of hydrophobic substituents (Me, Ph) 
were introduced in position 3 on the thiophene ring to investigate the space availability around 
the core (Table 2). The meta-meta thiophenes bearing a methyl (compound 13) or phenyl 
(compound 14) as well as the meta-para thiophene bearing a hydroxyphenyl substituent 
(compound 12) showed a drop of activity compared to the reference compound 7 (IC50= 216 
nM vs. IC50> 1000 nM, 567 nM and 493 nM for 12, 13 and 14, respectively). It is striking that 
only in case of the meta-meta disubstituted series the insertion of a polar meta-hydroxyphenyl 
substituents leads to an increase in activity (15, IC50= 119 nM vs. 12, IC50> 1000 nM). This 
exemplifies that there is space available for further substitution around the heterocycle only in 
case of the meta-meta bis(hydroxyphenyl) substitution pattern and that the third meta-OH 
group is certainly at an appropriate distance to establish supplementary hydrogen bond 
interactions with the active site. 
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Table 2: inhibition of human 17β-HSD1 and 17β-HSD2 by compounds bearing a 
supplementary substituent on the thiophene core structure 
 
S
R
OH OH
S
R
OH
OH
7
13-15
1
12
 
cmpd R
 
IC50 (nM)a 
selectivity 
factord cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
17β- 
HSD1b 
17β- 
HSD2c 
1 H 69 1950 28 7 H 173 745 4 
 
    13 CH3 567 856 1 
 
    14 
 
493e nt  
12 
OH
 
>1000 nt  15 
OH
 
119 188 2 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction,  
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ecalculated value, obtained 
with the LOGIT transformed; ni: no inhibition, nt: not tested 
 
Concerning the substitution of the hydroxyphenyl rings, different groups were introduced 
either on the meta-hydroxyphenyl ring (compounds 16 to 20) or on the para-hydroxyphenyl 
moiety (compounds 21 to 28, Table 3). The ortho-position was not considered, as these 
compounds would not be planar any more. 
Introduction of a substituent in position 5 on the meta-hydroxyphenyl moiety resulted in case 
of a methyl group in a drop of activity (16, IC50= 629 nM vs. 1, IC50= 69 nM). The introduction 
of a fluorine atom led to slight increase in activity in comparison to the unsubstituted 
compound 1 (17, IC50= 42 nM vs. 1, IC50= 69 nM). Moving these functional groups to position 
4 gave a highly active fluorinated compound 19 (IC50= 113 nM) and a very weak methylated 
inhibitor 18 (IC50> 5000 nM). Substituents have also been introduced in position 5 on the para-
hydroxyphenyl ring: a polar group like a hydroxy (compound 22) or a bulky substituent like a 
phenyl (compound 25) in ortho- of the para-OH induced a decrease in activity compared to 
thiophene 1 (IC50= 69 nM vs. IC50= 402 nM and >5000 nM for 22 and 25, respectively). The 
introduction of a fluorine substituent into the same position led to the highly potent compound 
23 (IC50= 8 nM) while substituents like methyl or trifluoromethyl showed equal or slightly 
better activities compared to the reference compound 1 (IC50= 69 nM vs. IC50= 46 nM and 38 
nM for 21 and 24, respectively). Other functional groups showing a higher flexibility like 
ethylacrylate (compound 26), phenylacrylamide (compound 27) or phenylpropaneamide 
(compound 28) were also synthesized and the resulting compounds 26, 27 and 28 turned out to 
have weaker inhibitory activity compared to the unsubstituted thiophene 1 (IC50= 69 nM vs. 
130, 427 and 620 nM for 26, 27 and 28, respectively). The low activity of the unconjugated 
compound 28 indicates that an overall distributed electronic density is an important parameter 
for activity. These results indicate that there is space available in this area for substituents but 
the nature of the substituents are probably not yet optimal (Table 3). 
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Table 3: effect of a supplementary substituent on the hydroxyphenyl moieties on the inhibition 
of the human 17β-HSD1 and 17β-HSD2 
 
S
OH
OH
S
OH
OH
R
1
16-20
R
21-28
4
5
 
cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
1 H 69 1950 28 
16 5-CH3 629 2584 4 
17 5-F 42 463 11 
18 4-CH3 >5000 nt  
19 4-F 113 183 2 
20 4-OH >5000 nt  
21 CH3 46 1971 49 
22 OH 402 1636 4 
23 F 8 940 118 
24 CF3 38 97 3 
25 Ph >5000 nt  
26 
O
OEt
 
130 502 4 
27 
O
N
H
 
427 468 1 
28 
O
N
H
 
620 982 2 
 
aMean values of three determinations, standard deviation less than 15 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
 
The influence of the introduction of a second fluorine on the highly active thiophene 23 (IC50= 
8 nM), either one F on each hydroxyphenyl ring or two F on the same hydroxyphenyl moiety, 
was also examined (Table 4). When the two F were located on each hydroxyphenyl moieties, 
the 4-substituted fluoro derivative (compound 30) is slightly more potent that the one with the 
fluorine in 5-position (29, IC50= 29 nM, vs. 30, IC50= 17 nM). A slight decrease in activity was 
observed when the two fluorine substituents were present at the same hydroxyphenyl ring 
(compound 31, IC50= 56 nM). The exchange of the para-OH function of 23 by a fluorine atom 
(compound 32) confirmed the essential role of this para-hydroxy moiety as previously 
observed. 
RESULTS  - 84 - 
Table 4: effect of two additional fluorine atoms on the 17β-HSD1 and 17β-HSD2 inhibitory 
activity 
 
S
OH
OH
F
S
OH
OH
F
F
S
OH
F
F
23
29-30
R1
31 32
4
5
 
cmpd R1 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
23 H 8 940 118 
29 5-F 29 227 8 
30 4-F 17 218 13 
31  56 312 6 
32  780 2640 3 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); nt: not tested. 
 
Methyl and fluorine substituents have been identified as functional groups able to increase the 
inhibitory activity of the 2,5-bis(hydroxyphenyl) thiophene 1. Previously27 we reported that 
other central core structures like 2,4-thiophene, 2,5-thiazole and 1,4-benzene lead to highly 
active compounds. The influence of an additional methyl or fluorine substituent at these 
structures was therefore also investigated (Table 5). Introduction of CH3 or F into the para-
hydroxyphenyl ring of 33, 36, 38 and 40 resulting in compounds 34, 35, 37, 39 and 42 led to 
equally active derivatives in case of 34 and 35 (IC50= 64 nM vs. 21, IC50= 46 nM). A decrease 
in inhibitory activity in the thiazole and in the benzene classes of compounds was observed 
compared to the thiophene family (37, IC50= 143 nM vs. 21, IC50= 46 nM; 39 and 42, IC50= 
123 nM and 51 nM, respectively vs. 23, IC50= 8 nM). Amongst the investigated molecules, 
introduction of a methyl or fluorine substituent led only in the class of the bis(hydroxyphenyl) 
thiophenes to an increase in activity. 
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Table 5: influence of the core and a supplementary substituent on the inhibition of the human 
17β-HSD1 and 17β-HSD2 
OH
cycle
R2
R1
21-23
33-42
 
cmpd cycle R1 R2 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
21 
S
 
CH3 OH 46 1971 49 
23 F OH 8 940 118 
 
      
33 
S
 
H OH 77 1270 16 
34 CH3 OH 64 869 14 
35 F OH 64 510 8 
 
      
36 
S
N
 
H OH 50 4000 80 
37 CH3 OH 143 2023 14 
 
      
38 
 
H OH 471 4509 10 
39 F OH 123 872 7 
40 OH H 173 2259 21 
41 OH CH3 171 1248 7 
42 OH F 51 239 5 
 
aMean values of three determinations, standard deviation less than 13 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
Selectivity: inhibition of 17β-HSD2 and affinities to the estrogen receptors α and β 
 
In order to gain insight into the selectivity of the most active compounds, inhibition of 17β-
HSD2 and the relative binding affinities to the estrogen receptors α and β were determined. 
Since 17β-HSD2 catalyzes the inactivation of E2 into E1, inhibitory activity toward this 
enzyme must be avoided. The 17β-HSD2 inhibition was determined using an assay similar to 
the 17β-HSD1 test. Placental microsomes were incubated with tritiated E2 in the presence of 
NAD+ and inhibitor. Separation and quantification of labelled product (E1) was performed by 
HPLC using radio detection. A selection of the most potent 17β-HSD1 inhibitors was tested for 
inhibition of 17β-HSD2. IC50 values and selectivity factors (IC50 HSD2 / IC50 HSD1) are 
presented in Tables 1 to 5. 
Mono-hydroxylated compounds (Table 1) exhibited a poor selectivity regarding 17β-HSD2, 
the most selective one being compound 5 with a selectivity factor of 5. This finding suggests 
that the para-OH is important for activity as well as for selectivity (selectivity of the para-meta 
derivative 1: 28). Introduction of further substituents (Tables 2 to 5) into the highly active 
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bis(hydroxyphenyl) scaffold induced a loss of selectivity against 17β-HSD2 except in case of 
compounds 21 and 23, which exhibit excellent selectivity factors of 49 and 118, respectively 
toward 17β-HSD2. 
A further prerequisite for 17β-HSD1 inhibitors to be used as potential drugs is that they do not 
show affinity for ERα and ERβ, since binding to these receptors could counteract the 
therapeutic concept of selective 17β-HSD1 inhibition. The binding affinities of the most 
selective compounds of this study were determined using recombinant human protein in a 
competition assay applying [3H]-E2 and hydroxyapatite (Table 6). All tested compounds show 
very marginal to marginal affinity to the ERs except compound 23, which binds weakly to ERβ 
(RBA= 1 %). Compound 21 was evaluated for estrogenic effects on the ER-positive, mammary 
tumor T-47D cell line. No agonistic, i.e. stimulatory effect was observed after application of 
compound 21 even at a concentration 1000 fold higher compared to E2.  
 
Table 6: binding affinities for the human estrogen receptors α and β of selected compounds 
 
cmpd RBA
a
 (%) 
ERαb ERβb 
1 0.1< RBA <1 1.5 
17 0.1< RBA <1 0.1< RBA <1 
21 < 0.01 < 0.01 
23 0.01< RBA <0.1 1 
30 0.1 0.01< RBA <0.1 
34 0.01< RBA <0.1 0.01< RBA <0.1 
37 0.01< RBA <0.1 < 0.01 
 
aRBA (relative binding affinity), E2: 100 %, mean values of three determinations, standard deviations less than 10 
%; bHuman recombinant protein, incubation with 10 nM 3H-E2 and inhibitor for 1 h. 
 
Further biological evaluations 
 
Additionally, the intracellular potency of compounds 21 and 23 on E2 formation was evaluated 
using a cell line which expresses both 17β-HSD1 and 17β-HSD2 (T47D cells). Compound 21 
and 23 inhibited the formation of E2 after incubation with labelled E1 showing IC50 values of 
426 nM and 282 nM, respectively. These results indicate that both compounds are able to 
permeate the cell membrane and inhibit the transformation of E1 into E2. 
Compounds 21 and 23 were further investigated for inhibition of the two most important 
human hepatic enzymes: CYP3A4 and CYP2D6, which are responsible for 75 % of drug 
metabolism. At a concentration of 2 µM, both compounds turned out to be equally active 
inhibiting the CYP3A4 by 80 (21) and 71 % (23), respectively and CYP2D6 by 55 (21) and 56 
% (23), respectively. The relatively high inhibition of these enzymes has to be taken into 
consideration in the process of further developing these compounds but should not have an 
impact on the proof of concept in-vitro. 
The pharmacokinetic profiles of compound 21 and 23 were determined in rats after oral 
administration in a cassette dosing approach. Each group consisted of 4 male rats and the 
compounds were administered in doses of 10 mg/kg. Plasma samples were collected over 24 h 
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and plasma concentrations were determined by HPLC-MS/MS. The pharmacokinetic 
parameters are presented in Table 7. The maximal concentration (Cmax obs) as well as the AUC-
value is higher for compound 23 (Cmax= 1388.2 ng/mL, AUC= 19407 ng/mL) than for 
compound 21 (Cmax= 905.0 ng/mL, AUC= 12275 ng/mL). The maximal plasma concentration 
(tmax obs) for compounds 21 and 23 was reached after 4.0 and 8.0 h, respectively, after oral 
administration. These data show that both compounds exhibit excellent pharmacokinetic 
properties in the rat and might therefore be good candidates for further experiments in disease-
oriented rat models. 
 
Table 7: pharmacokinetic parameters of compounds 21 and 23 in male rats after oral 
application (10 mg/kg) 
 
parametersa cmpd 21 23 
Cmax obs (ng/mL) 905.0 1388.2 
Cz (ng/mL) 43.3 24.9 
tmax obs (h) 4.0 8.0 
tz (h) 24.0 24.0 
t1/2z (h) 3.8 2.7 
AUC0-∞ (ng/mL) 12275 19407 
 
a
 Cmax obs, maximal measured concentration; Cz, last analytical quantifiable concentration; 
tmax obs, time to reach the maximum measured concentration; tz, time of the last sample which has an analytical 
quantifiable concentration; t1/2z, half-life of the terminal slope of a concentration time curve; AUC0-∞, area under 
the concentration- time curve extrapolated to infinity. 
 
Computational chemistry 
 
Molecular modelling 
 
From the biological results it became apparent that introduction of a fluorine atom in ortho-
position to the para-OH phenyl thiophene structure (compound 23) led to a significant increase 
in the 17β-HSD1 inhibitory activity. To get an insight into the binding mode of this compound 
and to better understand the favourable interactions achieved by this inhibitor in the active site, 
computational studies were performed by means of the docking software GOLDv3.2 and 
Autodock 4.1. 
The choice of the 3D-structure of the enzyme, i.e. crystal structure, used for the docking 
studies is crucial for obtaining reliable results. It was decided to focus on X-ray structures of 
17β-HSD1 having a high resolution and showing a ternary complex (to get closer to the in vivo 
3D-enzyme structure). Three structures appeared to fulfil the criteria: 1FDT and 1A27 both 
describing the ternary complex: enzyme-E2-NADP+ and 1I5R, describing the binary complex: 
enzyme-steroidal hybride inhibitor (HYC), the latter being an adenosine moiety linked to an E2 
core via a C9-linker. These three crystal structures differ mainly in the location of the amino 
acids belonging to the flexible loop αG’βF (Pro187-Pro200). Since this loop borders both the 
SUB and the COF, its conformational variations strongly influence the size of both binding 
cavities. It is therefore important to take care of the position of this loop in the structures used 
for the docking studies.  
In the X-ray structure 1FDT, the residues 187-200 are not well resolved, but two plausible 
conformations for the loop (noted 1FDT-A and 1FDT-B) have been described33 The backbones 
of these two loops are similar (RMSD of ~ 1 Å), while the main difference is given by the 
orientation of the sidechains, mainly concerning the four amino acids Phe192, Met193, Glu194 
and Lys195. In 1FDT-A, Phe192 and Met193 are turned toward the outer part of the enzyme 
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while Glu194 and Lys195 are oriented toward the substrate and the cofactor (extending the 
substrate binding site = open conformation). On the other hand, in 1FDT-B these two couples 
of residues show a reversed orientation limiting length and volume of the steroid binding site 
compared to 1FDT-A (= closed conformation). Although others21 have only considered 1FDT-
B, we decided to investigate both conformations of this loop.  
Interestingly, the flexible loop in 1A27 shows a comparable geometry as observed in 1FDT-B, 
with Phe192 and Met193 oriented toward the nicotinamide moiety, also restricting the space in 
the substrate binding site. In case of 1I5R, the loop is shifted in direction of the cofactor, 
resulting in a different conformation compared to both 1FDT-A and 1FDT-B. Although, like 
for 1FDT-A, it extends the SUB.  
Compound 23 was docked with NADPH into four different X-ray structures: 1FDT-A, 1FDT-
B, 1A27 and 1I5R. Two different binding modes were observed for compound 23: in case of 
1FDT-B and 1A27, the inhibitor is located exclusively in the steroid binding site (Figure 1) 
adopting a similar orientation as previously described for the bis(hydroxyphenyl) oxazole B26 
(chart 1) while for 1FDT-A and 1I5R, the inhibitor is located in between the steroid and the 
cofactor binding sites, interacting with the nicotinamide moiety. In the following, this binding 
mode will be named as alternative binding mode (Figure 2).  
 
 
 
Figure 1. docking complex between 17β-HSD1 (X-ray 1FDT-B) and compound 23 (blue; 
SUB binding mode). NADPH, interacting residues and ribbon rendered tertiary structure of the 
active site are shown. Residues of the flexible loop are rendered in sticks and colored in 
yellow. Hydrogen bonds and pi-pi stackings (and hydrophobic interactions) are drawn in yellow 
and blue dashed lines, respectively. For comparison, E2 is depicted in magenta lines. Figures 
were generated with Pymol (http://www.pymol.org). 
 
In case of the steroidal binding mode (1FDT-B and 1A27, Figure 1) the following specific 
interactions can be observed: hydrogen bond interactions between the meta-hydroxy group of 
23 and Ser142/Tyr155 (dO-O= 2.6 Å for both amino acids) and between the para-OH group and 
His221/Glu282 (dO-N= 2.8 Å and dO-O= 3.8 Å, Figure 1). Additionally, hydrophobic 
interactions and pi-pi stackings (Phe226, Phe259) are also involved. 
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Figure 2. docking complex between 17β-HSD1 (X-ray 1FDT-A) and compound 23 (green; 
alternative binding mode). NADPH, interacting residues and ribbon rendered tertiary structure 
of the active site are shown. Residues of the flexible loop are rendered in sticks and colored in 
blue. Hydrogen bonds and pi-pi stackings (and hydrophobic interactions) are drawn in yellow 
and blue dashed lines, respectively. For comparison, E2 is depicted in magenta lines. 
 
In the alternative binding mode obtained using 1FDT-A and 1I5R (Figure 2), compound 23 is 
also stabilized by hydrogen bond interactions: the meta-OH group forms a strong H-bond with 
the phosphate group of the cofactor (dO-O= 2.9 Å). The fluorine atom could establish halogen 
bonds with the backbone -NH- of Val143 and Gly144 (dF-N= 3.2 Å and 3.8 Å, respectively), in 
addition to a halogen bond with the OH-group of Ser142 (dF-O= 3.5 Å) which is involved in the 
catalytic process. Further, the para-OH points perpendicular toward Phe259 (dO-centroid= 4.5 Å) 
indicating a possible OH-pi interaction. This could explain the importance of this group 
observed in the SARs. Moreover, strong pi-pi stacking interactions seem to stabilize the 
inhibitor in this binding mode: between the meta-OHphenyl-thiophene moiety and the 
nicotineamide part of the cofactor (parallel-displaced configuration; distance between the two 
ring centers, 4.3 Å) and between the para-OH-phenyl-thiophene moiety and Phe226 (T-shape 
conformation; closest C-C contact distance 3.7 Å). Moreover, electrostatic interactions 
between the sulfur atom of the heterocycle with the surrounding amino acids like Tyr155 and 
Ser142 might also play a role as described.41 
The results presented so far suggest that both binding modes have to be considered as possible 
for this class of inhibitors. They depend mainly on the orientation of the flexible loop. There is 
only one conformation of the loop leading to a steroidal binding mode (1FDT-B/1A27). In case 
of 1FDT-A/1I5R the pose showing the alternative binding mode is obtained using two X-ray 
structures having two different conformations of the loop. Unfortunately, due to the almost 
identical scoring function values observed for both poses with the docking programs (Gold and 
Autodock), it was not possible to determine which model (1FDT-A/1I5R or 1FDT-B/1A27) is 
the most appropriate to describe the interactions between the inhibitor and the enzyme and 
therefore which is the most plausible binding mode.  
Comparing both poses obtained by docking of 23 in 1FDT-A and 1FDT-B shows that there is a 
common area in the neighbourhood of the catalytic tetrade which corresponds to the D-ring of 
the enzyme-substrate complex (Figure in Supporting Information). 
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Molecular Electrostatic Potential (MEP) 
 
Recently we reported on the influence of the electronic density (MEP maps, “semi-QMAR”) 
on the potency of the inhibitors in this class of compounds.27 The 3D-structures of the 
inhibitors were virtually divided into three areas and a given optimal range of ESP values (in 
Hartree) was determined for each region (-1.7 to -1.2 × 10-2 for I, -1.6 to -0.9 × 10-2 for II and -
1.2 to -0.5 × 10-2 for III). The MEPs of compound 23 were calculated as shown in Figure 3. 
The molecular ESP distribution observed (-1.8 to -1.2 × 10-2 for I, -1.6 to -0.8 × 10-2 for II and 
-1.1 to -0.4 × 10-2 for III) fitted well to the optimal ranges identified previously, confirming the 
correlation between the ESP range and the potency of the compounds. The MEP maps of the 
natural substrate E1 and of E2 were also calculated (Figure 3) and compared to the one of 23. 
The finding that the ESP distribution of 23 and E2/E1 is very different might be an indication 
that compound 23 does not bind in the same way as the steroid.  
 
 
Figure 3. structures and MEP maps of both ventral (steroidal α-side) and dorsal (steroidal β-
side) views of truncated NADPH (A), thiophene 23 (B), E1 (C) and E2 (D). MEP surfaces 
were plotted with GaussView 3.09. 
 
According to the alternative binding mode, the meta-hydroxyphenyl thiophene part of 23 
overlaps with the nicotinamide part of the cofactor and forms stabilizing pi-pi interactions. The 
ESP distribution of these two entities should therefore show complementarity. To get an 
insight into this, the MEP map of a truncated NADPH –the counterpart of the meta-OHphenyl-
thiophene moiety- was calculated by ab initio methods. As it can be seen in Figure 3 a certain 
complementarity was observed. The NADPH MEP maps give the explanation for the 
observation27 that a strong polarization between the vertex and the base of the central ring of 
the inhibitors is negative for binding. Positive ESP values on the vertex side lead to repulsion 
effects with the nicotinamide and therefore reduce the inhibitory activity. This finding indicates 
that this class of compound might bind according to the alternative binding mode (Figure 2). 
However, this hypothesis needs to be further investigated. 
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Discussion and Conclusion 
 
Structural optimizations of compound 1 led to the discovery of new substituted 2,5-
bis(hydroxyphenyl)thiophene derivatives: the fluorinated 23 and the methylated 21 being the 
most active and selective inhibitors identified.  
From a previous work in this class of compounds27 it was demonstrated that removal of one of 
the two hydroxyphenyl moieties is detrimental for the activity. In this paper it was shown that 
replacement of the para-OH function by a bioisoteric group like F, NH2, SH, CN leads to a 
drop of activity. The lack of hydrogen donating properties of the fluoro and cyano substituents 
might not be the only reason for this decrease in activity as the amino and the thiol derivatives 
are also less active than the parent compound 1. Interestingly, the omission of a C1-linker 
between the methylsulfonamide moiety and the phenyl ring (compound 9) resulted in an 
increase of potency. Deprivation of electrons from the phenyl ring, obviously is necessary for a 
good inhibition. The relatively high activity observed for compound 11 (IC50= 350 nM) 
especially compared to compound 9 (IC50= 523 nM) demonstrates that in the protein there is 
some space available in this position for a bulky substituent. Furthermore, the tolyl group 
might also be involved in the stabilization of the inhibitor in the binding site, establishing pi-
pi stacking interactions with appropriate amino acid residues present in this region. 
With the aim to increase the activity and the selectivity in this class of compound, substituents 
were introduced on the 2,5-bis(hydroxyphenyl)thiophenes 1 and 7. This was successful for 
compound 15 (IC50= 119 nM vs. 7, IC50= 216 nM). Apparently, the formation of an additional 
hydrogen bond is responsible for this increase in inhibitory activity, while a pure pi-pi stacking 
interaction as supposed for compound 14 is not sufficient. The 2,5-disubstituted thiophenes 12 
and 15 differ only in the position of one hydroxy group (para: compound 12, meta: compound 
15). The fact that compound 15 shows a much higher activity (IC50= 119 nM vs. 12, IC50> 
1000 nM) indicates that only in case of 15 the geometry of the OH groups is acceptable for a 
reasonable interaction. It demonstrates, as observed already,23, 26 a sharp SAR and a reduced 
flexibility in this region of the active site. 
The trisubstituted compound 14 bearing a phenyl substituent at the thiophene differs from the 
triazole A28 (Chart 2) only in the nature of the heterocycle. The following comparisons 
highlight the importance of the heterocycle for the potency of the molecules: inactive 
compound A vs. thiophene 14 (IC50= 493 nM), thiophene 21 (IC50= 46 nM) vs. thiazole 37 
(IC50= 143 nM) and thiophene 23 (IC50= 8 nM) vs. benzene 39 (IC50= 123 nM). It becomes 
apparent that the thiophene ring is the most appropriate heterocycle for high inhibitory activity. 
Provided that all compounds bind according to the same binding mode, there are different 
explanations for these results: 1. the presence of one or several nitrogens in this area of the 
enzyme is not well tolerated, 2. the absence of the sulfur leads to an inadequate repartition of 
the electron density in the molecule, 3. a reduced flexibility in the binding site is responsible 
that the enzyme can not adjust its geometry to the different hydroxyphenyl moieties (depending 
on the heterocycle, the angles between the phenyl-OHs are different). 
A high increase in activity and selectivity could be reached by introduction of substituents into 
the hydroxyphenyl moiety, especially when the substituent is located ortho- of the para-
hydroxyphenyl group (compounds 21 to 24). Not all substituents are equally well tolerated: 
there is no space available for a phenyl group (compound 25). An additional OH group 
(compound 22) is obviously not able to establish specific interactions while small lipophilic 
substituents (methyl, compounds 21; fluorine, compound 23 and trifluoromethyl, compound 
24) are enhancing the activity. There is enough space in this region of the enzyme to introduce 
a flexible chain (26) but conjugation seems to be necessary to achieve a higher activity as 
already observed with the tolylsulfonamide substituent (compound 11).  
The positive influence of the fluorine atom has often been demonstrated in medicinal 
chemistry42-44 and was also proven in this study with compound 23 (IC50 = 8 nM). The position 
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of the fluorine is decisive for an increase in activity: it has to be in meta-position (17 and 23). 
Highest activity was achieved in ortho- of the hydroxy group (compound 23). This indicates 
that either direct interactions of the fluorine with amino acid residues in this region of the 
active site or the increase of acidity of the neighbouring OH groups might be responsible for 
this effect. 
Introduction of a second fluorine atom into this fluorohydroxyphenyl ring (compound 31) does 
not enhance the activity suggesting that the effects of the fluorine are not additional. A second 
fluorine was also added to the other hydroxyphenyl moiety (in ortho- and meta- of the meta-
OH group) leading to compounds 29 and 30. However, no enhancement of the activity 
compared to the monofluorinated 23 was observed indicating that there are no specific 
interactions of the second fluoro substituent. 
A close look at the X-ray structures of 17β-HSD1 crystallized in presence of different steroidal 
ligands showed that the flexible loop (amino acids 187-200) can adopt different geometries 
depending on the nature of the ligand and on the absence or presence of the cofactor in the 
catalytic region. It indicates that some parts of the enzyme can adapt their geometry to the 
molecule present in the active site in order to stabilize it. However, other parts are rigid, 
explaining the sharp SAR observed in this paper and previously.26, 27 
Two plausible conformations of the loop in the ternary complex enzyme-E2-NADP+, PDB 
code: 1FDT, have been described (1FDT-A, 1FDT-B). We have shown that both can be used 
for docking studies. In case of 1FDT-A the substrate binding site is extended, enhancing the 
volume of the active site. It is therefore a good model to evaluate an alternative binding mode 
for inhibitors which are larger than the steroid. A binding mode as observed for steroids in the 
X-ray structures was found when the loop closes the SUB (1FDT-B). Surprisingly, when the 
inhibitors were docked to the protein with the loop in the open conformation, they interact with 
the nicotinamide part of the cofactor. MEP calculations showed a certain complementarity 
between the electronic density of 23 and of the nicotinamide moiety of the cofactor indicating 
that this alternative binding mode is not only plausible, it might be the one which is more 
likely.  
Up to now, designing compounds as potential 17β-HSD1 inhibitors, several groups35, 45-47 tried 
to mimic the cofactor. Our finding of the above mentioned alternative binding mode makes 
another strategy very promising: the cofactor, which is likely to be present in the active site 
when the inhibitor is entering, could be used as partner to achieve additional interactions rather 
than trying to displace it.  
The most potent 17β-HSD1 inhibitors 21 and 23 exhibit a higher selectivity toward 17β-HSD2 
compared to parent compound, (selectivity factors 49 and 118, respectively vs. 28 for 1). This 
indicates that the amino acids close to the CH3 or F substituents must have different properties 
in the two 17β-HSD enzymes, which could be further exploited to increase selectivity.  
The most potent inhibitors show only marginal to very little affinity to the ERα and no 
stimulation of cell proliferation (agonistic effect) in the ER-positive T-47D cell line could be 
observed. The weak affinity of compound 23 for ERβ may not be critical as it is reported that 
ERβ exhibits anti-proliferative effects in breast cancer cells.48 
Compound 23 might be used in an appropriate animal model to prove the concept of 17β-
HSD1 inhibition with non-steroidal inhibitors. This compound shows a good pharmacokinetic 
profile in rats. 
In this paper, we described the synthesis of substituted bis(hydroxyphenyl)thiophenes, 
thiazoles and benzenes as inhibitors of 17β-HSD1 and the evaluation of their biological 
properties. The most promising compounds of this study, 21 and 23, exhibit high selectivity 
toward 17β-HSD2, marginal binding to ERα and excellent pharmacokinetic profiles in rats 
after peroral application. These new compounds provide useful tools to validate 17β-HSD1 as 
a target for the treatment of estrogen-dependent diseases. 
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Experimental section 
 
Chemical methods 
 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, 
Lancaster, Roth, Merck or Fluka and were used without purification.  
Column chromatography (CC) was performed on silica gel (70-200 m) coated with silica, preparative 
thin layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel) and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel).  
IR spectra were recorded on a Bruker Vector 33 spectrometer (neat sample). 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (500 MHz) at 300 K. 
Chemical shifts are reported in δ (parts per million: ppm), by reference to the hydrogenated residues of 
deuteriated solvent as internal standard (CDCl3: δ = 7.24 ppm (1H NMR) and δ = 77 ppm (13C NMR), 
CD3OD: δ = 3.35 ppm (1H NMR) and δ = 49.3 ppm (13C NMR), CD3COCD3: δ = 2.05 ppm (1H NMR) 
and δ = 29.9 ppm (13C NMR), CD3SOCD3: δ = 2.50 ppm (1H NMR) and δ = 39.5 ppm (13C NMR)). 
Signals are described as s, d, t, q, dd, m, dt for singlet, doublet, triplet, quadruplet, doublet of doublets, 
multiplet and doublet of triplets, respectively. All coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were recorded on a TSQ Quantum (Thermofischer) instrument. Elemental analyses 
were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland University. 
 
Compounds 2-bromo-5-(3-methoxyphenyl)thiophene (1b),27 2-(3-methoxyphenyl)-5-(4-
methoxyphenyl)thiophene (1a),27 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol (1),27 2-(3-methoxyphenyl)-
5-phenylthiophene (2a),27 3-(5-phenyl-2-thienyl)phenol (2),27 2,5-bis(3-methoxyphenyl)thiophene 
(7a),27 3,3'-thiene-2,5-diyldiphenol (7),27 2-bromo-5-(4-methoxyphenyl)thiophene (16c),27 4-bromo-2-
iodo-1-methoxy-benzene (25d), 5-bromo-2-methoxybiphenyl (25c),50 [6-methoxy-1,1'-biphenyl-3-
yl]boronic acid (25b),50 [3-(hydroxymethyl)-4-methoxyphenyl]-boronic acid (26d),51 4-bromo-2-(3-
methoxyphenyl)thiophene (33b),27 2-(3-methoxyphenyl)-4-(4-methoxyphenyl)thiophene (33a),27 3-[4-
(4-hydroxyphenyl)-2-thienyl]phenol (29),27 5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (36b),27 2-(3-
methoxyphenyl)-5-(4-methoxyphenyl)-1,3-thiazole (36a),27 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-
yl]phenol (36),27 4'-bromo-3-methoxybiphenyl (38b),27 3,4''-dimethoxy-1,1':4',1''-terphenyl (38a),27 
1,1':4',1''-terphenyl-3,4''-diol (38),27 3,3''-dimethoxy-1,1':4',1''-terphenyl (40a)27 and 1,1':4',1''-terphenyl-
3,3''-diol (40)27 were prepared following described procedures. 
 
General procedure for Suzuki coupling 
Method A 
A mixture of aryl bromide (1 eq), aryl boronic acid (1.2 eq), caesium carbonate (2.2 eq) and 
tetrakis(triphenylphosphine) palladium (0.01 eq) was suspended in an oxygen free DME/EtOH/water 
(1:1:1) solution. The reaction mixture was exposed to microwave irradiation (15 min, 150 W, 150 °C, 
15 bars). After cooling to rt, water was added and the aqueous layer was extracted with ethyl acetate. 
The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by column chromatography (CC). 
 
Method B: 
A mixture of arylbromide (1 eq), aryl boronic acid (1 eq), sodium carbonate (2 eq) and 
tetrakis(triphenylphosphine) palladium (0.05 eq) in an oxygen free toluene/water (1:1) solution was 
stirred at 100 °C for 20 h under nitrogen atmosphere. The reaction mixture was cooled to rt. The 
aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC. 
 
General procedure for ether cleavage 
Method C:  
To a solution of methoxyphenyl derivative (1 eq) in dry dichloromethane at -78 °C (dry ice/acetone 
bath), boron tribromide in dichloromethane (1 M, 3 eq per methoxy function) was added dropwise. The 
reaction mixture was stirred for 20 h at rt under nitrogen atmosphere. Water was added to quench the 
reaction, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
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washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The product was 
purified by preparative thin layer chromatography (TLC). 
 
2-(4-Fluorophenyl)-5-(3-methoxyphenyl)thiophene (3a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 4-fluorophenylboronic 
acid (94 mg, 0.67 mmol), caesium carbonate (383 mg, 1.24 mmol) and tetrakis(triphenylphosphine) 
palladium (6.4 mg, 5.6 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 9:1); yield: 75 % (120 mg). 
 
3-[5-(4-Fluorophenyl)-2-thienyl]phenol (3). The title compound was prepared by reaction of 2-(4-
fluorophenyl)-5-(3-methoxyphenyl)thiophene (3a) (80 mg, 0.28 mmol) and boron tribromide (0.84 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); 
yield: 68 % (52 mg); MS (ESI): 270 (M+H)+; Anal. (C16H11FOS) C, H, N. 
 
4-[5-(3-Methoxyphenyl)-2-thienyl]aniline (4a). The title compound was prepared by reaction of 2-
bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 4-aminophenylboronic acid (92 mg, 
0.67 mmol), caesium carbonate (383 mg, 1.24 mmol) and tetrakis(triphenylphosphine) palladium (6.4 
mg, 5.6 µmol) according to method A. The product was purified by CC (hexane/ethyl acetate 7:3); 
yield: 63 % (100 mg).  
 
3-[5-(4-Aminophenyl)-2-thienyl]phenol (4). The title compound was prepared by reaction of 4-[5-(3-
methoxyphenyl)-2-thienyl]aniline (4a) (100 mg, 0.37 mmol) and boron tribromide (1.11 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 
82 % (82 mg); MS (ESI): 268 (M+H)+; Anal. (C16H13NOS) C, H, N. 
 
4-[5-(3-Methoxyphenyl)-2-thienyl]benzenethiol (5a). The title compound was prepared by reaction of 
2-bromo-5-(3-methoxyphenyl)thiophene (1b) (250 mg, 0.93 mmol), 4-mercaptophenylboronic acid 
(172 mg, 1.12 mmol), caesium carbonate (636 mg, 2.05 mmol) and tetrakis(triphenylphosphine) 
palladium (10.8 mg, 9.3 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 7:3); yield: 61 % (160 mg). 
 
3-[5-(4-Sulfanylphenyl)-2-thienyl]phenol (5). The title compound was prepared by reaction of 4-[5-
(3-methoxyphenyl)-2-thienyl]benzenethiol (5a) (150 mg, 0.50 mmol) and boron tribromide (1.50 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); 
yield: 81 % (115 mg); MS (ESI): 285 (M+H)+; Anal. (C16H12OS2) C, H, N. 
 
4-[5-(3-Methoxyphenyl)-2-thienyl]benzonitrile (6a). The title compound was prepared by reaction by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (200 mg, 0.74 mmol), 4-cyanophenylboronic 
acid (131 mg, 0.89 mmol), caesium carbonate (508 mg, 1.64 mmol) and tetrakis(triphenylphosphine) 
palladium (8.5 mg, 7.4 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 7:3); yield: 27 % (60 mg).  
 
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzonitrile (6). The title compound was prepared by reaction of 
4-[5-(3-methoxyphenyl)-2-thienyl]benzonitrile (6a) (42 mg, 0.14 mmol) and boron tribromide (0.42 
mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 6:4); 
yield: 62 % (25 mg); MS (APCI): 277 (M)+; Anal. (C17H11NOS) C, H, N. 
 
2-(3-Fluorophenyl)-5-(3-methoxyphenyl)thiophene (8a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3-fluorophenylboronic 
acid (94 mg, 0.67 mmol), caesium carbonate (381 mg, 1.22 mmol) and tetrakis(triphenylphosphine) 
palladium (6.5 mg, 5.6 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 9:1); yield: 82 % (130 mg).  
  
3-[5-(3-Fluorophenyl)-2-thienyl]phenol (8). The title compound was prepared by reaction of 2-(3-
fluorophenyl)-5-(3-methoxyphenyl)thiophene (8a) (130 mg, 0.45 mmol) and boron tribromide (1.35 
mmol) according to method C. The product was purified by preparative TLC 
RESULTS  - 95 - 
(dichloromethane/methanol 99:1); yield: 66 % (82 mg); MS (ESI): 271 (M+H)+; Anal. (C16H11FOS) C, 
H, N.  
 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (160 mg, 0.60 mmol), 3-
methylsulfonylaminophenylboronic acid (155 mg, 0.72 mmol), caesium carbonate (410 mg, 1.32 mmol) 
and tetrakis(triphenylphosphine) palladium (6.9 mg, 6.0 µmol) according to method A. The product was 
purified by CC (petroleum ether/ethyl acetate 6:4); yield: 75 % (150 mg). 
 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9). The title compound was 
prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]phenyl)methanesulfonamide (9a) (150 
mg, 0.44 mmol) and boron tribromide (1.32 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 61 % (92 mg); MS (ESI): 346 (M+H)+; Anal. 
(C17H15NO3S2) C, H, N 
 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3-
[(methylsulphonylamino)methyl]benzeneboronic acid (153 mg, 0.67 mmol), caesium carbonate (382 
mg, 1.23 mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 µmol) according to method A. 
The product was purified by CC (petroleum ether/ethyl acetate 8:2); yield: 58 % (122 mg). 
 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10). The title compound was 
prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]benzyl)methanesulfonamide (10a) (122 
mg, 0.37 mmol) and boron tribromide (1.11 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 33 % (44 mg); MS (ESI): 360 (M+H)+; Anal. 
(C18H17NO3S2) C, H, N. 
 
N-(3-[5-(3-Methoxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11a). The title 
compound was prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 
mmol), [3-[[(4-methylphenyl)sulfonyl]amino]phenyl]-boronic acid (195 mg, 0.67 mmol), caesium 
carbonate (383 mg, 1.23 mmol) and tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 µmol) 
according to method A. The product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 88 
% (214 mg). 
 
N-(3-[5-(3-Hydroxyphenyl)-2-thienyl]phenyl)-4-methylbenzenesulfonamide (11). The title 
compound was prepared by reaction of N-(3-[5-(3-methoxyphenyl)-2-thienyl]phenyl)-4-
methylbenzenesulfonamide (11a) (214 mg, 0.49 mmol) and boron tribromide (1.47 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 75 % (156 
mg); MS (APCI): 421 (M)+; Anal. (C23H19NO3S2) C, H, N. 
 
3,5-Dibromo-2-(3-methoxyphenyl)thiophene (12c). The title compound was prepared by reaction of 
2,3,5-tribromothiophene (100 mg, 0.31 mmol), 3-methoxybenzeneboronic acid (46 mg, 0.31 mmol), 
sodium carbonate (67 mg, 0.62 mmol) and tetrakis(triphenylphosphine) palladium (17.9 mg, 15.5 µmol) 
according to method B heating the reaction 4 h instead of 20 h. The product was purified by CC 
(petroleum ether/ethyl acetate 9:1); yield: 23 % (25 mg). 
 
3-Bromo-2-(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12b). The title compound was 
prepared by reaction of 3,5-dibromo-2-(3-methoxyphenyl)thiophene (12c) (500 mg, 1.43 mmol), 4-
methoxybenzeneboronic acid (268 mg, 1.72 mmol), sodium carbonate (333 mg, 3.15 mmol) and 
tetrakis(triphenylphosphine) palladium (82.6 mg, 71.5 µmol) according to method B. The product was 
purified by CC (petroleum ether/ethyl acetate 9:1); yield: 52 % (278 mg). 
 
2,3-Bis(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12a). The title compound was prepared 
by reaction of 3-bromo-2-(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12b) (250 mg, 0.67 
mmol), 3-methoxybenzeneboronic acid (124 mg, 0.80 mmol), sodium carbonate (142 mg, 1.34 mmol) 
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and tetrakis(triphenylphosphine) palladium (38.7 mg, 33.5 µmol) according to method B. The product 
was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 72 % (194 mg). 
 
3,3’-[5-(4-Hydroxyphenyl)thiene-2,3-diyl]diphenol (12). The title compound was prepared by 
reaction of 2,3-bis(3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (12a) (100 mg, 0.24 mmol) and 
boron tribromide (2.16 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 92 % (79 mg); MS (ESI): 359 (M-H)+; Anal. (C22H16O3S) C, H, N. 
 
3,3’-(3-Methylthiene-2,5-diyl]diphenol (13). The title compound was prepared by reaction of 2,5-
dibromo-3-methylthiophene (150 mg, 0.58 mmol), 3-hydroxybenzeneboronic acid (179 mg, 1.27 
mmol), caesium carbonate (868 mg, 2.79 mmol) and tetrakis(triphenylphosphine) palladium (6.7 mg, 
5.8 µmol) according to method A. The product was purified by CC (hexane/ethyl acetate 4:6); yield: 45 
% (73 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, N. 
 
3-Bromo-2,5-bis(3-methoxyphenyl)thiophene (14b). The title compound was prepared by reaction of 
3,5-dibromo-2-(3-methoxyphenyl)thiophene (12c) (250 mg, 0.72 mmol), 3-methoxybenzeneboronic 
acid (134 mg, 0.86 mmol), sodium carbonate (148 mg, 1.44 mmol) and tetrakis(triphenylphosphine) 
palladium (41.6 mg, 36.0 µmol) according to method B. The product was purified by CC (petroleum 
ether/ethyl acetate 9:1); yield: 72 % (194 mg). 
 
2,5-Bis(3-methoxyphenyl)-3-phenylthiophene (14a). The title compound was prepared by reaction of 
3-bromo-2,5-bis(3-methoxyphenyl)thiophene (14b) (102 mg, 0.27 mmol), benzeneboronic acid (38 mg, 
0.27 mmol), sodium carbonate (58 mg, 0.54 mmol) and tetrakis(triphenylphosphine) palladium (15.6 
mg, 13.5 µmol) according to method B. The product was purified by CC (petroleum ether/ethyl acetate 
9:1); yield: 54 % (51 mg). 
 
3,3’-(3-Phenylthiene-2,5-diyl)diphenol (14). The title compound was prepared by reaction of 2,5-
bis(3-methoxyphenyl)-3-phenylthiophene (14a) (50 mg, 0.13 mmol) and boron tribromide (0.78 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 
53 % (49 mg); MS (ESI): 345 (M+H)+; Anal. (C22H16O2S) C, H, N. 
 
2,3,5-Tris(3-methoxyphenyl)thiophene (15a). The title compound was prepared by reaction of 3-
bromo-2,5-bis(3-methoxyphenyl)thiophene (14b) (102 mg, 0.27 mmol), 3-methoxybenzene boronic 
acid (42 mg, 0.27 mmol), sodium carbonate (58 mg, 0.54 mmol) and tetrakis(triphenylphosphine) 
palladium (15.6 mg, 13.5 µmol) according to method B. The product was purified by CC (petroleum 
ether/ethyl acetate 9:1); yield: 34 % (37 mg). 
 
3,3’,3’’-Thiene-2,3,5-triyltriphenol (15). The title compound was prepared by reaction of 2,3,5-tris(3-
methoxyphenyl)thiophene (15a) (37 mg, 0.09 mmol) and boron tribromide (0.81 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 67 % (21 
mg); MS (ESI): 361 (M+H)+; Anal. (C22H16O3S) C, H, N. 
 
5-(4-Methoxyphenyl)-2-(boronic acid)thiophene (16b). To a solution of 2-bromo-5-(4-
methoxyphenyl)thiophene (16c) (100 mg, 0.37 mmol, 1 eq) in anhydrous THF cooled to -78 °C for 5 
min, n-BuLi (1.6 M in hexane, 0.28 mL, 0.44 mmol, 1.2 eq) was added dropwise and stirred at -78 °C. 
After 15 min, triethyl borate (0.37 mL, 2.22 mmol, 6 eq) was added at -78°C and the mixture was 
stirred for 2 h. After warming to rt, the crude material was acidified with 20 mL of a 1N hydrochloric 
acid solution. The aqueous layer was washed with ethyl acetate. The combined organic layers were 
dried over sodium sulfate, filtered and evaporated under reduced pressure. The title compound was not 
characterized and used without further purification. 
 
2-(3-Methoxyphenyl-5-methylphenyl)-5-(4-methoxyphenyl)thiophene (16a). The title compound 
was prepared by reaction of 1-bromo-3-methoxy-5-methylbenzene (150 mg, 0.74 mmol), [5-(4-
methoxyphenyl)-2-thienyl]-boronic acid (16b) (206 mg, 0.88 mmol), sodium carbonate (181 mg, 1.76 
mmol) and tetrakis(triphenylphosphine) palladium (42.7 mg, 37.0 µmol) according to method B. The 
product was purified by CC (hexane/ethyl acetate 7:3); yield: 22 % (50 mg). 
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3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol (16). The title compound was prepared by 
reaction of 2-(3-methoxyphenyl-5-methylphenyl)-5-(4-methoxyphenyl)thiophene (16a) (50 mg, 0.16 
mmol) and boron tribromide (0.96 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 90 % (41 mg); MS (ESI): 281 (M-H)+; Anal. 
(C17H14O2S) C, H, N. 
 
2-(3-Fluoro-5-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (17a). The title compound was 
prepared by reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (200 mg, 0.75 mmol), 3-fluoro-
5-methoxybenzeneboronic acid (152 mg, 0.89 mmol), caesium carbonate (513 mg, 1.65 mmol) and 
tetrakis(triphenylphosphine) palladium (8.7 mg, 7.5 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 43 % (122 mg). 
 
3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol (17). The title compound was prepared by 
reaction of 2-(3-fluoro-5-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (17a) (100 mg, 0.32 mmol) 
and boron tribromide (1.92 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 7:3); yield: 88 % (80 mg); MS (APCI): 286 M+; Anal. (C16H11FO2S) C, H, 
N.
 
 
5-[5-(4-Methoxyphenyl)-2-thienyl]-2-methylphenol (18a). The title compound was prepared by 
reaction of 5-bromo-2-methylphenol (250 mg, 1.34 mmol), [5-(4-methoxyphenyl)-2-thienyl]-boronic 
acid (16b) (690 mg, 2.95 mmol), caesium carbonate (914 mg, 2.94 mmol) and 
tetrakis(triphenylphosphine) palladium (15.5 mg, 13.4 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 47 % (193 mg). 
 
5-[5-(4-Hydroxyphenyl)-2-thienyl]-2-methylphenol (18). The title compound was prepared by 
reaction of 5-[5-(4-methoxyphenyl)-2-thienyl]-2-methylphenol (18a) (161 mg, 0.54 mmol) and boron 
tribromide (3.24 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 7:3); yield: 27 % (42 mg); MS (ESI): 283 (M+H)+; Anal. (C17H14O2S) C, H, N. 
 
2-(4-Fluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (19a). The title compound was 
prepared by reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (200 mg, 0.75 mmol), 4-fluoro-
3-methoxybenzeneboronic acid (152 mg, 0.89 mmol), caesium carbonate (553 mg, 1.78 mmol) and 
tetrakis(triphenylphosphine) palladium (8.7 mg, 7.5 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 49 % (149 mg). 
 
2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol (19). The title compound was prepared by 
reaction of 2-(4-fluoro-3-methoxyphenyl)-5-(4-methoxyphenyl)thiophene (19a) (100 mg, 0.32 mmol) 
and boron tribromide (1.92 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 7:3); yield: 88 % (80 mg); MS (ESI): 287 (M+H)+; Anal. (C16H11FO2S) C, 
H, N. 
 
2-(3,4-Dimethoxyphenyl)-5-(4-methoxyphenyl)thiophene (20a). The title compound was prepared by 
reaction of 2-bromo-5-(4-methoxyphenyl)thiophene (16c) (195 mg, 0.73 mmol), 3,4-dimethoxybenzene 
boronic acid (160 mg, 0.88 mmol), caesium carbonate (500 mg, 1.61 mmol) and 
tetrakis(triphenylphosphine) palladium (8.4 mg, 7.3 µmol) according to method A. The product was 
purified by CC (dichloromethane/methanol 99:1); yield: 46 % (119 mg). 
 
4-[5-(4-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol (20). The title compound was prepared by 
reaction of 2-(3,4-dimethoxyphenyl)-5-(4-methoxyphenyl)thiophene (20a) (100 mg, 0.31 mmol) and 
boron tribromide (2.79 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 17 % (49 mg); MS (ESI): 285 (M+H)+; Anal. (C16H12O3S) C, H, N. 
 
2-(4-Methoxy-3-methylphenyl)-5-(3-methoxyphenyl)thiophene (21a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (250 mg, 0.92 mmol), 3-methyl-
4-methoxybenzeneboronic acid (152.8 mg, 0.92 mmol), sodium carbonate (243 mg, 2.36 mmol) and 
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tetrakis(triphenylphosphine) palladium (53.1 mg, 46.0 µmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 54 % (154 mg). 
 
4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol (21). The title compound was prepared by 
reaction of 2-(4-methoxy-3-methylphenyl)-5-(3-methoxyphenyl)thiophene (21a) (100 mg, 0.32 mmol) 
and boron tribromide (1.92 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 6:4); yield: 79 % (72 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, 
N. 
 
2-(3,4-Dimethoxyphenyl)-5-(3-methoxyphenyl)thiophene (22a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (206 mg, 1.14 mmol), 3,4-
dimethoxybenzeneboronic acid (247 mg, 1.36 mmol), caesium carbonate (779 mg, 2.51 mmol) and 
tetrakis(triphenylphosphine) palladium (13.2 mg, 11.4 µmol) according to method A. The product was 
purified by CC (dichloromethane/methanol 99:1); yield: 34 % (126 mg). 
 
4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol (22). The title compound was prepared by 
reaction of 2-(3,4-dimethoxyphenyl)-5-(3-methoxyphenyl)thiophene (22a) (100 mg, 0.32 mmol) and 
boron tribromide (2.88 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 6:4); yield: 61 % (56 mg); MS (ESI): 283 (M-H)+; Anal. (C16H12O3S) C, H, N. 
 
2-(3-Fluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (23a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (370 mg, 1.37 mmol), 3-fluoro-4-
methoxybenzeneboronic acid (255 mg, 1.50 mmol), caesium carbonate (717 mg, 3.01 mmol) and 
tetrakis(triphenylphosphine) palladium (15.8 mg, 13.7 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 98 % (421 mg). 
 
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol (23). The title compound was prepared by 
reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (23a) (240 mg, 0.76 mmol) 
and boron tribromide (4.56 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 1:1); yield: 90 % (195 mg); MS (ESI): 285 (M-H)+; Anal. (C16H11FO2S) C, 
H, N. 
 
2-(3-Methoxyphenyl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]thiophene (24a). The title compound 
was prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (408 mg, 1.51 mmol), 3-
trifluoromethyl-4-methoxybenzeneboronic acid (398 mg, 1.81 mmol), caesium carbonate (1033 mg, 
3.32 mmol) and tetrakis(triphenylphosphine) palladium (17.5 mg, 15.1 µmol) according to method A. 
The product was purified by CC (hexane/ethyl acetate 7:3); yield: 75 % (412 mg). 
 
4-[5-(3-Hydroxyphenyl)-2-thienyl]-2-(trifluoromethyl)phenol (24). The title compound was prepared 
by reaction of 2-(3-methoxyphenyl)-5-[4-methoxy-3-(trifluoromethyl)phenyl]thiophene (24a) (300 mg, 
0.82 mmol) and boron tribromide (4.95 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 1:1); yield: 98 % (272 mg); MS (ESI): 285 (M-H)+; Anal. 
(C17H11F3O2S) C, H, N. 
 
2-(6-Methoxybiphenyl-3-yl)-5-(3-methoxyphenyl)thiophene (25a). The title compound was prepared 
by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (287 mg, 1.07 mmol), [6-methoxy-1,1'-
biphenyl-3-yl]boronic acid (25b) (338 mg, 1.29 mmol), sodium carbonate (250 mg, 2.35 mmol) and 
tetrakis(triphenylphosphine) palladium (61.8 mg, 53.5 µmol) according to method B. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 35 % (135 mg). 
 
5-[5-(3-Hydroxyphenyl)-2-thienyl]biphenyl-2-ol (25). The title compound was prepared by reaction 
of 2-(6-methoxybiphenyl-3-yl)-5-(3-methoxyphenyl)thiophene (25a) (100 mg, 0.26 mmol) and boron 
tribromide (1.56 mmol) according to method C. The product was purified by preparative TLC 
(hexane/ethyl acetate 1:1); yield: 88 % (81 mg); MS (ESI): 343 (M-H)+; Anal. (C22H16O2S) C, H, N. 
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[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]methanol (26c). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (408 mg, 1.51 mmol), [3-
(hydroxymethyl)-4-methoxyphenyl]-boronic acid (26d) (329 mg, 1.81 mmol), caesium carbonate (1032 
mg, 3.32 mmol) and tetrakis(triphenylphosphine) palladium (17.5 mg, 15.1 µmol) according to method 
A. The product was purified by CC (hexane/ethyl acetate 8:2); yield: 12 % (59 mg).  
 
2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]benzaldehyde (26b). To a solution of [2-methoxy-5-
[5-(3-methoxyphenyl)-2-thienyl]phenyl]methanol (26c) (100 mg, 0.31 mmol, 1 eq) in dichloromethane, 
pyridium chlorochromate (66 mg, 0.31 mmol, 1 eq) was added in small portions over 5 min and stirred 
at rt. After 30 min, the reaction was quenched with water. The resulting organic layer was dried over 
sodium sulfate, filtered and concentrated to dryness. The title compound was not characterized and used 
in the next step without purification.  
 
Ethyl (2E)-3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a). To a solution of 
sodium hydride (10.4 mg, 0.43 mmol, 1 eq) in anhydrous THF triethyl phosphonate (93 µL, 0.46 mmol, 
1.1 eq) was added dropwise and stirred at rt. After 15 min, 2-methoxy-5-[5-(3-methoxyphenyl)-2-
thienyl]benzaldehyde (26b) (100 mg, 0.31 mmol, 0.6 eq) was added and stirred for 4 h at rt. To quench 
the reaction water was added and the resulting organic layer was washed with brine, dried over sodium 
sulfate, filtered, evaporated and purified by CC (hexane/ethyl acetate 7:3); yield: 98 % (120 mg).  
 
Ethyl (2E)-3-[2-hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]acrylate (26). The title 
compound was prepared by reaction of ethyl (2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-
thienyl]phenyl]acrylate (26a) (60 mg, 0.15 mmol) and boron tribromide (0.90 mmol) according to 
method C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 17 % (10 
mg); MS (APCI): 366 (M)+; Anal. (C21H18O4S) C, H, N. 
 
(2E)-3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27a). Ethyl 
(2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]acrylate (26a) (720 mg, 2.22 mmol, 1 eq) 
in a solution of THF/water (2:1), was refluxed for 20 h together with lithium hydroxide (320 mg, 13.33 
mmol, 6 eq). After cooling to rt, ether was added, the aqueous layer was acidified with hydrochloric 
acid 1N and washed with dichloromethane. The combined organic layers were dried over sodium 
sulfate, filtered and evaporated under reduced pressure. The resulting carboxylic acid was solubilized in 
dichloromethane (180 mg, 0.53 mmol, 1 eq) and refluxed for 20 h with EDCI (102 mg, 0.53 mmol, 1 
eq) and HOBt (72 mg, 0.53 mmol, 1 eq). After cooling to rt, the organic layer was washed with a 1.5 M 
sodium hydrogenocarbonate solution, brine, dried over sodium sulfate, evaporated under reduced 
pressure and purified by CC (hexane/ethyl acetate 7:3); yield: 51 % (120 mg); MS (ESI): 442 (M+H)+. 
 
(2E)-3-[2-Hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27).  
The title compound was prepared by reaction of (2E)-3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-
thienyl]phenyl]-N-phenylacrylamide (27a) (55 mg, 0.13 mmol) and boron tribromide (0.78 mmol) 
according to method C. The product was purified by preparative TLC (hexane/ethyl acetate 4:6); yield: 
31 % (17 mg); MS (ESI): 414 (M+H)+; Anal. (C25H19NO3S) C, H, N. 
 
3-[2-Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28a). (2E)-3-[2-
Methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-phenylacrylamide (27a) (50 mg, 0.11 mmol, 1 
eq) was solubilized in thr mixture of THF/EtOH (1:1). After addition of palladium hydroxide (1.7 mg, 
0.01 mmol, 0.1 eq) the reaction was stirred at rt under nitrogen atmosphere for 20 h. The crude mixture 
was filtered and the organic layer was evaporated under reduced pressure; yield: quantitative. 
 
3-[2-Hydroxy-5-[5-(3-hydroxyphenyl)-2-thienyl]phenyl]-N-phenylpropanamide (28). The title 
compound was prepared by reaction of 3-[2-methoxy-5-[5-(3-methoxyphenyl)-2-thienyl]phenyl]-N-
phenylpropanamide (28a) (55 mg, 0.13 mmol) and boron tribromide (0.78 mmol) according to method 
C. The product was purified by preparative TLC (hexane/ethyl acetate 1:1); yield: 20 % (10 mg); MS 
(ESI): 416 (M+H)+; Anal. (C25H21NO3S) C, H, N. 
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2-Bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b). The title compound was prepared by 
reaction of 2,5-dibromothiophene (500 mg, 2.10 mmol), 3-fluoro-4-methoxybenzeneboronic acid (357 
mg, 2.10 mmol), sodium carbonate (432 mg, 4.20 mmol) and tetrakis(triphenylphosphine) palladium 
(121 mg, 1.05 mmol) according to method B. The product was purified by CC (hexane/ethyl acetate 
95:5); yield: 85 % (427 mg). 
 
2-(3-Fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (29a). The title compound 
was prepared by reaction of 2-bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b) (100 mg, 0.41 
mmol), 3-fluoro-5-methoxybenzeneboronic acid (85 mg, 0.50 mmol), caesium carbonate (280 mg, 0.90 
mmol) and tetrakis(triphenylphosphine) palladium (4.7 mg, 4.1 µmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 82 % (113 mg). 
 
2-Fluoro-4-[5-(3-fluoro-5-hydroxyphenyl)thien-2-yl]phenol (29). The title compound was prepared 
by reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (30a) (100 mg, 
0.30 mmol) and boron tribromide (1.80 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 6:4); yield: 38 % (35 mg); MS (APCI): 304 (M)+; Anal. 
(C16H10F2O2S) C, H, N. 
 
2-(3-Fluoro-4-methoxyphenyl)-5-(4-fluoro-3-methoxyphenyl)thiophene (30a). The title compound 
was prepared by reaction of 2-bromo-5-(3-fluoro-4-methoxyphenyl)thiophene (29b) (100 mg, 0.41 
mmol), 4-fluoro-3-methoxybenzeneboronic acid (85 mg, 0.50 mmol), caesium carbonate (279 mg, 0.90 
mmol) and tetrakis(triphenylphosphine) palladium (4.7 mg, 4.1 µmol) according to method A. The 
product was purified by CC (hexane/ethyl acetate 9:1); yield: 72 % (100 mg). 
 
2-Fluoro-4-[5-(4-fluoro-3-hydroxyphenyl)thien-2-yl]phenol (30). The title compound was prepared 
by reaction of 2-(3-fluoro-4-methoxyphenyl)-5-(3-fluoro-5-methoxyphenyl)thiophene (30a) (100 mg, 
0.30 mmol) and boron tribromide (1.80 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 6:4); yield: 75 % (69 mg); MS (APCI): 304 (M)+; Anal. 
(C16H10F2O2S) C, H, N.  
 
2-(3,5-Difluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (31a). The title compound was 
prepared by reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (430 mg, 1.60 mmol), 3,5-
difluoro-4-methoxybenzeneboronic acid (357 mg, 1.92 mmol), caesium carbonate (1094 mg, 3.52 
mmol) and tetrakis(triphenylphosphine) palladium (18.5 mg, 16.0 µmol) according to method A. The 
product was purified by CC (petroleum ether/ethyl acetate 9:1); yield: 42 % (223 mg).  
 
2,6-Difluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol (31). The title compound was prepared by 
reaction of 2-(3,5-difluoro-4-methoxyphenyl)-5-(3-methoxyphenyl)thiophene (31a) (220 mg, 0.62 
mmol) and boron tribromide (3.72 mmol) according to method C. The product was purified by 
preparative TLC (hexane/ethyl acetate 5:5); yield: 10 % (18 mg); MS (ESI): 305 (M+H)+; Anal. 
(C16H10F2O2S) C, H, N. 
 
2-(3,4-Difluorophenyl)-5-(3-methoxyphenyl)thiophene (32a). The title compound was prepared by 
reaction of 2-bromo-5-(3-methoxyphenyl)thiophene (1b) (150 mg, 0.56 mmol), 3,4-
difluorobenzeneboronic acid (105 mg, 0.67 mmol), caesium carbonate (383 mg, 1.23 mmol) and 
tetrakis(triphenylphosphine) palladium (6.5 mg, 5.6 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 9:1); yield: 90 % (152 mg). 
 
3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol (32). The title compound was prepared by reaction of 2-
(3,4-difluorophenyl)-5-(3-methoxyphenyl)thiophene (32a) (120 mg, 0.40 mmol) and boron tribromide 
(1.20 mmol) according to method C. The product was purified by CC (dichloromethane/methanol 99:1); 
yield: 85 % (98 mg); MS (ESI): 289 (M+H)+; Anal. (C16H9F2OS) C, H, N. 
 
4-(4-Methoxy-3-methylphenyl)-2-(3-methoxyphenyl)thiophene (34a). The title compound was 
prepared by reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (33b) (400 mg, 1.49 mmol), 3-methyl-
4-methoxybenzeneboronic acid (296 mg, 1.79 mmol), caesium carbonate (1019 mg, 3.27 mmol) and 
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tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 µmol) according to method A. The product was 
purified by CC (hexane/ethyl acetate 7:3); yield: 69 % (320 mg). 
 
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol (34). The title compound was prepared by 
reaction of 4-(4-methoxy-3-methylphenyl)-2-(3-methoxyphenyl)thiophene (34a) (180 mg, 0.58 mmol) 
and boron tribromide (3.48 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 1:1); yield: 54 % (88 mg); MS (ESI): 281 (M-H)+; Anal. (C17H14O2S) C, H, 
N. 
 
4-(3-Fluoro-4-methoxyphenyl)-2-(3-methoxyphenyl)thiophene (35a). The title compound was 
prepared by reaction of 4-bromo-2-(3-methoxyphenyl)thiophene (33b) (400 mg, 1.49 mmol), 3-fluoro-
4-methoxybenzeneboronic acid (303 mg, 1.78 mmol), caesium carbonate (1019 mg, 3.30 mmol) and 
tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 µmol) according to method A. The product was 
purified by CC (petroleum ether/ethyl acetate 9:1); yield: 80 % (403 mg). 
 
2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol (35). The title compound was prepared by 
reaction of 4-(3-fluoro-4-methoxyphenyl)-2-(3-methoxyphenyl)thiophene (35a) (400 mg, 1.27 mmol) 
and boron tribromide (7.63 mmol) according to method C. The product was purified by CC 
(dichloromethane/methanol 98:2); yield: 22 % (88 mg); MS (ESI): 287 (M-H)- 
 
4-(4-Methoxy-3-methylphenyl)-2-(3-methoxyphenyl)-1,3-thiazole (37a). The title compound was 
prepared by reaction of 5-bromo-2-(3-methoxyphenyl)-1,3-thiazole (36b) (402 mg, 1.49 mmol), 3-
methyl-4-methoxybenzeneboronic acid (247 mg, 1.79 mmol), caesium carbonate (1019 mg, 3.27 mmol) 
and tetrakis(triphenylphosphine) palladium (17.2 mg, 14.9 µmol) according to method A. The product 
was purified by CC (hexane/ethyl acetate 7:3); yield: 69 % (320 mg). 
 
4-[2-(3-Hydroxyphenyl)-1,3-thiazol-5-yl]-2-methylphenol (37). The title compound was prepared by 
reaction of 4-(4-methoxy-3-methylphenyl)-2-(3-methoxyphenyl)-1,3-thiazole (37a) (80 mg, 0.26 mmol) 
and boron tribromide (1.56 mmol) according to method C. The product was purified by preparative 
TLC (hexane/ethyl acetate 3:7); yield: 16 % (11 mg), MS (ESI): 274 (M+H)+; Anal. (C16H13NO2S) C, 
H, N. 
 
3-Fluoro-3'',4-dimethoxy-1,1':4',1''-terphenyl (39a). The title compound was prepared by reaction of 
4'-bromo-3-methoxybiphenyl (38b) (175 mg, 0.67 mmol), 3-fluoro-4-methoxybenzeneboronic acid 
(136.7 mg, 0.88 mmol), caesium carbonate (457 mg, 1.47 mmol) and tetrakis(triphenylphosphine) 
palladium (7.7 mg, 6.7 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 98:2); yield: 58 % (117 mg). 
 
3''-Fluoro-1,1':4',1''-terphenyl-3,4''-diol (39). The title compound was prepared by reaction of 3-
fluoro-3'',4-dimethoxy-1,1':4',1''-terphenyl (39a) (115 mg, 0.37 mmol) and boron tribromide (2.22 
mmol) according to method C. The product was purified by preparative TLC 
(dichloromethane/methanol 99:1); yield: 62 % (65 mg); MS (ESI): 281 (M+H)+. 
 
3,3''-Dimethoxy-4-methyl-1,1':4',1''-terphenyl (41a). The title compound was prepared by reaction of 
4'-bromo-3-methoxybiphenyl (38b) (230 mg, 0.87 mmol), 4-methoxy-3-methylbenzeneboronic acid 
(172 mg, 1.04 mmol), caesium carbonate (595 mg, 1.91 mmol) and tetrakis(triphenylphosphine) 
palladium (10.1 mg, 8.7 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 98:2); yield: 53 % (140 mg). 
 
4-Methyl-1,1':4',1''-terphenyl-3,3''-diol (41). The title compound was prepared by reaction of 3,3''-
dimethoxy-4-methyl-1,1':4',1''-terphenyl (41a) (120 mg, 0.39 mmol) and boron tribromide (2.34 mmol) 
according to method C. The product was purified by preparative TLC (dichloromethane/methanol 
97:3); yield: 38 % (42 mg); MS (ESI): 277 (M+H)+.  
 
4-Fluoro-3,3''-dimethoxy-1,1':4',1''-terphenyl (42a). The title compound was prepared by reaction of 
4'-bromo-3-methoxybiphenyl (38b) (200 mg, 0.76 mmol), 4-fluoro-3-methoxybenzeneboronic acid 
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(154 mg, 0.91 mmol), caesium carbonate (520 mg, 1.67 mmol) and tetrakis(triphenylphosphine) 
palladium (8.8 mg, 7.6 µmol) according to method A. The product was purified by CC (hexane/ethyl 
acetate 9:1); yield: 75 % (175 mg). 
 
4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol (42). The title compound was prepared by reaction of 4-
fluoro-3,3''-dimethoxy-1,1':4',1''-terphenyl (42a) (175 mg, 0.57 mmol) and boron tribromide solution 
(3.42 mmol) according to method C. The product was purified by preparative TLC (hexane/ethyl 
acetate 1:1); yield: 63 % (100 mg); MS (ESI): 281 (M+H)+. 
 
Biological Methods 
 
[2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer, Boston. Quickszint Flow 302 
scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described 
procedures.35, 52, 53 Fresh human placenta was homogenized and centrifuged. The pellet fraction contains 
the microsomal 17β-HSD2, while 17β-HSD1 was obtained after precipitation with ammonium sulfate 
from the cytosolic fraction. 
 
1. Inhibition of 17β-HSD1  
 
Inhibitory activities were evaluated by a well established method with minor modifications.54-56 Briefly, 
the enzyme preparation was incubated with NADH [500 µM] in the presence of potential inhibitors at 
37 °C in a phosphate buffer (50 mM) supplemented with 20 % of glycerol and EDTA (1mM). Inhibitor 
stock solutions were prepared in DMSO. Final concentration of DMSO was adjusted to 1 % in all 
samples. The enzymatic reaction was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]- 
E1 (final concentration: 500 nM, 0.15 µCi). After 10 min, the incubation was stopped with HgCl2 and 
the mixture was extracted with ether. After evaporation, the steroids were dissolved in acetonitrile. E1 
and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 rp chromatography 
column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren) connected to a HPLC-system (Agilent 
1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of the steroids were 
performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The conversion rate was 
calculated according to following equation: 100
1%2%
2%% ⋅
+
=
EE
E
conversion . Each value was 
calculated from at least three independent experiments.  
 
2. Inhibition of 17β-HSD2 
 
The 17β-HSD2 inhibition assay was performed similarly to the 17β-HSD1 procedure. The microsomal 
fraction was incubated with NAD+ [1500 µM], test compound and a mixture of unlabelled- and [2, 4, 6, 
7-3H]-E2 (final concentration: 500 nM, 0.11 µCi) for 20 min at 37 °C. Further treatment of the samples 
and HPLC separation was carried out as mentioned above. 
 
3. ER affinity 
 
The binding affinity of select compounds to the ERα and ERβ was determined according to 
Zimmermann et al.57 Briefly, 0.25 pmol of ERα or ERβ, respectively, were incubated with [2, 4, 6, 7-
3H]-E2 (10 nM) and test compound for 1 h at rt. The potential inhibitors were dissolved in DMSO (5 % 
final concentration). Non-specific-binding was performed with diethylstilbestrol (10 µM). After 
incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 mL TE-
buffer). The formed complex was separated, washed and resuspended in ethanol. For radiodetection, 
scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were 
measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). For determination of 
the relative binding affinity (RBA), inhibitor and E2 concentrations required to displace 50 % of the 
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receptor bound labelled E2 were determined. RBA values were calculated according to the following 
equation: [ ] ( )( ) 100
2%
50
50
⋅=
compoundIC
EICRBA . The RBA value for E2 was arbitrarily set at 100 %. 
 
4.Evaluation of the estrogenic activity using T-47D cells 
 
Phenol red-free medium was supplemented with sodium bicarbonate (2 g/L), streptomycin (100 
µg/mL), insuline zinc salt (10 µg/mL), sodium pyruvate (1 mM), L-glutamine (2 mM), penicillin (100 
U/mL) and DCC-FCS 5% (v/v). RPMI 1640 (without phenol red) was used for the experiments. Cells 
were grown for 48 h in phenol red-free medium. Compound 21 wasadded at a final concentration of 
100 nM. Inhibitors and E2 were diluted in ethanol (final ethanol concentration was adjusted to 1%). As 
a positive control E2 was added at a final concentration of 0.1 nM. Ethanol was used as negative 
control. Medium was changed every two to three days and supplemented with the respective additive. 
After eight days of incubation, the cell viability was evaluated measuring the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT). The cleavage of MTT to a blue 
formazan by mitochondrial succinat-dehydrogenase was quantified spectrophotometrically at 590 nm as 
described by Denizot and Lang58 with minor modifications. The control proliferation was arbitrarily set 
at 1 and the stimulation induced by the inhibitor was calculated according to following equation: 
( )[ ]
( )[ ] %10012
1% ⋅
−−
−−
=
inducedEionproliferat
inducedcompoundionproliferat
nstimulatio . Each value is calculated as a 
mean value of at least three independent experiments 
 
5. Inhibition of human hepatic CYPs 
 
The commercially available P450 inhibition kits from BD GentestTM (Heidelberg, Germany) were used 
according to the instructions of the manufacturer. Compounds 21 and 23 were tested for inhibition of 
the following enzymes: CYP2D6 and 3A4. Percentage of inhibition at 2 µM for compounds 21 and 23 
were determined. 
  
6. In-Vivo Pharmacokinetics 
 
Male Wistar rats weighing 300-330 g (Janvier France) were housed in a temperature- controlled room 
(20-22 °C) and maintained in a 12 h light/12 h dark cycle. Food and water were available ad libitum. 
They were anesthetized with a ketamine (135 mg/kg)/ xylyzine (10 mg/kg) mixture and cannulated with 
silicone tubing via the right jugular vein and attached to the skull with dental cement. Prior to the first 
blood sampling, animals were connected to a counterbalanced system and tubing to perform blood 
sampling in the freely moving rat.  
Compounds 21 and 23 were applied orally in a cassette dosing in 4 rats at the dose of 10 mg/kg body 
weight by using a feeding needle. The compounds were dissolved in a mixture labrasol/water (1:1) and 
given at a volume of 5mL/kg. Blood samples (0.2 mL) were taken at 0, 1, 2, 3, 4, 6, 8, 10 and 24 h 
postdose and collected in heparinised tubes. They were centrifuged at 3000g for 10 min, and plasma 
was harvested and kept at -20 °C until analyzed.  
HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor-HPLC-system 
coupled with a TSQ Quantum (Thermo/Fisher) triple quadrupole mass spectrometer equipped with an 
electrospray interface (ESI).  
 
Computational Chemistry 
 
1. Molecular Modelling 
 
All molecular modelling studies were performed on Intel(R) P4 CPU 3.00 GHz running Linux CentOS 
5.2. The X-ray structures of 17β-HSD1 (PDB-ID: 1A27, 1FDT and 1I5R) were obtained from the 
Protein Databank59 and further prepared using the BIOPOLYMER module of SYBYL v8.0 (Sybyl, 
Tripos Inc., St. Louis, Missouri, USA). Water molecules, E2 (or HYC for 1I5R) and sulfate ions were 
stripped from the PDB files and missing protein atoms were added and correct atom types set. Finally 
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hydrogen atoms and neutral end groups were added. All basic and acidic residues were considered 
protonated and deprotonated, respectively. Since almost all histidines are oriented toward the outer part 
of the enzyme, accessible for the surface, they were considered as protonated (HIP) after a prediction 
run made by MolProbity.60 For 1I5R the cofactor NADPH was merged into the enzyme after an 
accurate overlay with the hybrid inhibitor HYC and the X-rays 1A27 and 1FDT. Further, every crystal 
structure was minimized for 500 steps with the steepest descent minimizer as implemented in SYBYL 
with the backbone atoms kept at fixed positions in order to fix close contacts, followed by 2000 steps 
conjugate gradient minimization requested for an overall better starting structure. 
Inhibitor 23 was built with SYBYL and energy-minimized in MMFF94s force-field as implemented in 
Sybyl. Subsequently an ab-initio geometry optimizations was performed gas phase at the B3LYP/6-
311**G (d,p) level of density functional theory (DFT) by means of the Gaussian03 software,61, 62 in 
order to obtain the RESP charges of compound 23, thought to better perform in Autodock4. 
Two different softwares were used for docking studies: GOLDv3.263 and Autodock4,64, 65 using the 
graphical user interface AutoDockTools (ADT 1.5.2). Since both allow flexible docking of ligands, no 
conformational search was employed to the ligand structure. For both programs the compound 23 was 
docked in 50 independent genetic algorithm (GA) runs.  
GOLDv3.2: Active-site origin was set at the center of the steroid binding site, while the radius was set 
equal to 13 Å. The automatic active-site detection was switched on. Further, a slightly modified 
GOLDSCORE fitness function (increased scaling for hydrophobic contacts) was used and genetic 
algorithm default parameters were set as suggested by the GOLD authors.  
Autodock4: The docking area has been defined by a box, centered on the mass center of the CD-rings 
of the cocrystallized E2. Grids points of 60 × 70 × 74 with 0.375 Å spacing were calculated around the 
docking area for all the ligand atom types using AutoGrid4. The Lamarckian genetic algorithm local 
search (GALS) method was used. Each docking run was performed with a population size of 200. A 
mutation rate of 0.02 and a crossover rate of 0.8 were used to generate new docking trials for 
subsequent generations. The GALS method evaluates a population of possible docking solutions and 
propagates the most successful individuals from each generation into the next one.  
Both programs performed in a similar way, supporting the herein suggested binding modes. The quality 
of the docked poses was evaluated based mainly on visual inspection of the putative binding modes of 
the ligand, and secondly on the scoring functions, which give a good measure to discriminate between 
the found binding modes for one single X-ray conformation, but do not help us to compare the poses of 
different X-rays.  
 
2. MEP 
 
For selected compounds ab-initio geometry optimisations were performed gas phase at the B3LYP/6-
311**G (d,p) level of density functional theory (DFT) by means of the Gaussian03 software and the 
molecular electrostatics potential map (MEP) was plotted using GaussView3, the 3D molecular 
graphics package of Gaussian.66 These electrostatic potential surfaces were generated by mapping 6-
311G** electrostatic potentials onto surfaces of molecular electron density (isovalue = 0.0002e/Å). The 
MEP maps are color coded, where red stands for negative values (3.1*10-2 Hartree) and blue for 
positive ones (4.5*10-2 Hartree).  
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4. Summary and Conclusion 
 
 
The aim of the present thesis was the development of a class of non-steroidal highly potent 
and selective inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) as potential 
therapeutics for the treatment of estrogen-dependent pathologies. Following the 
pharmacophore model established in our group, bis(hydroxyphenyl)substituted azoles and 
arenes were designed with the goal to reach high 17β-HSD1 inhibitory activity as well as 
selectivity versus 17β-HSD2, the enzyme which catalyzes the intracellular deactivation of E2 
into E1, and the estrogen receptors α and β. In order to deliver a suitable candidate which 
could be applied as a drug, the biological properties of the most potent inhibitors were further 
investigated aiming at metabolic stability in rat liver microsomes, inhibition of hepatic CYP 
enzymes and intestinal absorption using a CaCo2-permeability assay. In a final step, the 
pharmacokinetic profile of the most promising candidates was evaluated in rats after oral 
administration in a cassette dosing approach. 
 
Chapter 3.I deals with the design, synthesis and biological evaluation of a series of 19 
bis(hydroxyphenyl) azoles. As the compounds have to mimic the steroidal substrate, different 
substitutions patterns concerning the phenolic OH groups (meta and para), in which the O-O 
distance is the same range as observed for E1 (d= 11 Å), were investigated to find out the one 
which fits best to the active site. Additionally, the influence of the central ring for 17β-HSD1 
inhibition was also investigated. Heterocycles containing nitrogen and/or oxygen were selected 
as their heteroatoms might be able to establish supplementary interactions with the amino acids 
Tyr218/Ser222 which are located close to the C6 position of the steroid. It was established that 
the inhibitory activity of the di-substituted azole derivatives depends on the presence of 
hydroxy rather than methoxy groups on the phenyl substituents and on the OH substitution 
pattern: meta-para and para-meta substituted compounds being more active than para-para 
substituted ones. The fact that only several meta-para, para-meta di-substituted azoles showed 
inhibitory activity, indicates that also the heterocycle is involved in the stabilization of the 
inhibitor in the active site of the enzyme. The presence of a hydrogen bond donor function on 
the heterocycle seemed to be detrimental for activity (2,4-disubstituted imidazoles I.9-11,‡1 
1,3-disubstituted pyrazoles I.12-13), whereas several compounds bearing H-bond acceptor 
atoms in the central aromatic ring (1,4-disubstituted 1,2,3-triazoles I.7-8, 1,3-disubstituted 
isoxazole I.16, 2,4- and 2,5-disubstituted 1,3-oxazoles I.18, I.19) are active (Table 4). It is 
hypothesized that the increase of inhibitory activity is due to the establishment of an additional 
H-bond interaction between the heteroatoms of the azole moiety and Tyr218/Ser222.  
Interestingly, aiming the N, O containing heterocycles, it becomes evident that the location 
of the heteroatoms in the aromatic scaffold has a decisive effect on the 17β-HSD inhibitory 
action: the 3,5-disubstituted isoxazole I.16 and the 2,4-disubstituted oxazole I.19 turned out to 
be selective 17β-HSD2 inhibitors while their 2,5-disubstituted oxazole isomer I.18 shows 
higher 17β-HSD1 inhibitory activity (Table 4). Consistent with these findings, it can be 
assumed that besides a high amino acid similarity, both enzymes present also important 
structural differences in the area of the binding site where the heterocycle is anchored.  
Aiming at the selectivity over the ERs, all the tested compounds showed very marginal to 
weak binding affinities to the receptors (Table 4). In the literature, it has been described that 
the high binding affinity of similar ER ligands like tris(hydroxyphenyl) pyrazoles104-109 
depends only on the presence of the three hydroxyphenyl moieties, the heterocycle playing 
                                                 
‡For the sake of clarity, all compounds that are referred to in chapter 4 are presented as a combination of a Roman 
numeral (I-IV) and an Arabic numeral. The roman numeral indicates in which paper they are published and the 
Arabic numeral corresponds to the compound number of the publication. (e.g. I.9 is compound 9 from paper I) 
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only a passive role, orienting the peripheral substituents in an appropriate topology. 
Contrariwise, in the case of our bis(hydroxyphenyl) substituted azoles, it becomes evident that 
the combination of at least two parameters is necessary to reach activity and selectivity: an 
adequate O-O substitution pattern and a suitable heterocycle. Therefore, the concept of varying 
the heterocyclic moiety as well as the position of the OH groups on the hydroxyphenyl 
moieties is further investigated in the following subprojects of this work (Chapter 3.II and 
3.III) to get on insight into the impact of these two criteria on activity and selectivity. 
 
Table 4: inhibition of human 17β-HSD1, 17β-HSD2 and binding affinities for the estrogen 
receptors α and β by selected azole derivative. 
 
Cmpd Structure 
IC50 (nM)a Selectivity 
factord 
RBAe (%) 
17β- 
HSD1b 
17β- 
HSD2c ERα ERβ 
I.7 
NN
N
HO
OH
 
1320 8120 6 <0.01 <0.01 
 
      
I.8 
N N
N
HO
OH
 
840 7280 9 0.01<  RBA < 0.1 
0.01<  
RBA < 0.1 
 
      
I.16 
N O
HO
OH
 
1610 270 0.2 0.01<  RBA < 0.1 <0.01 
 
      
I.18 O
N
HO
OH
 
310 17500 56 0.01<  RBA < 0.1 0.5 
 
      
I.19 N
O
HO
OH
 
1850 250 0.1 0.01<  RBA < 0.1 
0.01<  
RBA < 0.1 
 
aMean value of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate E1, 500 nM, cofactor NADH, 500 µM; cHuman placenta, microsomal fraction, substrate E2, 500 nM, 
cofactor NAD+, 1500 µM; dIC50 HSD2/IC50 HSD1; eRBA: relative binding affinity, E2: 100 %, mean value of 
three determinations, standard deviation less than 10 %. 
 
It is striking that compounds sharing the same meta-para O-O substitution pattern and 
bearing a heterocycle without hydrogen bond donating function like the 1,4-disubstituted 
imidazole I.6 are inactive while the corresponding 1,2,3-triazole isomer I.8 is a fairly potent 
inhibitor of the enzyme. Therefore we focussed in the second part of this thesis (chapter 3.II) 
on triazole core structures and especially on 1,3,4-triazoles (Figure 17). Thereby, we gained 
further insights into the impact of an additional nitrogen atom and on the influence of the 
nitrogen distribution in the central ring on inhibitory activity.  
In addition, a non polar substituent was introduced on the heterocycle, with the aim, on the 
one side to tackle the hydrogen bond donating function of the heterocycle. On the other side, 
these additional substituents should be able to increase the potency of compounds by the 
induction of supplementary hydrophobic interactions with amino acids of the binding site (e.g. 
pi-pi stacking with Tyr218 in case of compounds II.7-9). Moreover, it would also deliver 
important knowledges about the space availability around the heterocycle.  
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Figure 17: design strategy followed in chapter 3.II 
 
Analysis of the biological data of these molecules presented in Table 5, revealed interesting 
structure-activity relationships regarding 17β-HSD type 1 and 2 inhibitory potencies. As a 
general rule, molecules bearing a 1,2,3-triazole moiety show higher inhibitory activities toward 
17β-HSD1 than their corresponding 1,2,4-triazole isomers. Obviously, the nitrogen in the 
vertex position on the heterocycle and/or the supplementary substituent is not tolerated by the 
type 1 enzyme. The introduction in N-1 position of a methyl or phenyl moiety on the triazole 
core (compounds II.4-9) leads to a strong limitation of the free rotatability around the C-C 
bonds between each aromatic ring. Thus, a coplanar conformation becomes energetically 
disfavoured compared to the di-substituted derivatives. The hydroxyphenyl moieties might 
therefore not be able to adopt the required geometry to establish polar interactions with the 
enzyme active site. 
It is also noteworthy that the loss of planarity is correlated with an increase of 17β-HSD2 
activity. This observation is in accordance with the almost published 17β-HSD2 inhibitors 
which also lack planarity.110-112 These important structural features should be of high relevance 
for the future design of selective non-steroidal 17β-HSD2 inhibitors.  
 
Table 5: Inhibition of human 17β-HSD1 and 17β-HSD2 by bis(hydroxyphenyl) triazoles 
N
N
N
N
N N
R1
R2
II.1
I.7-8
R1
R2
II.4-9
R
 
cmpd R R1 R2 
IC50 value (µM)a 
17β-HSD1b 17β-HSD2c 
II.1  3-OH 3-OH 17d ni 
I.7  4-OH 3-OH 1.32 8.12 
I.8  3-OH 4-OH 0.84 7.28 
II.4 CH3 3-OH 3-OH ni ni 
II.5 CH3 4-OH 3-OH ni 20d 
II.6 CH3 3-OH 4-OH ni 21d 
II.7 Ph 3-OH 3-OH ni 41d 
II.8 Ph 4-OH 3-OH ni 44d 
II.9 Ph 3-OH 4-OH ni ni 
 
aMean values of three determinations, standard deviation less than 18 %; bHuman placenta, cytosolic fraction, 
substrate [3H]-E1 + E1 [500 nM], cofactor NADH [500 µM]; cHuman placenta, microsomal fraction, substrate 
[3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 µM]; d% inhibition at 1 µM; ni: no inhibition (<10 % inhibition at 1 
µM). 
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In Chapters 3.I and 3.II, it has been identified that the inhibitory activity of this class of 
compounds depends on the O-O substitution pattern and on the nature and location of the 
heteroatoms present in the central aromatic ring. Regarding the properties of the heterocycle, 
hydrogen bond donor functions turned out to be detrimental, while hydrogen bond acceptor 
atoms are favourable. Chapter 3.III is principally concerned with the design and the synthesis 
of bis(hydroxyphenyl) azoles and arenes. Besides the investigation of molecules bearing 5-
membered sulfur containing heterocycles, it is also evaluated whether 6-membered rings are 
suitable cores to link the two hydroxyphenyl moieties. 
Most of the compounds described in Chapter 3.III turned out to be even more active than 
the previously identified 2,5-disubstituted oxazole I.18. Regarding the OH-OH substitution 
pattern of the inhibitors similar findings, as seen in Chapter 3.I., can be observed: to reach 17β-
HSD1 activity, the distance between the two oxygens of the OH groups of the molecule has to 
be close to the value observed for E1 (d= 11 Å). Therefore only compound with a meta-para, 
para-meta and meta-meta substitution pattern (8.5< d< 12.8 Å) shows activity while the para-
para analogues are inactive (d> 12.5 Å). 
In order to obtain insights in the role of the OH-groups on inhibitory activity, several 
thiophenes bearing only one hydroxy substituent (III.19-20) were synthesized and their 
biological activities compared to the di-substituted (III.22) analogues. The slightly decrease in 
case of the replacement of the para-OH with a hydrogen and the dramatical loss of activity in 
case of the exchange of the meta-OH by a H atom, indicates that both hydroxy groups are 
important for activity, with the meta-OH being, obviously, more important than the para-
hydroxy (Table 6).  
 
Table 6: influence of the number and location of the OH groups on 17β-HSD1 and 17β-HSD2 
inhibitory activity 
 
S
R1
R2
 
 
cmpd R1 R2 
IC50 (nM)a selectivity 
factord 17β-HSD1b 17β-HSD2c 
III.17 H H ni nt -- 
III.19 3-OH H 342 2337 7 
III.20 4-OH H ni nt -- 
III.22 4-OH 3-OH 69 1953 28 
 
aMean values of three determinations, standard deviation less than 12 %; bHuman placenta, cytosolic fraction, 
substrate [3H]-E1 + E1 [500 nM], cofactor NADH [500 µM]; cHuman placenta, microsomal fraction, substrate 
[3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
Considering the influence of the heterocycle, the exchange of the N-Me moiety of the 
inactive 1,2,4-triazole II.6 by a sulfur leads to a fairly potent compound III.10 (IC50= 413 nM, 
Table 7). This finding indicates that a sulfur atom in this position has a positive influence on 
the binding affinity of the enzyme. The role of the nitrogen and the sulfur was further 
investigated by varying the position as well as the number of heteroatoms in the central ring. 
Regarding the biological data of the 1,3-thiazole derivatives, it becomes apparent that the 
location of the sulfur and the nitrogen is decisive for the activity of the compounds: the 2,4-
disubstituted thiazole III.22 turned out to be a very weak inhibitor of the enzyme (IC50> 1000 
nM) while its 2,5-disubstituted isomer III.3 is the most potent compound (IC50= 50 nM). In 
contrary, in the thiophene class of compounds the variation of the position of the sulfur atom 
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seems not to be relevant: both compounds exhibited similar inhibition values (IC50= 77 nM and 
69 nM for III.27 and III.22, respectively). 
Surprisingly, the 1,3-thiazole III.3 (IC50= 50 nM) and thiophene III.22 (IC50= 69 nM) 
show almost similar inhibition values. The nitrogen of III.3 is obviously not contributing to the 
binding, i.e. no hydrogen bond interaction can be formed between this heteroatom and the 
binding site of the enzyme. 
In the six-membered ring class of compounds, phenylene III.35, pyridine III.37 and 
tetrazine III.39 show similar inhibitory activities suggesting that the nitrogen of the different 
ring are tolerated by the enzyme active site but do not contribute to specific interactions (H-
bond, Table 7), as it is observed for the 5-membered heterocycles. 
Looking at the selectivity toward 17β-HSD2, the biological results show that most of the 
meta-meta di-substituted inhibitors present only a poor selectivity toward the type 2 enzyme 
except for two members of the six-membered ring class of compounds (compounds III.37 and 
III.39, selectivity factor of 34 and 25, respectively). Considering the meta-para disubstituted 
inhibitors, compound III.3 is the most potent molecule with a selectivity factor of 80.  
 
Table 7: inhibition of human 17β-HSD1 and 17β-HSD2 by selected bis(hydrophenyl) 
substituted azoles and arenes 
 
 
 
 
 
 
cmpd Het R1 R2 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
II.6 N N
N
 
3-OH 4-OH ni nt  
III.10 
S N
N
 
3-OH 4-OH 413 2194 5 
III.7 
S
N
 
3-OH 4-OH >1000 nt  
III.27 
S
 
3-OH 4-OH 77 1271 16 
III.22 
S
 
3-OH 4-OH 69 1953 28 
III.3 
S
N
 
3-OH 4-OH 50 4004 80 
 
      
III.4 
S
N
 
3-OH 3-OH 243 2500 10 
III.8 
N
S
 
3-OH 3-OH 455 2220 5 
III.20 
S
 
3-OH 3-OH 173 745 4 
III.28 
S
 
3-OH 3-OH 185 559 3 
 
R1
R2
Het
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cmpd Het R1 R2 
IC50 (nM)a 
selectivity 
factord 17β-HSD1 
17β-
HSD2 
III.35 
 
3-OH 3-OH 173 2259 13 
III.37 
N
 
3-OH 3-OH 101 3399 34 
III.39 N
N
N
N
 
3-OH 3-OH 201 5102 25 
 
aMean values of three determinations, standard deviation less than 12 % except III.3: 18 % for 17β-HSD1; 
bHuman placenta, cytosolic fraction, substrate [3H]-E1 + E1 [500 nM], cofactor NADH [500 µM]; cHuman 
placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ 
IC50 (17β-HSD1); ni: no inhibition, nt: not tested 
 
As it is shown in Table 7, the nature, the number as well as the location of the heteroatoms 
in the central aromatic ring plays a crucial role for the potency of this class of compounds. 
Besides their ability to establish polar interactions (e.g. H-bond in case of the nitrogen), they 
have also an important impact on the electron density of the whole molecule.  
Therefore, the charge density distribution of a sample of molecules was calculated and their 
corresponding MEP maps plotted. For a better comparison, the MEP maps were divided into 
three different regions corresponding to the three aromatic rings of the compounds (Figure 19). 
 
Trying to establish a semiquantitative MEP-activity relationship (“semi-QMAR”), optimal 
ESP ranges for area I, II and III for high inhibition activity were identified: for region I ESP 
from –1.7 to –1.2 ·10-2, for region II –1.6 to –0.9 ·10-2 and for region III –1.2 to –0.5 ·10-2 
Hartree. Similarly, the optimal ∆ values of ESP for each region were determined: 0.5, 0.7 and 
0.7 Hartree, respectively. The shift of a certain ESP distribution range on the scale or the 
change of the ∆ value results in a decrease of inhibitory activity.  
The high importance of the location of the heteroatoms on the central aromatic ring on the 
MEP maps is well demonstrated with the 1,3-thiazole III.2 and III.3 isomers, which only 
differ by the position of the nitrogen in the thiazole moiety. The change of the position of the 
nitrogen (compound III.3 vs. compound III.2) in the thiazole ring has a decisive influence on 
the electronic distribution in each area making compound III.2 inactive. 
Regarding the 2,4-disubstituted imidazole I.12, a polarization between top and bottom 
sides of the molecule resulting in a high ∆ for area II (∆= 7.2 ·10-2 Hartree) might be the main 
reason for the inactivity of this compound. 
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Figure 19: (A) structure and 17β-HSD1 inhibitory activity of compounds I.12, III.2, I.18, 
III.22 and III.3 ordered by increasing activity; (B) MEP maps, dorsal and ventral view; (C1) 
ESP distribution range (Hartree; ·10-2); (C2) mean value of distribution range (Hartree, ·10-2); 
(C3) ∆ of ESP; (D) “semi-QMAR”. MEP surfaces were plotted with GaussView 3.09. 
 
The selectivity profile of the compounds was further investigated. The binding affinities of 
molecules with fair to high selectivity toward 17β-HD2 were therefore examined on ERα and 
ERβ (Table 8). All tested compounds show very marginal to weak affinity to the ERs. Since 
binding affinity does not explore intrinsic activity at the receptor, the compounds were further 
analyzed on the estrogen dependent mammary tumor cell-line T-47D. Cell proliferation was 
monitored after incubation with the test compounds. No agonistic, i.e. stimulatory effect was 
observed even at a concentration 1000-fold higher than E2 indicating that this class of 
compounds is devoid of estrogenic activity.  
 
Table 8: binding affinities for the human estrogen receptor α and β of selected compounds 
 
cmpd RBA (%)
a
 
ERαb ERβb 
III.3 <0.01 0.01< RBA< 0.1 
 
  
III.22 0.1< RBA< 1 1.5 
 
  
III.27 0.01< RBA< 0.1 0.1< RBA< 1 
 
  
III.35 < 0.001 0.01< RBA< 0.1 
 
  
III.37 0.01< RBA< 0.1 < 0.01 
 
aRBA (relative binding affinity), E2: 100 %, mean values of three determinations, standard deviations less than 10 
%; bHuman recombinant protein, incubation with 10 nM [3H]-E2 and inhibitor for 1 h. 
 
In order to get an insight into the pharmacokinetic properties of this class of compounds, a 
representative compound of the thiazoles III.4, thiophenes III.25 and of the phenylenes III.35 
compound classes were evaluated for its phase 1 metabolic stability using rat liver microsomes. 
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The tested compounds show longer half-lives (t1/2= 12.6, 18.6 and 22.7 min for III.4, III.25 
and III.35, respectively) than the antihistaminic drug diphenhydramine (t1/2= 6.8 min).  
The pharmacokinetic profiles of the most active and selective azole III.3 and aza-benzenes 
III.39 were determined in rats after oral administration in a cassette dosing approach. The 
examination of the availability in the plasma reveals that both compounds show relative short 
half-lives (t1/2= 1.5 and 1.2 h for III.3 and III.39, respectively) and reasonable plasma levels in 
case of III.39 (AUC0-tz= 1204.0 ng/mL following a dose of 10 mg/kg). The low plasma levels 
observed for III.3 might be due to glucuronidation or sulfatation of the parent compound. 
 
In conclusion, non-steroidal 17β-HSD1 inhibitors with a bis(hydroxyphenyl) thiophene, 
thiazole and benzene molecular scaffold proved to be significantly superior to the previously 
identified bis(hydroxyphenyl) oxazole I.19. These molecules are highly selective toward 17β-
HSD2 and the ERs, show good metabolic stability in rat liver microsomes and a reasonable PK 
profile. The structural motives obtained in this part were pursued and refined in Chapter 3.IV. 
  
Chapter 3.IV describes the efforts of improving the activity and selectivity of 
bis(hydroxyphenyl) thiophenes, thiazoles and benzenes by the introduction of an additional 
substituent on the inhibitor backbone. Therefore, based on the molecular scaffolds of III.3, 
III.22 and III.35, several structurally modified derivatives were synthesized and their 
biological properties were evaluated. 
In chapter 3.III, it was found that removing one of the two hydroxyphenyl moieties of 
compound IV.1 is detrimental for 17β-HSD1 inhibitory activity. The replacement of the para-
OH function by one of its bioisoteric groups like F, NH2, SH, CN leads to a drop of activity 
(compounds IV.2-6). The lack of hydrogen donating function of the fluoro and cyano 
substituents might not be the only reason for this decrease in activity as the amino and the thiol 
derivatives are also less active than the reference compound IV.1. Interestingly, the insertion of 
a C1-linker between the methylsulfonamide moiety and the phenyl ring resulted also in a loss 
of potency (compound IV.11). This finding supports the fact that the delocalization of the 
electronic density, resulting in a deprivation of electrons in the phenyl ring is necessary for a 
good inhibition (Table 9).  
 
Looking at the selectivity of these compounds, the biological data presented in Table 9 
shows that mono-hydroxylated molecules exhibit a poor selectivity over 17β-HSD2, the most 
selective one being compound IV.5 with a selectivity factor of 5. This finding suggests that the 
para-OH is important for activity but is also influencing the selectivity of this class of 
compounds. 
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Table 9: effect of the exchange of one OH group on the inhibitory activity of 
bis(hydroxyphenyl) thiophene 
 
S
OH R
S
OH
R
IV.1-6 IV.2
IV.7-11
 
cmpd R 
IC50 (nM)a 
selectivity 
factord cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
17β- 
HSD1b 
17β- 
HSD2c 
IV.1 OH 69 1950 28 IV.7 OH 173 745 4 
IV.2 H 342 2337 7 IV.2 H 342 2337 7 
IV.3 F 717 3655 5 IV.8 F 535 1824 3 
IV.4 NH2 >5000 nt  IV.9 N
H
SO2
 
523 1575 3 
IV.5 SH >5000 nt  IV.10 NH
SO2
 
>1000 nt  
IV.6 CN >1000 nt  IV.11 NH
SO2
 
350 276 1 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested. 
 
With the aim to increase the activity and the selectivity, substituents were added on the 2,5-
bis(hydroxyphenyl) thiophene IV.1 and IV.7. The introduction of a substituent into the 
thiophene core (compounds IV.12 to IV.15) seems to be detrimental for activity, except for 
compound IV.15 (IC50= 119 nM vs. IV.7, IC50= 216 nM). Obviously, a supplementary 
hydrogen bond between the additional hydroxyphenyl moiety of IV.15 with polar amino acid 
residues might be responsible for the increase in inhibitory activity. A pure pi-pi stacking 
interaction as observed in compound IV.14 is obviously not enough to achieve an enhancement 
of activity. The 2,5-disubstituted thiophenes IV.12 and IV.15 differ only in the shift of one 
hydroxy group from the para- (compound IV.12) into the meta-position (compound IV.15). 
The gain in activity observed for compound IV.15 (IC50= 119 nM vs. IV.12, IC50> 1000 nM) 
indicates that only in case of IV.15 the geometry of the OH moiety allows additional hydrogen 
bond interactions.  
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Table 10: influence of an additional substituent on 17β-HSD1 and 17β-HSD2 inhibitory 
activity 
S
R
OH OH
S
R
OH
OH
IV.7
IV.13-15
IV.1
IV.12
 
cmpd R
 
IC50 (nM)a 
selectivity 
factord cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- 
HSD1b 
17β- 
HSD2c 
17β- 
HSD1b 
17β- 
HSD2c 
IV.1 H 69 1950 28 IV.7 H 173 745 4 
 
    IV.13 CH3 567 856 1 
 
    IV.14 
 
493e nt  
IV.12 
OH
 
>1000 nt  IV.15 
OH
 
119 188 2 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ecaculated value, obtained 
with the LOGIT transformation; ni: no inhibition, nt: not tested. 
 
The trisubstituted compound IV.14 bearing a phenyl substituent at the thiophene differs 
from the triazole II.7 only in the nature of the heterocycle. The inactivity observed for 
compound II.7 supports the important role exerted by the central aromatic ring on inhibitory 
activity, the thiophene being always the best core. Taking the hypothesis that all the 
compounds bind according to the same binding mode, different reasons could explain these 
results: 1. the presence of one or several nitrogens or the absence of the sulfur in the 
heterocycle leads to an inadequate repartition of the electron density in the molecule, 2. a 
reduced flexibility of the enzyme which cannot adjust its geometry to the different 
hydroxyphenyl moieties (the position of each hydroxyphenyl moiety being different in the 
active site as the heterocycles and especially the location of the heteroatoms in this ring 
induces different angles between the phenyl-OH). 
An abrupt rise in activity and selectivity could be reached by insertion of substituents on 
the hydroxyphenyl moieties, especially when the substituent is located in ortho- of the para-
hydroxyphenyl (compounds IV.21-24). The inhibitory data of some representative compounds 
out of this series are shown in Table 11. All substituents are not equally well tolerated: no 
space is available for introduction of a bulky phenyl group (compound IV.25), the polar 
additional OH (compound IV.22) is not able to establish specific interactions while small 
lipophilic substituents (methyl, compounds IV.21; fluorine, compound IV.23 and 
trifluoromethyl, compound IV.24) are enhancing the activity compared to the core structure 1 
(IC50= 69 nM vs. IC50= 46 nM, 8 nM, 38 nM for IV.21, IV.23 and IV.24, respectively). 
Furthermore, space to introduce a flexible chain (compounds IV.26-28) is available in this 
region of the enzyme but conjugation (compound 26) seems to be necessary to achieve a higher 
activity. 
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Table 11: effect of an additional substituent on the hydroxyphenyl moieties on the 
inhibition of human 17β-HSD1 and 17β-HSD2 
 
S
OH
OH
R
 
cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
IV.1 H 69 1950 28 
IV.21 CH3 46 1971 49 
IV.22 OH 402 1636 4 
IV.23 F 8 940 118 
IV.24 CF3 38 97 3 
IV.25 Ph >5000 nt  
IV.26 
O
OEt
 
130 502 4 
IV.27 
O
N
H
 
427 468 1 
IV.28 
O
N
H
 
620 982 2 
 
aMean values of three determinations, standard deviation less than 15 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); ni: no inhibition, nt: not 
tested 
 
The insertion of a fluorine atom induces a significant increase of the activity and 
selectivity. Introduction of a second fluorine atom on the fluorohydroxyphenyl ring 
(compounds IV.31) does not enhance the activity anymore suggesting that the effects of these 
atoms are not additional. The presence of two fluorohydroxyphenyl moieties on the thiophene 
(compounds IV.29 and IV.30) is slightly better tolerated when the fluorine is located in ortho- 
to the hydroxy moiety (compound IV.30) leading to a derivative equally active as the 
monofluorinated IV.23. A plausible explanation could be that in case of compound IV.29, the 
fluorine is located to far away from the hydroxy group to have any influence on its pKa-value 
leading therefore to a slightly decrease in activity compared to compound IV.30 (Table 12). 
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Table 12: effect of two additional fluorine atoms on the 17β-HSD1 and 17β-HSD2 inhibitory 
activity 
S
OH
OH
F
S
OH
OH
F
F
R
IV.31
IV.23
IV.29-30
 
cmpd R 
IC50 (nM)a 
selectivity 
factord 17β- HSD1b 
17β- 
HSD2c 
IV.23 H 8 940 118 
IV.29 5-F 29 227 8 
IV.30 4-F 17 218 13 
IV.31  56 312 6 
 
aMean values of three determinations, standard deviation less than 10 %; bHuman placenta, cytosolic fraction, 
substrate 3H-E1 + E1 [500 nM], cofactor NADH [500 µM], cHuman placenta, microsomal fraction, substrate 3H-
E2 + E2 [500 nM], cofactor NAD+ [1500 µM], dIC50 (17β-HSD2)/ IC50 (17β-HSD1); nt: not tested. 
 
 
The close look at the X-ray structures of 17β-HSD1 crystallized in presence of different 
ligands showed that the flexible loop (amino acids 187-200) can adopt different geometry 
depending on the nature of the ligand and on the absence or presence of the cofactor in the 
catalytic region. It indicates that some parts of the enzyme are able to adapt their geometries to 
the molecule present in the active site in order to stabilize it. 
Two plausible conformations of the loop in the ternary complex enzyme, E2 and cofactor 
(PDB-ID: 1FDT) have been described (1FDT-A, 1FDT-B). In case of 1FDT-A, the loop is in 
the open conformation extending the substrate binding site. It is therefore expected that it is a 
good model to evaluate the binding mode of non-steroidal inhibitors which might have a 
geometry different to the one of the steroid. Two different binding modes have been identified 
for this class of inhibitors depending on the position of the flexible loop. A steroidal binding 
mode was found when the loop closes the SUB (1FDT-B). Surprisingly, an alternative binding 
mode was also identified when the loop is in the open conformation: the inhibitor interacts with 
the nicotinamide part of the cofactor (Figure 20).  
MEPs calculations can show a certain complementarity between the electronic density of 
the inhibitor IV.23 and the nicotinamide moiety of the cofactor indicating that this alternative 
binding mode is plausible and might be the favourite one.  
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Figure 20: overlay of the binding poses of compound IV.23 obtained with 1FDT-A (presented 
in lilac) and with 1FDT-B (marked in light blue). For the sake of clarity, the amino acids of the 
flexible loop are drawn in blue and yellow for 1FDT-A and 1FDT-B, respectively. 
 
The most potent 17β-HSD1 inhibitors IV.21 and IV.23 exhibit a high selectivity toward 
17β-HSD2, the fluorinated derivative IV.23 being the best one (selectivity factors of 49 and 
118, respectively). This result indicates that inspite of a high active site similarity between the 
type 1 and type 2 enzymes, the amino acids close to the CH3 (compound IV.21) and the F 
substituents (compound IV.23) must exhibit different properties, which could be further 
exploited to increase selectivity. Moreover, the molecules show marginal to very little affinity 
to ERα (RBA< 1 %) and no stimulation of cell proliferation (agonistic effect) in the ER-
positive T-47D cell line could be observed. The weak affinity measured, in case of compound 
IV.23, for ERβ (RBA = 1 %) may not be critical as it is reported that ERβ exhibits anti-
proliferative effects in breast cancer cells.113 
The selectivity over CYP3A4 and CYP2D6, the two most hepatic CYP enzymes which are 
responsible for 75 % of drug metabolism was investigated. At a concentration of 2 µM, 
compounds IV.21 and IV.23 turned out to be equally active on both enzymes inhibiting the 
CYP3A4 activity by 80  and 71 % and CYP2D6 by 55 % and 56 %, respectively. The high 
affinity observed for both isoenzymes has to be taken into consideration in the process of drug 
development but might not be relevant for the proof of concept. In addition, the PK-profile of 
these two molecules was determined in a cassette dosing experiment and compared to the 
results obtained for the most potent compounds of chapter III (Figure 21). Compounds IV.21 
and IV.23 reach higher plasma concentrations after peroral application in rats (following a 10 
mg/kg dose, AUC0-∞= 19407 and 12275 ng×h/mL for IV.21 and IV.23, respectively) than the 
parent compounds III.3 and III.39 (Figure 21) which is indicative of an excellent 
bioavailability. 
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Figure 21: mean profile (±SEM of plasma levels (ng/mL) in rat versus time after oral 
application (10 mg/kg) of compounds III.3, III.36, IV.21 and IV.23 determined in a cassette 
dosing experiment. 
 
 
In summary, the present work describes the design, synthesis and biological evaluation 
which led to the identification of a new class of non-steroidal 17β-HSD1 inhibitors: 
bis(hydroxyphenyl) azoles and arenes. Beside a strong 17β-HSD1 inhibition with IC50 values in 
the low nanomolar range and an excellent 17β-HSD2 selectivity (up to 100-fold), the 
compounds show also low to marginal binding affinity to the estrogen receptors and good cell 
permeability. In view of the pharmacokinetic properties, two of the investigated compounds 
reach excellent plasma-levels indicative of a high bioavailability and might be therefore 
excellent candidates to validate the concept of selective 17β-HSD1 inhibition as treatment for 
estrogen dependent diseases. In addition, the investigations of the present work provide a 
concise structure-activity study for 17β-HSD1 inhibition which can be used in the future 
development of new inhibitors interacting with 17β-HSD1. Moreover, this work delivers also 
information about SARs which are important for selective 17β-HSD2 inhibition. These 
findings might be of particular interest for the design of compounds for the treatment of 
estrogen deprivation disorders such as osteoporosis.  
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